Intel (INTC) 10-K 31 Jan 25 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($) shares in Millions, $ in Billions	12 Months Ended
	Dec. 28, 2024	Jan. 24, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 28, 2024
Document Transition Report	false
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Company Fiscal Year End Date	--12-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	408
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,330
Entity Public Float			$ 132.4
Documents Incorporated by Reference [Text Block]	Portions of the registrant's proxy statement related to its 2025 Annual Stockholders' Meeting to be filed subsequently are incorporated by reference into Part III of this Form 10-K. Except as expressly incorporated by reference, the registrant's proxy statement shall not be deemed to be part of this report.

Audit Information

Audit Information	12 Months Ended
	Dec. 28, 2024
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	San Jose, California

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenue	$ 53,101	$ 54,228	$ 63,054
Cost of sales	35,756	32,517	36,188
Gross margin	17,345	21,711	26,866
Research and development	16,546	16,046	17,528
Marketing, general, and administrative	5,507	5,634	7,002
Restructuring and other charges	6,970	(62)	2
Operating expenses	29,023	21,618	24,532
Operating income (loss)	(11,678)	93	2,334
Gains (losses) on equity investments, net	242	40	4,268
Interest and other, net	226	629	1,166
Income (loss) before taxes	(11,210)	762	7,768
Provision for (benefit from) taxes	8,023	(913)	(249)
Net income (loss)	(19,233)	1,675	8,017
Less: net income (loss) attributable to non-controlling interests	(477)	(14)	3
Net income (loss) attributable to Intel	$ (18,756)	$ 1,689	$ 8,014
Earnings (loss) per share attributable to Intel—basic	$ (4.38)	$ 0.40	$ 1.95
Earnings (loss) per share attributable to Intel—diluted	$ (4.38)	$ 0.40	$ 1.94
Weighted average shares of common stock outstanding:
Basic (shares)	4,280	4,190	4,108
Diluted (shares)	4,280	4,212	4,123

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (19,233)	$ 1,675	$ 8,017
Other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(555)	272	(510)
Actuarial valuation and other pension benefits (expenses), net	60	66	855
Translation adjustments and other	(1)	9	(27)
Other comprehensive income (loss)	(496)	347	318
Total comprehensive income (loss)	(19,729)	2,022	8,335
Less: comprehensive income (loss) attributable to non-controlling interests	(477)	(14)	3
Total comprehensive income (loss) attributable to Intel	$ (19,252)	$ 2,036	$ 8,332

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Current assets:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 8,249	$ 7,079
Short-term investments	13,813	17,955
Accounts receivable, net	3,478	3,402
Inventories	12,198	11,127
Other current assets	9,586	3,706
Total current assets	47,324	43,269
Property, plant, and equipment, net	107,919	96,647
Equity investments	5,383	5,829
Goodwill	24,693	27,591
Identified intangible assets, net	3,691	4,589
Other long-term assets	7,475	13,647
Total assets	196,485	191,572
Current liabilities:
Short-term debt	3,729	2,288
Accounts payable	12,556	8,578
Accrued compensation and benefits	3,343	3,655
Income taxes payable	1,756	1,107
Other accrued liabilities	14,282	12,425
Total current liabilities	35,666	28,053
Debt	46,282	46,978
Other long-term liabilities	9,505	6,576
Commitments and Contingencies (Note 19)
Stockholders' equity:
Preferred stock, $0.001 par value, 50 shares authorized; none issued	0	0
Common stock, $0.001 par value, 10,000 shares authorized; 4,330 shares issued and outstanding (4,228 issued and outstanding in 2023) and capital in excess of par value	50,949	36,649
Accumulated other comprehensive income (loss)	(711)	(215)
Retained earnings	49,032	69,156
Total Intel stockholders' equity	99,270	105,590
Non-controlling interests	5,762	4,375
Total stockholders' equity	105,032	109,965
Total liabilities and stockholders' equity	$ 196,485	$ 191,572

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Dec. 28, 2024	Dec. 30, 2023
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50	50
Preferred stock, shares issued	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	10,000	10,000
Common stock, shares issued	4,330	4,228
Common stock, shares outstanding	4,330	4,228

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 7,079	$ 11,144	$ 4,827
Cash flows provided by (used for) operating activities:
Net income (loss)	(19,233)	1,675	8,017
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	9,951	7,847	11,128
Share-based compensation	3,410	3,229	3,128
Restructuring and other charges	3,491	(424)	1,074
Amortization of intangibles	1,428	1,755	1,907
(Gains) losses on equity investments, net	(246)	(42)	(4,254)
(Gains) losses on divestitures	0	0	(1,059)
Deferred taxes	6,132	(2,033)	(5,148)
Impairments and net (gain) loss on retirement of property, plant, and equipment	2,252	33	301
Changes in assets and liabilities:
Accounts receivable	(75)	731	5,327
Inventories	(1,105)	2,097	(2,436)
Accounts payable	634	(801)	(29)
Accrued compensation and benefits	(218)	(614)	(1,533)
Income taxes	(356)	(1,498)	613
Other assets and liabilities	2,223	(484)	(1,603)
Total adjustments	27,521	9,796	7,416
Net cash provided by (used for) operating activities	8,288	11,471	15,433
Cash flows provided by (used for) investing activities:
Additions to property, plant, and equipment	(23,944)	(25,750)	(24,844)
Proceeds from capital-related government incentives	1,936	1,011	246
Acquisitions, net of cash acquired	(82)	(13)	(681)
Purchases of short-term investments	(37,940)	(44,414)	(43,647)
Maturities and sales of short-term investments	41,463	44,077	48,730
Sales of equity investments	1,047	472	4,961
Proceeds from divestitures	0	0	6,579
Other investing	(736)	576	(1,575)
Net cash provided by (used for) investing activities	(18,256)	(24,041)	(10,231)
Cash flows provided by (used for) financing activities:
Issuance of commercial paper, net of issuance costs	7,349	0	3,945
Repayment of commercial paper	(7,349)	(3,944)	0
Partner contributions	12,714	1,511	874
Proceeds from sales of subsidiary shares	0	2,959	1,032
Additions to property, plant, and equipment	(1,178)	0	0
Issuance of long-term debt, net of issuance costs	2,975	11,391	6,548
Repayments of Long-term Debt	(2,288)	(423)	(4,984)
Proceeds from sales of common stock through employee equity incentive plans	987	1,042	977
Restricted stock unit withholdings	(631)	(534)	(486)
Payment of dividends to stockholders	(1,599)	(3,088)	(5,997)
Other financing	158	(409)	(794)
Net cash provided by (used for) financing activities	11,138	8,505	1,115
Net increase (decrease) in cash and cash equivalents	1,170	(4,065)	6,317
Cash and cash equivalents, end of period	8,249	7,079	11,144
Non-cash supplemental disclosures:
Acquisition of property, plant, and equipment	8,125	4,804	5,431
Interest, net of capitalized interest	987	613	459
Income taxes, net of refunds	$ 2,202	$ 2,621	$ 4,282

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock and Capital in Excess of Par	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Non-Controlling Interests
Beginning Balance, shares at Dec. 25, 2021		4,070
Beginning Balance at Dec. 25, 2021	$ 95,391	$ 28,006	$ (880)	$ 68,265	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8,017			8,014	3
Other comprehensive income (loss)	318		318
Net proceeds from partner contributions	1,906	$ 75			1,831
Employee equity incentive plans and other, shares		79
Employee equity incentive plans and other	1,009	$ 1,009
Share-based compensation	3,128	$ 3,099			29
Restricted stock unit withholdings, shares		(12)
Restricted stock unit withholdings	(486)	$ (609)		123
Cash dividends declared	(5,997)			(5,997)
Ending Balance, shares at Dec. 31, 2022		4,137
Ending Balance at Dec. 31, 2022	103,286	$ 31,580	(562)	70,405	1,863
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	1,675			1,689	(14)
Other comprehensive income (loss)	347		347
Net proceeds from partner contributions	4,005	$ 1,620			2,385
Employee equity incentive plans and other, shares		107
Employee equity incentive plans and other	1,044	$ 1,044
Share-based compensation	3,229	$ 3,088			141
Restricted stock unit withholdings, shares		(16)
Restricted stock unit withholdings	(533)	$ (683)		150
Cash dividends declared	$ (3,088)			(3,088)
Ending Balance, shares at Dec. 30, 2023	4,228	4,228
Ending Balance at Dec. 30, 2023	$ 109,965	$ 36,649	(215)	69,156	4,375
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(19,233)			(18,756)	(477)
Other comprehensive income (loss)	(496)		(496)
Net proceeds from partner contributions	12,714	$ 11,012			1,702
Partner distributions	(43)				(43)
Employee equity incentive plans and other, shares		123
Employee equity incentive plans and other	988	$ 988
Share-based compensation	3,367	$ 3,162			205
Restricted stock unit withholdings, shares		(21)
Restricted stock unit withholdings	(631)	$ (862)		231
Cash dividends declared	$ (1,599)			(1,599)
Ending Balance, shares at Dec. 28, 2024	4,330	4,330
Ending Balance at Dec. 28, 2024	$ 105,032	$ 50,949	$ (711)	$ 49,032	$ 5,762

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 0.38	$ 0.74	$ 1.46

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Note 1 : Basis of Presentation We have a 52- or 53-week fiscal year that ends on the last Saturday in December. Fiscal years 2024 and 2023 were 52-week fiscal years; 2022 was a 53-week fiscal year. Fiscal 2025 is a 52-week fiscal year. Our Consolidated Financial Statements include the accounts of Intel and our wholly owned and majority-owned subsidiaries, which include entities consolidated under the variable interest and voting interest models. We have eliminated intercompany accounts and transactions. We made certain reclassifications within our Consolidated Financial Statements during 2024, and, in certain cases, adjusted prior periods to conform to the current period presentation. These reclassifications had no impact on previously reported net income (loss), cash flows, or stockholders' equity. Use of Estimates The preparation of Consolidated Financial Statements in conformity with US GAAP requires us to make estimates and judgments that affect the amounts reported in our Consolidated Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. Effective January 2023, we increased the estimated useful life of certain production machinery and equipment from 5 to 8 years. When compared to the estimated useful life in place as of the end of 2022, we estimated this change increased gross margin in 2023 by approximately $2.5 billion and decreased R&D expense by approximately $400 million. As of December 30, 2023, we estimated this change decreased ending inventory values by approximately $1.3 billion. These estimates were based on the assets in use and under construction as of the beginning of 2023 and were calculated at that point in time.

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
Accounting Policies [Text Block]	Note 2 : Accounting Policies Revenue Recognition We recognize net product revenue when we satisfy performance obligations as evidenced by the transfer of control of our products or services to customers. Substantially all of our revenue is derived from product sales. Our products often include a software component, such as firmware, that is highly interdependent and interrelated with the product and is substantially accounted for as a combined performance obligation. In accordance with contract terms, the revenue for combined performance obligations and standalone product sales is recognized at the time of product shipment from our facilities or delivery to the customer location, as determined by the agreed-upon shipping terms. We measure revenue based on the amount of consideration we expect to be entitled to in exchange for products or services. Variable consideration is estimated and reflected as an adjustment to the transaction price. We determine variable consideration, which consists primarily of various sales price concessions, by estimating the most likely amount of consideration we expect to receive from the customer based on historical analysis of customer purchase volumes. Sales rebates earned by customers are offset against their receivable balances. Rebates earned by customers when they do not have outstanding receivable balances are recorded within other accrued liabilities . We make payments to our customers through cooperative advertising programs for marketing activities for some of our products. We generally record the payment as a reduction in revenue in the period that the revenue is earned, unless the payment is for a distinct service, which we record as an expense when the marketing activities occur. Long-Lived Assets Property, Plant, and Equipment We compute depreciation using the straight-line method over the estimated useful life of assets. We also capitalize interest on borrowings related to eligible capital expenditures. Capitalized interest is added to the cost of qualified assets and depreciated over the estimated useful life. At least annually, we evaluate the period over which we expect to recover the economic value of our property, plant, and equipment, considering factors such as the process technology cadence between node transitions, changes in machinery and equipment technology, and re-use of machinery and tools across each generation of process technology. As we make manufacturing process conversions and other factory planning decisions, we use assumptions involving the use of management judgments regarding the remaining useful lives of assets, primarily process-specific semiconductor manufacturing tools and building improvements. When we determine that the useful lives of assets are shorter or longer than we had originally estimated, we adjust the rate of depreciation to reflect the assets' revised useful lives. Effective January 2023, the estimated useful lives of certain machinery and equipment in our wafer fabrication facilities were increased from 5 to 8 years. This change in estimate was applied prospectively beginning in the first quarter of 2023. Assets are categorized and evaluated for impairment at the lowest level of identifiable cash flows. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use and fungibility of the assets. If the carrying value of an asset grouping is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired. Identified Intangible Assets We amortize acquisition-related intangible assets that are subject to amortization over their estimated useful lives. We perform periodic reviews of significant finite-lived identified intangible assets to determine whether facts and circumstances indicate that the carrying amount may not be recoverable. These reviews can be affected by various factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines. Periodically, we also evaluate the estimated remaining useful lives of purchased intangible assets and whether events or changes in circumstances warrant a revision to the remaining periods of amortization. We may adjust the period over which these assets are amortized to reflect the period over which they are expected to contribute to our cash flows. Goodwill Our reporting units substantially align with our operating segments. We reevaluate our identified reporting units annually or when triggered, such as upon reorganization of our operating segments. We perform an annual impairment assessment of goodwill at the reporting unit level in the fourth quarter of each year, or more frequently if indicators of potential impairment exist. The reporting unit's carrying value used in an impairment assessment represents the assignment of various assets and liabilities, excluding certain corporate assets and liabilities, such as cash, investments, and debt. The impairment assessment may include both qualitative and quantitative factors to assess the likelihood of an impairment. Qualitative factors used include industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. We may also perform a quantitative analysis to support the qualitative factors by applying sensitivities to assumptions and inputs used in measuring a reporting unit's fair value. Our quantitative impairment assessment considers both the income approach and the market approach to estimate a reporting unit's fair value. Significant estimates include market segment growth rates, our assumed market segment share, estimated gross margins, operating expenses, and discount rates based on a reporting unit's weighted average cost of capital. We test the reasonableness of the inputs and outcomes of our discounted cash flow analysis against available market data. These estimates change from year to year based on operating results, market conditions, and other factors and could materially affect the determination of the fair value and potential goodwill impairment for each reporting unit. Our quantitative assessment is sensitive to changes in underlying estimates and assumptions, the most sensitive of which is the discount rate. Inventories We compute inventory cost on a first-in, first-out basis. Our process and product development life cycle corresponds with substantive engineering milestones. These engineering milestones are regularly and consistently applied in assessing the point at which our activities and associated costs change in nature from R&D to cost of sales, and when cost of sales can be capitalized as inventory. For a product to be manufactured in high volumes and sold to our customers under our standard warranty, it must meet our rigorous technical quality specifications. We have identified the start of manufacturing volume for sale to customers as the point at which the costs incurred to manufacture our products are included in the valuation of inventory. Prior to the start of manufacturing volume for sale to customers, costs that do not meet the criteria for R&D are included in cost of sales in the period incurred. The valuation of inventory includes determining which fixed production overhead costs can be included in inventory based on the normal capacity of our manufacturing and assembly and test facilities. We apply our historical loading compared to our total available capacity to determine our expectations of normal capacity level. If the factory loading is below the established normal capacity level, a portion of our fixed production overhead costs would not be included in the cost of inventory; instead, it would be recognized as cost of sales in that period. We refer to these costs as excess capacity charges. Excess capacity charges were $174 million in 2024, $834 million in 2023, and $423 million in 2022. Inventory is valued at the lower of cost or net realizable value, based upon assumptions about future demand and market conditions. Product-specific facts and circumstances reviewed in the inventory valuation process include a review of our customer base, the stage of the product life cycle, variations in market pricing, and an assessment of selling price in relation to product cost. Lower of cost or net realizable value inventory reserves fluctuate as we ramp new process technologies, with costs generally improving over time due to scale and improved yields. Additionally, inventory valuation is impacted by cyclical changes in market conditions and the associated pricing environment. Government Incentives Government incentives, including cash grants and refundable tax credits, are recognized when there is reasonable assurance that the incentive will be received and we will comply with the conditions specified in the agreement or statutory requirements. We record capital-related incentives as a reduction to property, plant, and equipment, net within our Consolidated Balance Sheets and recognize a reduction to depreciation expense over the useful life of the corresponding acquired asset. We record operating-related incentives as a reduction to expense in the same line item on the Consolidated Statements of Operations as the expenditure for which the incentive is intended to compensate. Fair Value When determining fair value, we consider the principal or most advantageous market in which we would transact, as well as assumptions that market participants would use when pricing the asset or liability. Our financial assets are measured and recorded at fair value on a recurring basis, except for equity securities measured using the measurement alternative, equity method investments, certain other receivables, and grants receivable. We assess fair value hierarchy levels for our issued debt and fixed-income investment portfolio based on the underlying instrument type. The three levels of inputs that may be used to measure fair value are: ▪ Level 1 . Quoted prices in active markets for identical assets or liabilities. We evaluate security-specific market data when determining whether a market is active. ▪ Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in less active markets, or model-derived valuations. All significant inputs used in our valuations, such as discounted cash flows, are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. We use yield curves, overnight indexed swap curves, currency spot and forward rates, and credit ratings as significant inputs in our valuations. Level 2 inputs also include non-binding market consensus prices, as well as quoted prices that were adjusted for security-specific restrictions. When we use non-binding market consensus prices, we corroborate them with quoted market prices for similar instruments or compare them to output from internally developed pricing models such as discounted cash flow models. ▪ Level 3. Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. We monitor and review the inputs and results of these valuation models to help confirm that the fair value measurements are reasonable and consistent with market experience in similar asset and liability classes. Level 3 inputs also include non-binding market consensus prices, non-binding broker quotes, and probability-weighted outcomes that we are unable to corroborate with observable market data. Equity Investments We regularly invest in equity securities of public and private companies to promote business and strategic objectives. Equity investments are measured and recorded as follows: ▪ Marketable equity investments are equity securities with RDFV that are measured and recorded at fair value on a recurring basis with changes in fair value, whether realized or unrealized, recorded through the income statement. ▪ Non-marketable equity investments are equity securities without RDFV that are measured and recorded using a measurement alternative that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. ▪ Equity method investments are equity securities in investees we do not control but over which we have the ability to exercise significant influence. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss. Realized and unrealized gains and losses resulting from changes in fair value or the sale of our equity investments are recorded in gains (losses) on equity investments, net . The carrying value of our non-marketable equity investments is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities in an orderly transaction by the same issuer. Determining whether an observed transaction is similar to a security within our portfolio requires judgment based on the rights and preferences of the securities. Non-marketable equity investments and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. Our quarterly impairment analysis considers both qualitative and quantitative factors. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments using both the market and income approaches. ▪ Non-marketable equity investments are tested for impairment using a qualitative model similar to the model used for goodwill and property, plant, and equipment. Upon determining that an impairment may exist, the security's fair value is calculated and compared to its carrying value, and an impairment is recognized immediately if the carrying value exceeds the fair value. ▪ Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery. Impairments of non-marketable equity investments are recorded in gains (losses) on equity investments, net . Derivative Financial Instruments Our primary objective for holding derivative financial instruments is to manage currency exchange rate risk and interest rate risk, and, to a lesser extent, equity market risk, commodity price risk, and credit risk. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. We also enter into collateral security arrangements with certain of our counterparties to exchange cash collateral when the net fair value of certain derivative instruments fluctuates from contractually established thresholds. For presentation on our Consolidated Balance Sheets, we do not offset fair value amounts recognized for derivative instruments under master netting arrangements. Our derivative financial instruments, including related collateral amounts, are presented at fair value on a gross basis and are included in other current assets , other long-term assets , other accrued liabilities , or other long-term liabilities . Cash flow hedges use foreign currency contracts, such as currency forwards and currency swaps, to hedge exposures for variability in the US-dollar equivalent of non-US-dollar-denominated cash flows associated with our forecasted operating and capital purchases spending. The after-tax gains or losses from the effective portion of a cash flow hedge are reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings in the same period or periods in which the hedged transaction affects earnings, and in the same line item on the Consolidated Statements of Operations as the impact of the hedge transaction. For foreign currency contracts hedging our capital purchases, forward points are excluded from the hedge effectiveness assessment, and are recognized in earnings in the same income statement line item used to present the earnings effect of the hedged item. If the cash flow hedge transactions become improbable, the corresponding amounts deferred in accumulated other comprehensive income (loss) would be immediately reclassified to interest and other, net . Cash flows associated with these derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item. Fair value hedges use interest rate contracts, such as interest rate swaps, to hedge against changes in the fair value on certain of our fixed-rate indebtedness attributable to changes in the benchmark interest rate. The gains or losses on these hedges, as well as the offsetting losses or gains related to the changes in the fair value of the underlying hedged item attributable to the hedged risk, are recognized in earnings in the current period, primarily in interest and other, net . Cash flows associated with these derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item, primarily within net cash provided by (used for) financing activities . Non-designated hedges use foreign currency contracts to economically hedge the functional currency equivalent cash flows of recognized monetary assets and liabilities, and non-US-dollar-denominated debt instruments classified as hedged investments. We also use interest rate contracts to hedge interest rate risk related to our US-dollar-denominated fixed-rate debt investments classified as hedged investments. The change in fair value of non-designated derivatives is recorded through earnings in the line item on the Consolidated Statements of Operations to which the derivatives most closely relate, primarily in interest and other, net Debt Investments Debt investments include investments in corporate debt, government debt, and financial institution instruments. Unhedged debt investments with original maturities of approximately three months or less from the date of purchase are classified within cash and cash equivalents . Unhedged debt investments with original maturities at the date of purchase greater than approximately three months and all economically hedged debt investments are classified as short-term investments , as they represent the investment of cash available for current operations. For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument, or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value. Gains or losses on these investments arising from changes in fair value due to interest rate and currency market fluctuations and credit market volatility, largely offset by losses or gains on the related derivative instruments and balance sheet remeasurement, are recorded in interest and other, net . Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) . We determine the cost of the investment sold at the individual security level and record the interest income and realized gains or losses on the sale of these investments in interest and other, net . Unhedged debt investments are subject to periodic impairment reviews. For investments in an unrealized loss position, we determine whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. We recognize an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and write down the amortized cost basis of the investment if it is more likely than not we will be required or we intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in interest and other, net , and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss) . Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist principally of investments in debt instruments, derivative financial instruments, reverse repurchase agreements, and trade and other receivables. We generally place investments with high-credit-quality counterparties and, by policy, we limit the amount of credit exposure to any one counterparty based on our analysis of that counterparty's relative credit standing. As required per our investment policy, substantially all of our investments in debt instruments are in investment-grade instruments. Credit-rating criteria for derivative instruments are similar to those for other investments. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. Due to master netting arrangements, the amounts subject to credit risk related to derivative instruments are generally limited to the amounts, if any, by which the counterparty's obligations exceed our obligations with that counterparty. As of December 28, 2024, our total credit exposure to any single counterparty, excluding money market funds invested in US treasury and US agency securities and reverse repurchase agreements collateralized by treasury and agency securities, did not exceed $1.4 billion. To further reduce credit risk, we enter into collateral security arrangements with certain of our derivative counterparties and obtain and secure collateral from counterparties against obligations, including securities lending transactions when we deem it appropriate. Cash collateral exchanged under our collateral security arrangements is included in other current assets , other long-term assets , other accrued liabilities , or other long-term liabilities . For reverse repurchase agreements collateralized by other securities, we do not record the collateral as an asset or a liability unless the collateral is repledged. A substantial majority of our trade receivables are derived from sales to OEMs and ODMs. We also have accounts receivable derived from sales to industrial and communications equipment manufacturers in the computing and communications industries. We believe the net accounts receivable balances from our three largest customers (47% as of December 28, 2024) do not represent a significant credit risk, based on cash flow forecasts, balance sheet analysis, and past collection experience. We have adopted credit policies and standards intended to accommodate industry growth and inherent risk. We believe credit risks are moderated by the financial stability of our major customers. We assess credit risk through quantitative and qualitative analysis. From this analysis, we establish shipping and credit limits and determine whether we will seek to use one or more credit support protection devices, such as obtaining a parent guarantee, standby letter of credit, or credit insurance. Variable Interest Entities We have economic interests in entities that are VIEs. If we conclude we are the primary beneficiary of the VIE, we are required to consolidate the entity in our financial statements. To determine if we are the primary beneficiary, we evaluate whether we have the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Our evaluation includes identification of significant activities and an assessment of our ability to direct those activities based on governance provisions and arrangements to provide services to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is a VIE and, if so, whether we are the primary beneficiary. Non-Controlling Interests Our Consolidated Financial Statements include the accounts of majority-owned subsidiaries consolidated under the variable interest and voting interest models. Non-controlling interests represent the portion of equity not attributable to Intel and are reported as a separate component of equity, net of tax and transaction costs, on our Consolidated Balance Sheets. Net income (loss) and comprehensive income (loss) for majority-owned subsidiaries are attributed to Intel and to non-controlling interest holders on our Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income (Loss) based on respective ownership percentages. We account for changes in ownership of our majority-owned subsidiaries as equity transactions when we retain a controlling financial interest. Business Combinations We allocate the purchase price paid for assets acquired and liabilities assumed in connection with our acquisitions based on their estimated fair values at the time of acquisition. This allocation involves a number of assumptions, estimates, and judgments in determining the fair value of the following: ▪ inventory; property, plant, and equipment; pre-existing liabilities or legal claims; and contingent consideration; each as may be applicable; ▪ intangible assets, including the valuation methodology, estimations of future cash flows, discount rates, market segment growth rates, and our assumed market segment share, as well as the estimated useful life of intangible assets; ▪ deferred tax assets and liabilities, uncertain tax positions, and tax-related valuation allowances, which are initially estimated as of the acquisition date; and ▪ goodwill as measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Employee Equity Incentive Plans We use the straight-line amortization method to recognize share-based compensation expense over the service period of the award, net of estimated forfeitures. Upon exercise, cancellation, forfeiture, or expiration of stock options, or upon vesting or forfeiture of RSUs, we eliminate deferred tax assets for options and RSUs with multiple vesting dates for each vesting period on a first-in, first-out basis as if each vesting period were a separate award. For the majority of RSUs granted, the number of shares of common stock issued on the date the RSUs vest is net of the minimum statutory withholding requirements that we pay in cash to the appropriate taxing authorities on behalf of our employees. The obligation to pay the relevant taxing authority is contingent upon continued employment. In addition, the amount of the obligation is unknown, as it is based in part on the market price of our common stock when the awards vest. Income Taxes We compute the provision for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. We measure deferred tax assets and liabilities using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We assess the likelihood that we will be able to recover our deferred tax assets. If recovery is not likely, we must increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. Recovery of a portion of our deferred tax assets is affected by management's plans with respect to holding or disposing of certain investments; therefore, such changes could also affect our future provision for taxes. We recognize tax benefits from uncertain tax positions only if (based on the technical merits of the position) it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for (benefit from) taxes on the Consolidated Statements of Operations. Leases Leases consist of real property and machinery and equipment. Our lease terms may include options to extend or terminate when it is reasonably certain that we will exercise such options. For leases for supplier capacity, we account for the lease and non-lease components as a single lease component. For all other leases, we account for the lease and non-lease components separately and do not include the non-lease components in our leased assets and corresponding liabilities. Payments on leases may be fixed or variable, and variable lease payments are based on output of the underlying leased assets. Loss Contingencies

Operating Segments

Operating Segments	12 Months Ended
	Dec. 28, 2024
Segment Reporting [Abstract]
Operating Segments	Note 3 : Operating Segments We previously announced the implementation of our internal foundry operating model, which took effect in the first quarter of 2024, and creates a foundry relationship between our Intel Products business (collectively CCG, DCAI, and NEX) and our Intel Foundry business. Intel Products consists substantially of design and development of CPUs and related solutions for external customers. Intel Foundry consists substantially of process engineering, manufacturing, and foundry services groups that provide manufacturing, test, and assembly services to our Intel Products business and to external customers. Both businesses utilize marketing, sales, and other support functions. Our internal foundry model is a key component of our strategy and is designed to reshape our operational dynamics and drive greater transparency, accountability, and focus on costs and efficiency. We also previously announced our intent to operate Altera as a standalone business. Altera was previously included in our DCAI segment results and, beginning in the first quarter of 2024, is included in "all other." As a result of these changes, we modified our segment reporting in the first quarter of 2024 to align to this new operating model. All prior period segment data has been retrospectively adjusted to reflect the way our CODMs internally receive information and manage and monitor our operating segment performance. There are no changes to our Consolidated Financial Statements for any prior periods. We organize our business as follows: ▪ Intel Products: ▪ Client Computing Group (CCG) ▪ Data Center and AI (DCAI) ▪ Network and Edge (NEX) ▪ Intel Foundry ▪ All other: ▪ Altera ▪ Mobileye ▪ Other CCG, DCAI, and Intel Foundry qualify as reportable operating segments. NEX, Altera, and Mobileye do not qualify as reportable operating segments; however, we have elected to disclose certain of their results. When we enter into federal contracts, they are aligned to the sponsoring operating segment. The accounting policies applied to our segments follow those applied to Intel as a whole. A summary of the basis for which we report our operating segment revenues and operating margin is as follows: Intel Products: CCG, DCAI, and NEX ▪ Segment revenue: Consists of revenues from external customers. Our Intel Products operating segments represent most of Intel consolidated revenue and are derived from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which are based on Intel architecture. ▪ Segment expenses: Consists of intersegment charges for product manufacturing and related services from Intel Foundry, external foundry and other manufacturing expenses, product development costs, allocated expenses as described below, and direct operating expenses. Intel Foundry ▪ Segment revenue : Consists substantially of intersegment product and services revenue for wafer fabrication, substrates and other related products, and services sold to Intel Products, Altera, and certain other Intel internal businesses. We recognize intersegment revenue based on the completion of performance obligations. Product revenue is recognized upon transfer of ownership, which is generally at the completion of wafer sorting. Backend service revenue is recognized upon the completion of assembly and test milestones, which approximates the recognition of revenue over the service period. Intersegment sales are recorded at prices that are intended to approximate market pricing. Intel Foundry also includes certain third-party foundry and assembly and test revenue from external customers that totaled $385 million in 2024, $953 million in 2023, and $474 million in 2022. ▪ Segment expenses: Consists of direct expenses for technology development, product manufacturing and services provided by Intel Foundry to internal and external customers, allocated expenses as described below, and direct operating expenses. Direct expenses for product manufacturing include excess capacity charges. All Other Our "all other" category includes the results of operations from other non-reportable segments not otherwise presented, including our Altera and Mobileye businesses, start-up businesses that support our initiatives, and historical results of operations from divested businesses. The financial results of our all other category include intersegment product and services revenue and intersegment expenses. We allocate operating expenses from our sales and marketing group to the Intel Products operating segments and allocate operating expenses from our finance and administration groups to all of our operating segments, except Mobileye. We estimate that the substantial majority of our consolidated depreciation expense was incurred by Intel Foundry in 2024, 2023, and 2022. Intel Foundry depreciation expense is substantially included in overhead cost pools and then combined with other costs, and subsequently absorbed into inventory as each product passes through the manufacturing process and is sold to Intel Products or other customers. As a result, it is impracticable to determine the total depreciation expense included as a component of each Intel Products operating segment's operating income (loss). We do not allocate to our operating segments corporate operating expenses that primarily consist of: ▪ restructuring and other charges; ▪ share-based compensation; ▪ certain impairment charges; and ▪ certain acquisition-related adjustments, including amortization and any impairment of acquisition-related intangibles and goodwill. We do not allocate to our operating segments non-operating items such as: ▪ gains and losses from equity investments; ▪ interest and other income; and ▪ income taxes. Our interim Co-Chief Executive Officers are our CODMs. The CODMs primarily use operating income (loss) to evaluate each segment's performance and allocate resources. This measure is utilized during our budgeting and forecasting process to assess profitability and enable decision making regarding strategic initiatives, capital investments, and personnel across all operating segments. While operating income (loss) is the primary measure used by our CODMs to allocate resources, they often review materials that present operating segment gross margin. Accordingly, we have included gross margin as a secondary measure within the accompanying reconciliation of our operating segment and consolidated results. The measures regularly provided to and used by our CODMs under our new operating model continue to evolve; currently, our CODMs do not regularly review or receive discrete asset information by operating segment. Intersegment eliminations: Intersegment sales and related gross margin on inventory recorded at the end of the period or sold through to third-party customers is eliminated for consolidation purposes. The Intel Products operating segments and Intel Foundry are meant to reflect separate fabless semiconductor and foundry companies, respectively. Thus, certain intersegment activity is captured within the intersegment eliminations upon consolidation and presented at the Intel consolidated level. This activity primarily relates to inventory reserves, which are determined and recorded based on our accounting policies for Intel as a whole, but are only recorded by the Intel Products operating segments upon transfer of inventory from Intel Foundry. If a reserve is identified that relates to neither Intel Products operating segments nor Intel Foundry, the reserve is recognized as activity within the intersegment eliminations for Intel on a consolidated basis. Net revenue, cost of sales, gross margin, operating expenses, and operating income (loss) for each period were as follows: (In Millions) Dec 28, 2024 Intel Products CCG DCAI NEX Total Intel Products Intel Foundry All Other Corporate Unallocated Intersegment Eliminations Total Consolidated Revenue $ 30,290 $ 12,817 $ 5,842 $ 48,949 $ 17,543 $ 3,824 $ — $ (17,215) $ 53,101 Cost of sales 14,569 6,792 2,457 23,818 25,596 1,831 1,919 (17,408) 35,756 Gross margin (loss) 15,721 6,025 3,385 25,131 (8,053) 1,993 (1,919) 193 17,345 Operating expenses 4,801 4,687 2,454 11,942 5,355 2,077 9,299 350 29,023 Operating income (loss) $ 10,920 $ 1,338 $ 931 $ 13,189 $ (13,408) $ (84) $ (11,218) $ (157) $ (11,678) (In Millions) Dec 30, 2023 Intel Products CCG DCAI NEX Total Intel Products Intel Foundry All Other Corporate Unallocated Intersegment Eliminations Total Consolidated Revenue $ 29,258 $ 12,635 $ 5,774 $ 47,667 $ 18,910 $ 5,608 $ — $ (17,957) $ 54,228 Cost of sales 14,606 6,420 3,095 24,121 21,471 2,475 2,136 (17,686) 32,517 Gross margin (loss) 14,652 6,215 2,679 23,546 (2,561) 3,133 (2,136) (271) 21,711 Operating expenses 5,139 4,595 2,475 12,209 4,394 2,054 3,029 (68) 21,618 Operating income (loss) $ 9,513 $ 1,620 $ 204 $ 11,337 $ (6,955) $ 1,079 $ (5,165) $ (203) $ 93 (In Millions) Dec 31, 2022 Intel Products CCG DCAI NEX Total Intel Products Intel Foundry All Other Corporate Unallocated Intersegment Eliminations Total Consolidated Revenue $ 31,773 $ 16,856 $ 8,409 $ 57,038 $ 27,491 $ 5,530 $ — $ (27,005) $ 63,054 Cost of sales 16,826 7,081 3,856 27,763 28,052 2,425 2,875 (24,927) 36,188 Gross margin (loss) 14,947 9,775 4,553 29,275 (561) 3,105 (2,875) (2,078) 26,866 Operating expenses 6,740 5,577 3,021 15,338 4,608 1,931 2,758 (103) 24,532 Operating income (loss) $ 8,207 $ 4,198 $ 1,532 $ 13,937 $ (5,169) $ 1,174 $ (5,633) $ (1,975) $ 2,334 Corporate Unallocated Expenses Corporate unallocated expenses include certain operating and non-operating costs not allocated to specific operating segments. The nature of these expenses may vary, but primarily consist of restructuring and other charges, share-based compensation, certain impairment charges, and certain acquisition-related costs. (In Millions) Dec 28, 2024 Cost of Sales Operating Expenses Total Acquisition-related costs $ 879 $ 165 $ 1,044 Share-based compensation 875 2,535 3,410 Restructuring and other charges 1 — 6,970 6,970 Other 165 (371) (206) Total corporate unallocated expenses $ 1,919 $ 9,299 $ 11,218 (In Millions) Dec 30, 2023 Cost of Sales Operating Expenses Total Acquisition-related costs $ 1,235 $ 172 $ 1,407 Share-based compensation 705 2,524 3,229 Restructuring and other charges 1 — (62) (62) Other 196 395 591 Total corporate unallocated expenses $ 2,136 $ 3,029 $ 5,165 (In Millions) Dec 31, 2022 Cost of Sales Operating Expenses Total Acquisition-related costs $ 1,341 $ 185 $ 1,526 Share-based compensation 663 2,465 3,128 Patent settlement 204 — 204 Optane inventory impairment 723 — 723 Restructuring and other charges 1 — 2 2 Other (56) 106 50 Total corporate unallocated expenses $ 2,875 $ 2,758 $ 5,633 1 See "Note 7: Restructuring and Other Charges" within Notes to Consolidated Financial Statements for further information. Concentration of Revenue In 2024, substantially all of the revenue from our three largest customers was from the sale of platforms and other components by our Intel Products operating segments. Our three largest customers accounted for the following percentage of our net revenue: Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Customer A 19 % 19 % 19 % Customer B 14 % 11 % 12 % Customer C 12 % 10 % 11 % Total percentage of net revenue 45 % 40 % 42 % Net revenue by region, based on the billing location of the customer, was as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 China $ 15,532 $ 14,854 $ 17,125 United States 12,994 13,958 16,529 Singapore 10,187 8,602 9,664 Taiwan 7,804 6,867 8,287 Other regions 6,584 9,947 11,449 Total net revenue $ 53,101 $ 54,228 $ 63,054

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 28, 2024
Noncontrolling Interest [Abstract]
Non-Controlling Interests	Note 4 : Non-Controlling Interests Non-Controlling Ownership % Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Ireland SCIP 49 % — % — % Arizona SCIP 49 % 49 % 49 % Mobileye 12 % 12 % 6 % IMS Nanofabrication (IMS Nano) 32 % 32 % — % (In Millions) Ireland SCIP Arizona SCIP Mobileye IMS Nano Total Non-controlling interests as of Dec 30, 2023 $ — $ 2,359 $ 1,838 $ 178 $ 4,375 Partner contributions — 1,702 — — 1,702 Partner distributions (43) — — — (43) Changes in equity of non-controlling interest holders — — 205 — 205 Net income (loss) attributable to non-controlling interests 104 (173) (371) (37) (477) Non-controlling interests as of Dec 28, 2024 $ 61 $ 3,888 $ 1,672 $ 141 $ 5,762 (In Millions) Ireland SCIP Arizona SCIP Mobileye IMS Nano Total Non-controlling interests as of Dec 31, 2022 $ — $ 874 $ 989 $ — $ 1,863 Partner contributions — 1,511 — — 1,511 Changes in equity of non-controlling interest holders — — 848 167 1,015 Net income (loss) attributable to non-controlling interests — (26) 1 11 (14) Non-controlling interests as of Dec 30, 2023 $ — $ 2,359 $ 1,838 $ 178 $ 4,375 Semiconductor Co-Investment Program Ireland SCIP In the second quarter of 2024, we closed a transaction with Apollo Global Management, Inc. (Apollo) involving the sale of 49% of our interest in an Irish limited liability company (Ireland SCIP) for net proceeds of $11.0 billion, which increased our capital in excess of par value. Ireland SCIP is a VIE that we consolidate into our Consolidated Financial Statements because we are the primary beneficiary. Generally, distributions will be received from Ireland SCIP based on both parties' proportional ownership. Ireland SCIP has the rights to operate Fab 34 in Leixlip, Ireland, and has the rights to the related factory output. We have the right to purchase 100% of the related factory output from Ireland SCIP. We will retain sole ownership of Fab 34, will be engaged as the Fab 34 operator in exchange for variable payments from Ireland SCIP based on the related factory output, and will be required to maintain certain performance standards in our capacity as operator. We are required to substantially complete construction of Fab 34 in accordance with contractual parameters and timelines or we will be required to pay delay-related liquidated damages to Apollo beginning in 2026, not to exceed $1.1 billion in total. As of December 28, 2024, we expect certain construction milestones for Fab 34 will be delayed as we refined our near-term production capacity requirements and related capital outlays relative to those that are required per the Ireland SCIP agreement. As a result, in 2024 we recognized a loss of $755 million within Interest and other, net from the change in fair value of the liquidated damage provisions, which qualify as a non-designated derivative. Refer to "Note 16: Derivative Financial Instruments" within Notes to Consolidated Financial Statements for additional information. Though we expect certain construction delays in the near term, we intend to complete construction of Fab 34. We will be required to purchase minimum quantities of the related factory output from Ireland SCIP, or we will be subject to pay certain volume-related damages to Ireland SCIP, beginning at the earlier of when construction is complete or Q3 2027. As of December 28, 2024, other than cash and cash equivalents held by Ireland SCIP, substantially all of the remaining assets and liabilities of Ireland SCIP were eliminated in our Consolidated Financial Statements. Arizona SCIP We consolidate the results of an Arizona limited liability company (Arizona SCIP), a VIE, into our Consolidated Financial Statements because we are the primary beneficiary. Generally, contributions will be made to, and distributions will be received from Arizona SCIP based on Intel's and Brookfield Asset Management's (Brookfield's) proportional ownership. We will be the sole operator and main beneficiary of two new chip factories that will be constructed by Arizona SCIP, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to both operate Arizona SCIP at minimum production levels (measured in wafer starts per week) and limit excess inventory held on site or we will be subject to certain damages. We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona SCIP. The total construction costs were estimated at $29.0 billion when we entered into the definitive agreement with Brookfield in 2022. As of December 28, 2024, substantially all of the assets of Arizona SCIP consisted of property, plant, and equipment. The remaining assets and liabilities of Arizona SCIP were eliminated in our Consolidated Financial Statements. The assets held by Arizona SCIP, which can be used only to settle obligations of the VIE and are not available to us, were $11.5 billion as of December 28, 2024 ($4.8 billion as of December 30, 2023). Mobileye In 2022, Mobileye completed its IPO and certain other equity financing transactions. During 2023, we converted 38.5 million of our Mobileye Class B shares into Class A shares, representing 5% of Mobileye's outstanding capital stock, and subsequently sold the Class A shares for $42 per share as part of a secondary offering, receiving net proceeds of $1.6 billion and increasing our capital in excess of par value by $663 million, net of tax. We continue to consolidate the results of Mobileye into our Consolidated Financial Statements. In the third quarter of 2024, the non-cash impairment of goodwill related to our Mobileye reporting unit was attributed to Intel and to non-controlling interest holders based on our proportional ownership (see "Note 11: Goodwill" within Notes to Consolidated Financial Statements). IMS Nanofabrication

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 28, 2024
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 5 : Earnings (Loss) Per Share We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period, if applicable. Years Ended (In Millions, Except Per Share Amounts) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Net income (loss) $ (19,233) $ 1,675 $ 8,017 Less: net income (loss) attributable to non-controlling interests (477) (14) 3 Net income (loss) attributable to Intel $ (18,756) $ 1,689 $ 8,014 Weighted average shares of common stock outstanding—basic 4,280 4,190 4,108 Dilutive effect of employee equity incentive plans — 22 15 Weighted average shares of common stock outstanding—diluted 4,280 4,212 4,123 Earnings (loss) per share attributable to Intel—basic $ (4.38) $ 0.40 $ 1.95 Earnings (loss) per share attributable to Intel—diluted $ (4.38) $ 0.40 $ 1.94 Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. The potentially dilutive impact from the assumed issuance of common stock associated with a contractual conversion feature is determined by applying the if-converted method to the assumed exercise of the outstanding conversion feature. At December 28, 2024, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, the assumed issuance of common stock under the stock purchase plan, and the assumed issuance of common stock associated with a contractual conversion feature, as applicable, had an anti-dilutive effect on diluted loss per share and were excluded from the computation of diluted loss per share. At December 28, 2024, 114 million anti-dilutive shares (70 million in 2022) were excluded from the computation of diluted earnings (loss) per share. In 2023, securities that would have been anti-dilutive were insignificant.

Other Financial Statement Detai

Other Financial Statement Details	12 Months Ended
	Dec. 28, 2024
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 6 : Other Financial Statement Details Accounts Receivable We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $2.3 billion during 2024, $2.0 billion during 2023, and $665 million during 2022. After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution. Inventories Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Raw materials $ 1,344 $ 1,166 Work in process 7,432 6,203 Finished goods 3,422 3,758 Total inventories $ 12,198 $ 11,127 Property, Plant, and Equipment Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Land and buildings $ 56,544 $ 51,182 Machinery and equipment 103,150 100,033 Construction in progress 50,418 43,442 Total property, plant, and equipment, gross 210,112 194,657 Less: Accumulated depreciation (102,193) (98,010) Total property, plant, and equipment, net $ 107,919 $ 96,647 Our depreciable property, plant, and equipment assets are depreciated over the following estimated useful lives: machinery and equipment, 3 to 8 years; and buildings, 10 to 25 years. We invest in and deploy manufacturing assets in response to manufacturing capacity requirements based upon short- and long-term demand forecasts and economic returns relative to capital outlays. We regularly monitor, evaluate, and adjust our manufacturing capacity footprint in response to a number of volatile factors that impact our business, including demand for our products and services and the state of the semiconductor industry as a whole. In connection with the preparation of our Consolidated Financial Statements for the third quarter of 2024, we evaluated our current process technology node capacities relative to projected market demand for our products and services, and concluded that our manufacturing asset portfolio, primarily for our Intel 7 process node, exceeded manufacturing capacity requirements. Upon performing a re-use assessment, we impaired and accelerated depreciation for certain manufacturing assets. In total, we recorded non-cash impairments and accelerated depreciation charges of $2.3 billion and $992 million, respectively, in 2024, substantially all of which were recognized in cost of sales within our Intel Foundry operating segment. We also incurred certain other non-cash asset impairment charges of $442 million as a direct result of the 2024 Restructuring Plan (see "Note 7: Restructuring and Other Charges" within Notes to Consolidated Financial Statements). These charges were included as a component of "corporate unallocated expenses" within the restructuring and other category presented in "Note 3: Operating Segments" within Notes to Consolidated Financial Statements. We negotiate extended payment terms of greater than 90 days with certain of our capital vendors, which are reported as financing activities in the Consolidated Statements of Cash Flows when paid. Unpaid amounts related to the acquisition of property, plant, and equipment in 2024 under such extended payment terms, included in accounts payable and other accrued liabilitie s, totaled $3.2 billion. Property, plant, and equipment, net, by country at the end of each period was as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 United States $ 72,068 $ 63,234 Ireland 18,152 16,746 Israel 10,414 9,290 Other countries 7,285 7,377 Total property, plant, and equipment, net $ 107,919 $ 96,647 Government Incentives We enter into government incentive arrangements with local, regional, and national governments, both US and non-US. These arrangements vary in size, duration, and conditions and allow us to maintain a market-comparable foothold across various geographies. These incentives are primarily structured as cash grants and refundable tax credits. Capital-related incentives have terms of up to 15 years and operating-related incentives have terms that can vary widely. We are eligible to receive these incentives because we engage in qualifying capital investments, R&D, and other activities as defined by the relevant government entities. These include qualifying capital investments for semiconductor wafer and advanced packaging manufacturing facilities construction and acquisition of equipment. Each incentive requires that we comply with certain conditions for a period that may exceed the incentive terms. These conditions can include achievement of future operational targets and committing to minimum levels of capital investment. If conditions are not satisfied, the incentives may be subject to reduction, recapture, or termination. For example, in November 2024 we entered into a direct funding agreement with the US Department of Commerce under the CHIPS Act that contains detailed milestones we must achieve for us to receive the funds, including the achievement of various milestones with respect to capital expenditures, facility completion, process technology development, wafer production, Intel products insourcing, and external foundry customer acquisitions. It also contains restrictions on certain “change of control” transactions we are permitted to engage in, a requirement that we share with the US government project economic returns above specified thresholds, and various termination rights and remedies if we were to breach the agreement, including potential repayment of some or all of the awards. Capital-related incentives reduced gross property, plant, and equipment cost of sale s ($226 million in 2023, substantially all of which reduced cost of sales and $230 million in 2022, all of which reduced cost of sales . Of our total capital-related government incentives recognized in 2024, $3.3 billion was recognized as a non-cash investing activity ($1.1 billion in 2023 and $128 million in 2022). Related incentives recognized during each period consisted of the following: ▪ US federal government pursuant to the CHIPS Act. In September 2024, we were awarded up to $3.0 billion in direct funding for the Secure Enclave program to expand the trusted manufacturing of leading-edge semiconductors for the US government . In November 2024, we signed a Direct Funding Agreement with the US Department of Commerce for the award of $7.9 billion in government incentives. We recognized $1.3 billion of grants, including $253 million of operating grants, in 2024 under the CHIPS Act. Additionally, we recognized an advanced manufacturing investment tax credit of $2.6 billion in 2024 ($845 million in 2023), which may be refunded to us in cash to the extent it exceeds our outstanding income tax liabilities. ▪ US state governments. We recognized $115 million of grants in 2024 related to modernization and expansion of chip factories in Oregon ($723 million in 2023 related to two new leading-edge chip factories in Ohio). ▪ Non-US governments. We recognized $384 million of grants and refundable tax credits in 2024 ($645 million in 2023), substantially all and a majority of which, respectively, related to the expansion of silicon wafer manufacturing facilities in Ireland. Operating-related incentives, including those recognized under the CHIPS Act, benefited operating income by $442 million in 2024, the substantial majority of which was recorded in cost of sales ($202 million in 2023 and $104 million in 2022, a majority of which was recorded in cost of sales in both periods). T he amounts recorded on the Consolidated Balance Sheets related to grants receivable and capital-related refundable tax credits for each period were as follows: Years Ended (In Millions) Location Dec 28, 2024 Dec 30, 2023 Operating-related grants receivables Other current assets $ 272 $ 17 Other long-term assets $ 186 $ 130 Capital-related grants receivables Other current assets $ 859 $ 64 Other long-term assets $ 374 $ 348 Capital-related refundable tax credits Other current assets $ 2,099 $ — Capital-related refundable tax credits Income taxes payable $ — $ 365 Advertising Interest and Other, Net Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Interest income $ 1,245 $ 1,335 $ 589 Interest expense (1,034) (878) (496) Other, net 15 172 1,073 Total interest and other, net $ 226 $ 629 $ 1,166 Interest expense is net of $1.5 billion of interest capitalized in 2024 ($1.5 billion in 2023 and $785 million in 2022). Other, net in 2024 includes a $755 million loss from the change in fair value of a derivative related to Ireland SCIP and $560 million of interest received and recognized as a benefit in 2024 in relation to the European Commission competition matter that was recorded and paid in 2009 and refunded to us in 2022. Other, net

Restructuring and Other Charges

Restructuring and Other Charges	12 Months Ended
	Dec. 28, 2024
Restructuring Costs and Asset Impairment Charges [Abstract]
Restructuring and Other Charges	Note 7 : Restructuring and Other Charges Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Employee severance and benefit arrangements $ 2,481 $ 222 $ 1,038 Litigation charges and other 858 (329) (1,187) Asset impairment charges 3,631 45 151 Total restructuring and other charges $ 6,970 $ (62) $ 2 In the third quarter of 2024, the 2024 Restructuring Plan was announced, subsequently approved and committed to by our management team, and initiated to implement cost-reduction measures, including reductions in employee headcount, other operating expenditures, and capital expenditures. Restructuring charges are primarily composed of employee severance and benefit arrangements, non-cash charges related to asset impairments associated with exit activities, and charges relating to real estate exits and consolidations. These charges were included as "corporate unallocated expenses" within the restructuring and other category presented in "Note 3: Operating Segments" within Notes to Consolidated Financial Statements. We expect to recognize total charges of approximately $3.0 billion under the 2024 Restructuring Plan. The cumulative cost of the 2024 Restructuring Plan as of December 28, 2024, was $2.8 billion. Any changes to our estimates or timing will be reflected in our results of operations in future periods. We expect actions pursuant to the 2024 Restructuring Plan to be substantially complete by the fourth quarter of 2025, which is subject to change. Employee severance and benefit arrangements includes net charges relating to the 2024 Restructuring Plan of $2.2 billion in 2024. Charges relating to other actions taken to streamline operations and to reduce costs were $294 million in 2024. Charges accrued as of December 28, 2024, were recorded as current liabilities within accrued compensation and benefits on the Consolidated Balance Sheets . Charges in 2023 and 2022 primarily related to the 2022 Restructuring Program, which was approved to rebalance our workforce and operations in alignment with our strategy and was completed in the first quarter of 2024. The cumulative cost of the 2022 Restructuring Program as of December 28, 2024 was $1.3 billion. Restructuring activities related to employee severance and benefit arrangements under the 2024 and 2022 Restructuring Plans were as follows: (In Millions) 2024 Restructuring Plan 2022 Restructuring Program Accrued balance as of December 25, 2021 $ — $ — Accruals and adjustments — 1,038 Cash payments — (165) Accrued balance as of December 31, 2022 — 873 Accruals and adjustments — 222 Cash payments — (1,013) Accrued balance as of December 30, 2023 — 82 Accruals and adjustments 2,306 — Cash payments (2,004) (82) Accrued balance as of December 28, 2024 $ 302 $ — Litigation charges and other includes a charge of $780 million in 2024 arising out of the R2 litigation. In 2023, a $1.2 billion benefit was recorded due to the reduction in the previously accrued charge as a result of developments in the VLSI litigation. 2023 charges also included a $401 million charge for an EC-imposed fine and a $353 million termination fee in connection with our inability to timely obtain required regulatory approvals needed to acquire Tower. In 2009, we recorded and paid an EC-imposed fine that was subsequently annulled, which resulted in a benefit of $1.2 billion in 2022. Refer to "Note 19: Commitments and Contingencies" within Notes to Consolidated Financial Statements for information about litigation related items. Asset impairment charges in 2024 includes non-cash charges associated with the 2024 Restructuring Plan, including $442 million of non-cash impairments of construction-in-progress assets associated with our decision to exit and outsource manufacturing capabilities for certain internal test hardware; and $103 million of non-cash impairments of operating leased assets and related leasehold improvements resulting from real estate consolidations and exits. Real estate consolidations and exits did not significantly change our operating lease liabilities and may result in future cash outlays for facility restoration or the relocation of operations. These impairments were recorded within property, plant, and equipment, net of accumulated depreciation, except for the impairment of operating leased assets of $83 million that were recorded within other long-term assets on the Consolidated Balance Sheets as of December 28, 2024. impairment

Income Taxes

Income Taxes	12 Months Ended
	Dec. 28, 2024
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 8 : Income Taxes Provision for (Benefit From) Taxes Years Ended ($ In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Income (losses) before taxes: US $ (13,450) $ (4,749) $ (1,161) Non-US 2,241 5,511 8,929 Total income before taxes $ (11,210) $ 762 $ 7,768 Provision for (benefit from) taxes: Current: Federal $ 600 $ 538 $ 4,106 State (8) 23 68 Non-US 1,364 535 735 Total current provision for (benefit from) taxes 1,956 1,096 4,909 Deferred: Federal 6,192 (2,048) (5,806) State 67 (21) (40) Non-US (192) 60 688 Total deferred provision for (benefit from) taxes 6,067 (2,009) (5,158) Total provision for (benefit from) taxes $ 8,023 $ (913) $ (249) Effective tax rate 71.6 % (119.8) % (3.2) % The difference between the tax provision (benefit) at the statutory federal income tax rate and the tax provision as a percentage of income before income taxes (effective tax rate) for each period was as follows: Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Expected provision (benefit) at statutory federal income tax rate (21.0) % 21.0 % 21.0 % Increase (reduction) in rate resulting from: Federal valuation allowance 93.2 — — Goodwill impairment 2.1 — — Share-based compensation 4.2 34.3 3.0 Unrecognized tax benefits and settlements 1.3 16.3 4.5 Non-US income taxed at different rates (5.3) (60.6) (13.4) Research and development tax credits (5.6) (99.0) (11.4) Foreign derived intangible income benefit — (25.1) (9.7) Restructuring of certain non-US subsidiaries — (15.8) (2.2) Non-deductibility of European Commission fine — 11.1 (4.1) Other 2.7 (2.0) 9.1 Effective tax rate 71.6 % (119.8) % (3.2) % Our effective tax rate increased in 2024 compared to 2023, primarily driven by the effects associated with the establishment of a valuation allowance against our US federal deferred tax assets in 2024. We assess the recoverability of our deferred tax assets quarterly, weighing available positive and negative evidence. As a result of our assessment in the third quarter of 2024, we determined it was more likely than not that the deferred tax assets will not be recoverable based upon our three-year cumulative historical loss position as of the third quarter of 2024, largely resulting from the asset impairment and restructuring and other charges incurred during 2024. Additionally, our 2024 provision for taxes and 2023 benefit from taxes included R&D tax credits, which provide a tax benefit based on our eligible R&D spending and are not dependent on lower income before taxes. Our effective tax rate decreased in 2023 compared to 2022, primarily driven by our R&D tax credits and a higher proportion of our income being taxed in non-US jurisdictions. We derive the effective tax rate benefit, or detriment, attributed to non-US income taxed at different rates primarily from our operations in Hong Kong, Ireland, Israel, and Malaysia. The statutory tax rates in these jurisdictions range from 12.5% to 24.0%. We are subject to reduced tax rates in Israel and Malaysia as long as we conduct certain eligible activities and make certain capital investments. We have conditional reduced tax rates that expire at various dates through 2056, and we expect to apply for renewals upon expiration, if available. In 2024 the tax benefit specifically attributable to tax holidays was $67 million ($129 million in 2023 and $220 million in 2022) with a $0.02 impact on diluted earnings per share ($0.03 in 2023 and $0.05 in 2022). Deferred and Current Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and liabilities at the end of each period were as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Deferred tax assets: R&D expenditures capitalization $ 10,709 $ 7,726 State credits and net operating losses 2,830 2,624 Inventory 1,054 1,430 Accrued compensation and other benefits 970 931 Share-based compensation 444 586 Litigation charge 447 308 Other, net 1,510 926 Gross deferred tax assets 17,964 14,531 Valuation allowance (13,974) (3,047) Total deferred tax assets 3,990 11,484 Deferred tax liabilities: Property, plant, and equipment (4,063) (5,156) Licenses and intangibles (159) (494) Unrealized gains on investments and derivatives (224) (358) Other, net (403) (203) Total deferred tax liabilities (4,849) (6,211) Net deferred tax assets (liabilities) $ (859) $ 5,273 Reported as: Deferred tax assets 603 5,459 Deferred tax liabilities (1,462) (186) Net deferred tax assets (liabilities) $ (859) $ 5,273 Changes in the valuation allowance for deferred tax assets were as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Valuation allowance for deferred tax assets: Balance at Beginning of Year $ 3,047 $ 2,586 Additions Charged to Expenses/Other Accounts 10,927 461 (Deductions) Recoveries, Net — — Balance at End of Year $ 13,974 $ 3,047 Deferred tax assets are included within other long-term assets on the Consolidated Balance Sheets. The $10.9 billion change in valuation allowance from December 30, 2023 to December 28, 2024 is largely attributable to the uncertainty regarding the realizability of the US deferred tax assets. As of December 28, 2024, our federal and non-US net operating loss carryforwards for income tax purposes were $279 million and $2.7 billion, respectively. The majority of the federal and non-US net operating loss carryforwards have no expiration date. The remaining federal and non-US net operating loss carryforwards expire at various dates through 2040. As of December 28, 2024, we have undistributed earnings of certain foreign subsidiaries of approximately $21.0 billion that we have indefinitely invested, and on which we have not recognized deferred taxes. Estimating the amount of potential tax is not practicable because of the complexity and variety of assumptions necessary to compute the tax. Current income taxes receivable of $2.6 billion as of December 28, 2024 ($59 million as of December 30, 2023) are included in other current assets . Long-term income taxes payable of $1.6 billion as of December 28, 2024 ($2.6 billion as of December 30, 2023) are primarily composed of the transition tax from Tax Reform, which is payable over eight years beginning in 2018, as well as amounts for uncertain tax positions, reduced by the associated deduction for state taxes and non-US tax credits. Uncertain Tax Positions Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Beginning gross unrecognized tax benefits $ 1,124 $ 1,229 $ 1,020 Settlements and effective settlements with tax authorities (59) (288) (18) Changes in balances related to tax position taken during prior periods (8) — (120) Changes in balances related to tax position taken during current period 73 183 347 Ending gross unrecognized tax benefits $ 1,130 $ 1,124 $ 1,229 If the remaining balance of unrecognized tax benefits were recognized in a future period, it would result in a tax benefit of $946 million as of December 28, 2024 ($962 million as of December 30, 2023) and a reduction in the effective tax rate. Interest, penalties, and accrued interest related to unrecognized tax benefits were insignificant in the periods presented. We regularly engage in discussions and negotiations with tax authorities regarding tax matters in the various jurisdictions in which we conduct business. Although the timing of the resolutions and/or closures of audits is highly uncertain, it is reasonably possible that certain US federal and non-US tax audits may be concluded within the next 12 months, which could increase or decrease the balance of our gross unrecognized tax benefits. We estimate that the unrecognized tax benefits as of December 28, 2024, could decrease by as much as $314 million in the next 12 months. We file federal, state, and non-US tax returns. We are no longer subject to US federal and non-US tax examinations for years prior to 2018 and 2015, respectively. For US state tax returns, we are no longer subject to tax examination for years prior to 2015.

Investments

Investments	12 Months Ended
	Dec. 28, 2024
Investments [Abstract]
Investments	Note 9 : Investments Short-term Investments Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within cash and cash equivalents and short-term investments on the Consolidated Balance Sheets. Government debt includes instruments such as non-US government bills and bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of December 28, 2024 and December 30, 2023, substantially all time deposits were issued by institutions outside the US. The fair value of our economically hedged marketable debt investments was $13.5 billion as of December 28, 2024 ($17.1 billion as of December 30, 2023). For hedged investments still held at the reporting date, we recorded net losses of $464 million in 2024 (net gains of $534 million in 2023 and net losses of $748 million in 2022). Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) . The adjusted cost of our unhedged investments was $5.2 billion as of December 28, 2024 ($4.7 billion as of December 30, 2023), which approximated the fair value for these periods. The fair value of marketable debt investments, by contractual maturity, as of December 28, 2024, was as follows: (In Millions) Fair Value Due in 1 year or less $ 5,690 Due in 1–2 years 2,321 Due in 2–5 years 6,182 Due after 5 years 168 Instruments not due at a single maturity date 1 4,316 Total $ 18,677 1 Instruments not due at a single maturity date is composed of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents. Equity Investments Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Marketable equity investments 1 $ 848 $ 1,194 Non-marketable equity investments 4,535 4,635 Total $ 5,383 $ 5,829 1 Most of our marketable equity investments are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading-volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange. The components of gains (losses) on equity investments, net for each period were as follows: Years Ended (in Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Unrealized gains (losses) on marketable equity investments $ (218) $ (99) $ (829) Unrealized gains (losses) on non-marketable equity investments 1 92 17 299 Impairment charges (347) (214) (190) Unrealized gains (losses) on equity investments, net (473) (296) (720) Realized gains (losses) on sales of equity investments, net $ 715 $ 336 $ 4,988 Gains (losses) on equity investments, net $ 242 $ 40 $ 4,268 1 Unrealized gains (losses) on non-marketable investments includes observable price adjustments and our share of equity method investee gains (losses) and certain distributions. As of December 28, 2024, the cumulative amount of impairments for equity investments without readily determinable fair value was $1.4 billion ($1.1 billion as of December 30, 2023) and upward observable price adjustments were $1.4 billion ($1.4 billion as of December 30, 2023). McAfee Corp. During 2022, the sale of McAfee's consumer business was completed and we received $4.6 billion in cash for the sale of our remaining share of McAfee, recognizing a $4.6 billion gain in

Divestitures

Divestitures	12 Months Ended
	Dec. 28, 2024
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Note 10 : Divestitures NAND Memory Business We sold our NAND memory technology and manufacturing business (the NAND OpCo Business) to SK hynix Inc. (SK hynix), which we deconsolidated upon closing the first phase of the transaction on December 29, 2021. We have a receivable within other current assets for the transaction's remaining proceeds of $2.0 billion, which remains outstanding as of December 28, 2024 and will be received upon the second closing of the transaction, expected to be in March 2025. In connection with the transaction, we have a wafer manufacturing and sale agreement that includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to $500 million annually, and $1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics. We were reimbursed for costs that we incurred on behalf of the NAND OpCo Business for corporate function services, which include human resources, information technology, finance, supply chain, and other compliance requirements. We recorded a receivable due from the NAND OpCo Business, a deconsolidated entity, of $98 million within other current assets as of December 28, 2024 ($145 million recorded as of December 30, 2023).

Goodwill

Goodwill	12 Months Ended
	Dec. 28, 2024
Business Combination, Goodwill [Abstract]
Goodwill [Text Block]	Note 11 : Goodwill (In Millions) Dec 30, 2023 Acquisitions Transfers Impairments Dec 28, 2024 Client Computing $ 4,749 $ — $ (130) $ — $ 4,619 Data Center and AI 8,721 — (777) — 7,944 Network and Edge 2,809 — (29) — 2,780 Intel Foundry — — 222 (222) — Mobileye 10,919 — — (2,613) 8,306 Altera — — 781 — 781 All Other 393 86 (67) (149) 263 Total $ 27,591 $ 86 $ — $ (2,984) $ 24,693 (In Millions) Dec 31, 2022 Acquisitions Transfers Other Dec 30, 2023 Client Computing $ 4,254 $ — $ 495 $ — $ 4,749 Data Center and AI 9,013 — (292) — 8,721 Network and Edge 2,809 — — — 2,809 Mobileye 10,919 — — — 10,919 Accelerated Computing Systems and Graphics 596 — (596) — — All other — — 393 — 393 Total $ 27,591 $ — $ — $ — $ 27,591 Our quarterly qualitative impairment assessment for the third quarter of 2024 indicated that a more detailed quantitative analysis was necessary for certain of our reporting units, primarily due to the decline in our market capitalization below the carrying value of our net assets, as well as the decline in our Mobileye reporting unit's market capitalization below the carrying value of Mobileye's net assets. Our quantitative assessment was performed by measuring each reporting unit's fair value using the income approach, the market approach, or a combination of both. When using the income approach, we tested the reasonableness of the inputs and outcomes of our discounted cash flow analysis against available market data. As a result of our impairment tests, we recognized a non-cash goodwill impairment charge of $2.8 billion in the third quarter of 2024 within restructuring and other , most of which related to our Mobileye reporting unit, as the estimated fair value of the reporting unit was lower than the assigned carrying value. The process of valuing each reporting unit is inherently subjective as valuation models require the application of significant estimates and the use of unobservable inputs, including market segment share, projected financial information, and discount rates. No impairment was required for our other reporting units, even when considering a hypothetical increase in the discount rate of 1%, which would cause a significant decrease in the estimated fair value of the respective non-impaired reporting units. Finally, to corroborate our estimated fair value, we performed a market capitalization reconciliation as of September 28, 2024, concluding that the implied control premium was reasonable. The accumulated impairment loss as of December 28, 2024 was $3.9 billion: $2.6 billion associated with Mobileye, $364 million associated with CCG, $275 million associated with DCAI, $79 million associated with NEX, and the remainder associated with other reporting units. In the first quarter of 2024, as a result of modifying our segment reporting, we reallocated goodwill among our affected reporting units on a relative fair value basis. We performed a quantitative goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization. We concluded, based on our pre-reorganization impairment test, that goodwill was not impaired. As a result of our post-reorganization impairment test, we recognized a non-cash goodwill impairment loss of $222 million within restructuring and other in the first quarter of 2024 related to our Intel Foundry reporting unit, as the estimated fair value of the new reporting unit was lower than the assigned carrying value, which includes substantially all of our allocated property, plant, and equipment. The Intel Foundry reporting unit has no remaining goodwill. At the conclusion of our impairment assessment performed during the first quarter of 2024, the fair value substantially exceeded the carrying value for all remaining reporting units.

Identified Intangible Assets

Identified Intangible Assets	12 Months Ended
	Dec. 28, 2024
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Identified Intangible Assets [Text Block]	Note 12 : Identified Intangible Assets December 28, 2024 December 30, 2023 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 8,007 $ (6,445) $ 1,562 $ 10,520 $ (7,996) $ 2,524 Customer relationships and brands 1,907 (1,372) 535 1,986 (1,286) 700 Licensed technology and patents 3,387 (1,852) 1,535 3,088 (1,728) 1,360 Internal-use software 128 (73) 55 — — — Other non-amortizing intangibles 4 — 4 5 — 5 Total identified intangible assets $ 13,433 $ (9,742) $ 3,691 $ 15,599 $ (11,010) $ 4,589 During 2024 and 2023, we entered into and/or renewed several licensed technology arrangements totaling $562 million and $309 million respectively, which are subject to amortization. Amortization expenses recorded for and the weighted average useful life assigned to identified intangible assets in the Consolidated Statements of Operations for each period were as follows: Years Ended (In Millions) Location Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Weighted Average Useful Life 1 Developed technology Cost of sales $ 879 $ 1,235 $ 1,341 9 years Customer relationships and brands Marketing, general, and administrative 165 172 185 12 years Licensed technology and patents Cost of sales 360 348 381 12 years Internal-use software Marketing, general, and administrative 24 — — 5 years Total amortization expenses $ 1,428 $ 1,755 $ 1,907 1 Represents weighted average useful life in years of intangible assets as of December 28, 2024. We expect future amortization expense for the next five years and thereafter to be as follows: (In Millions) 2025 2026 2027 2028 2029 Thereafter Total Future amortization expenses $ 998 $ 858 $ 655 $ 431 $ 252 $ 493 $ 3,687

Borrowings

Borrowings	12 Months Ended
	Dec. 30, 2023
Debt Disclosure [Abstract]
Borrowings [Text Block]	Note 13 : Borrowings Short-Term Debt Short-term debt, which primarily includes the current portion of long-term debt, was $3.7 billion as of December 28, 2024, and $2.3 billion as of December 30, 2023. The current portion of long-term debt includes debt classified as short-term based on time remaining until maturity. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. As of December 28, 2024 and December 30, 2023, we had no commercial paper outstanding. Long-Term Debt Dec 28, 2024 Dec 30, 2023 ($ In Millions) Effective Interest Rate Amount Amount Fixed-rate senior notes: 2.88%, due May 2024 —% $ — $ 1,250 2.70%, due June 2024 —% — 600 3.40%, due March 2025 3.44% 1,500 1,500 3.70%, due July 2025 7.49% 2,250 2,250 4.88%, due February 2026 4.93% 1,500 1,500 2.60%, due May 2026 5.97% 1,000 1,000 3.75%, due March 2027 3.78% 1,000 1,000 3.15%, due May 2027 6.54% 1,000 1,000 3.75%, due August 2027 3.81% 1,250 1,250 4.88%, due February 2028 4.92% 1,750 1,750 1.60%, due August 2028 1.67% 1,000 1,000 4.00%, due August 2029 4.05% 850 850 2.45%, due November 2029 2.38% 2,000 2,000 5.13%, due February 2030 5.14% 1,250 1,250 3.90%, due March 2030 3.91% 1,500 1,500 5.00%, due February 2031 4.99% 500 — 2.00%, due August 2031 2.02% 1,250 1,250 4.15%, due August 2032 4.17% 1,250 1,250 4.00%, due December 2032 6.59% 750 750 5.20%, due February 2033 5.23% 2,250 2,250 5.15%, due February 2034 5.20% 900 — 4.60%, due March 2040 4.59% 750 750 2.80%, due August 2041 2.81% 750 750 4.80%, due October 2041 7.33% 802 802 4.25%, due December 2042 6.70% 567 567 5.63%, due February 2043 5.61% 1,000 1,000 4.90%, due July 2045 7.46% 772 772 4.10%, due May 2046 6.74% 1,250 1,250 4.10%, due May 2047 6.70% 1,000 1,000 4.10%, due August 2047 6.27% 640 640 3.73%, due December 2047 7.11% 1,967 1,967 3.25%, due November 2049 3.19% 2,000 2,000 4.75%, due March 2050 4.73% 2,250 2,250 3.05%, due August 2051 3.05% 1,250 1,250 4.90%, due August 2052 4.89% 1,750 1,750 5.70%, due February 2053 5.68% 2,000 2,000 5.60%, due February 2054 5.61% 1,150 — 3.10%, due February 2060 3.10% 1,000 1,000 4.95%, due March 2060 4.98% 1,000 1,000 3.20%, due August 2061 3.20% 750 750 5.05%, due August 2062 5.03% 900 900 5.90%, due February 2063 5.88% 1,250 1,250 Dec 28, 2024 Dec 30, 2023 ($ In Millions) Effective Interest Rate Amount Amount Oregon and Arizona bonds 1 : 3.80% - 4.10%, due December 2035 - 2040 3.87% 423 423 5.00%, due September 2042 3.63% 131 131 5.00%, due June 2049 —% — 438 4.00%, due June 2049 3.99% 438 — 5.00%, due September 2052 4.24% 445 445 Total senior notes and other borrowings 50,985 50,285 Unamortized premium/discount, issuance costs and other (392) (445) Hedge accounting fair value adjustments (582) (574) Long-term debt 50,011 49,266 Current portion of long-term debt 2 (3,729) (2,288) Total long-term debt $ 46,282 $ 46,978 1 These bonds may be remarketed or tendered on a periodic basis and will be classified within the current portion of long-term debt in the 12 months before remarketing or tendering. 2 As of December 28, 2024, current portion of long-term debt includes $36M of hedge accounting fair value adjustments ($0 as of December 30, 2023) Senior Notes In 2024, we issued a total of $2.6 billion aggregate principal amount of senior notes, and settled in cash $1.9 billion of our senior notes that matured in May 2024 and June 2024. In 2023, we issued a total of $11.0 billion aggregate principal amount of senior notes. Our fixed-rate senior notes pay interest semiannually. We may redeem the fixed-rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under the notes rank equally in right of payment with all of our other existing and future senior unsecured indebtedness and will effectively rank junior to all liabilities of our subsidiaries. Oregon and Arizona Bonds In 2024, we remarketed $438 million aggregate principal amount of bonds issued by the Industrial Development Authority of the City of Chandler, Arizona. In accordance with loan agreements we entered into with the Industrial Development Authority of the City of Chandler, Arizona, the bonds are unsecured general obligations. The bonds mature in 2049 and have a 4.0% coupon. The bonds are subject to optional tender starting in February 2029 and mandatory tender in June 2029, at which time we may remarket the bonds for a new term period. In 2023, we remarketed $423 million aggregate principal amount of bonds issued by the Industrial Development Authority of the City of Chandler, Arizona (the Arizona bonds) and the State of Oregon Business Development Commission (the Oregon bonds). The bonds are unsecured general obligations in accordance with loan agreements we entered into with each of the Industrial Development Authority of the City of Chandler, Arizona (CIDA) and the State of Oregon Business Development Commission. The bonds mature in 2035 and 2040 and have 3.8% and 4.1% coupons. Both the Arizona and Oregon bonds are subject to optional tender starting in February 2028 and mandatory tender in June 2028, at which time we may remarket the bonds for a new term period. Revolving Credit Facilities In 2024, we expanded both our 5-year $5.0 billion revolving credit facility agreement and our 364-day $5.0 billion credit facility agreement, to $7.0 billion and $8.0 billion, respectively, and the maturity dates were extended by one year to February 2029 and January 2025, respectively. These credit facilities are unsecured general obligations. The revolving credit facilities had no borrowings outstanding as of December 28, 2024 and December 30, 2023. In January 2025, we amended our 364-day $8.0 billion credit facility agreement to $5.0 billion, and the maturity date was extended by one year to January 2026. Debt Maturities Our aggregate debt maturities, based on outstanding principal as of December 28, 2024, by year payable, are as follows: (In Millions) 2025 2026 2027 2028 2029 2030 and thereafter Total $ 3,750 $ 2,500 $ 3,826 $ 3,173 $ 3,288 $ 34,448 $ 50,985

Fair Value

Fair Value	12 Months Ended
	Dec. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value [Text Block]	Note 14 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis December 28, 2024 December 30, 2023 Fair Value Measurements Total Fair Value Measurements Total (In Millions) Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Assets Cash equivalents: Corporate debt $ — $ — $ — $ — $ — $ 769 $ — $ 769 Financial institution instruments 1 4,121 743 — 4,864 2,241 835 — 3,076 Reverse repurchase agreements — 2,654 — 2,654 — 2,554 — 2,554 Short-term investments: Corporate debt — 5,365 — 5,365 — 6,951 — 6,951 Financial institution instruments 1 195 3,356 — 3,551 33 4,215 — 4,248 Government debt 2 33 4,864 — 4,897 — 6,756 — 6,756 Other current assets: Derivative assets 348 733 — 1,081 366 809 — 1,175 Marketable equity securities 848 — — 848 1,194 — — 1,194 Other long-term assets: Derivative assets — 1 — 1 — 21 — 21 Total assets measured and recorded at fair value $ 5,545 $ 17,716 $ — $ 23,261 $ 3,834 $ 22,910 $ — $ 26,744 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 562 $ 134 $ 696 $ — $ 541 $ 99 $ 640 Other long-term liabilities: Derivative liabilities 3 — 416 755 1,171 — 479 — 479 Total liabilities measured and recorded at fair value $ — $ 978 $ 889 $ 1,867 $ — $ 1,020 $ 99 $ 1,119 1. Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, commercial paper, time deposits, notes, and bonds issued by financial institutions 2. Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt 3. Level 3 derivative liabilities include liquidated damage provisions related to our Ireland SCIP arrangement Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity investments, equity method investments, and certain non-financial assets—such as intangible assets, goodwill, and property, plant, and equipment—are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity investments during the period, we classify these assets as Level 3. Similarly, impairments recognized on our goodwill, intangible assets, and property, plant, and equipment are categorized as Level 3 within the fair value hierarchy, as we utilize unobservable inputs such as prospective financial information, market segment growth rates, and discount rates in the fair value measurement process. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity investments and equity method investments that have not been remeasured or impaired in the current period, grants receivable, certain other receivables, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial assets approximates their carrying value. The aggregate carrying value of grants receivable as of December 28, 2024 was $1.7 billion (the aggregate carrying value of grants receivable as of December 30, 2023 was $559 million).

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 28, 2024
Equity [Abstract]
Other Comprehensive Income (Loss) [Text Block]	Note 15 : Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) by component and related tax effects for each period were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 25, 2021 $ 211 $ (1,114) $ 23 $ (880) Other comprehensive income (loss) before reclassifications (910) 923 (28) (15) Amounts reclassified out of accumulated other comprehensive (income) loss 410 82 (6) 486 Tax effects (10) (150) 7 (153) Other comprehensive income (loss) (510) 855 (27) 318 Balance as of December 31, 2022 (299) (259) (4) (562) Other comprehensive income (loss) before reclassifications 3 57 11 71 Amounts reclassified out of accumulated other comprehensive (income) loss 328 33 — 361 Tax effects (59) (24) (2) (85) Other comprehensive income (loss) 272 66 9 347 Balance as of December 30, 2023 (27) (193) 5 (215) Other comprehensive income (loss) before reclassifications (652) 54 (4) (602) Amounts reclassified out of accumulated other comprehensive (income) loss 96 11 2 109 Tax effects 1 (5) 1 (3) Other comprehensive income (loss) (555) 60 (1) (496) Balance as of December 28, 2024 $ (582) $ (133) $ 4 $ (711)

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments [Text Block]	Note 16 : Derivative Financial Instruments Volume of Derivative Activity The total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Foreign currency contracts $ 25,472 $ 30,064 $ 31,603 Interest rate contracts 17,899 18,363 16,011 Other 2,593 2,103 2,094 Total $ 45,964 $ 50,530 $ 49,708 The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of December 28, 2024 and as of December 30, 2023. Fair Value of Derivative Instruments in the Consolidated Balance Sheets December 28, 2024 December 30, 2023 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 40 $ 405 $ 255 $ 142 Interest rate contracts — 582 — 578 Total derivatives designated as hedging instruments 40 987 255 720 Derivatives not designated as hedging instruments: Foreign currency contracts 3 510 100 314 363 Interest rate contracts 184 25 261 36 Equity contracts 348 — 366 — Other 4 — 755 — — Total derivatives not designated as hedging instruments 1,042 880 941 399 Total derivatives $ 1,082 $ 1,867 $ 1,196 $ 1,119 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. 4 Embedded derivative related to our Ireland SCIP arrangement. Amounts Offset in the Consolidated Balance Sheets Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: December 28, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 948 $ — $ 948 $ (269) $ (679) $ — Reverse repurchase agreements 2,654 — 2,654 — (2,654) — Total assets $ 3,602 $ — $ 3,602 $ (269) $ (3,333) $ — Liabilities: Derivative liabilities subject to master netting arrangements 1,084 — 1,084 (269) (745) 70 Total liabilities $ 1,084 $ — $ 1,084 $ (269) $ (745) $ 70 December 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements 1,111 — 1,111 (617) (399) 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to the effective portion of cash flow hedges recognized in other comprehensive income (loss) were $652 million net losses in 2024 ($3 million net gains in 2023 and $910 million net losses in 2022). Substantially all of our cash flow hedges are foreign currency contracts for all periods presented. Amounts excluded from effectiveness testing were $205 million net losses in 2024 ($221 million net losses in 2023 and $117 million net losses in 2022). For information on the unrealized holding gains (losses) on derivatives reclassified out of accumulated other comprehensive income (loss) into the Consolidated Statements of Operations, see "Note 15: Other Comprehensive Income (Loss)" within Notes to Consolidated Financial Statements. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Statements of Operations Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Interest rate contracts $ (4) $ 198 $ (1,551) Hedged items 4 (198) 1,551 Total $ — $ — $ — The amounts recorded on the Consolidated Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Items in the Consolidated Balance Sheets in Which the Hedged Item Is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 28, 2024 Dec 30, 2023 Long-term debt $ (9,201) $ (11,419) $ 546 $ 578 Short-term debt (2,214) — 36 — Total $ (11,415) $ (11,419) $ 582 $ 578 Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Statements of Operations for each period were as follows: Years Ended (In Millions) Location of Gains (Losses) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Foreign currency contracts Interest and other, net $ 651 $ 106 $ 1,492 Interest rate contracts Interest and other, net 182 50 309 Other Various (411) 325 (502) Total $ 422 $ 481 $ 1,299 Our Ireland SCIP agreement with Apollo contains construction-related liquidated damage provisions that meet the definition of an embedded derivative that is not clearly and closely related to the relevant host contract, thus requiring bifurcation and separate accounting as a derivative liability. As of December 28, 2024, we assessed the probability of paying damages to Apollo and recognized a loss of $755 million in 2024 within Interest and other, net , and a derivative liability within Other long-term liabilities . We will periodically reassess the probability of paying such liquidated damages and recognize changes in the fair value of the underlying liability through Interest and other, net .

Retirement Benefit Plans

Retirement Benefit Plans	12 Months Ended
	Dec. 28, 2024
Retirement Benefits [Abstract]
Retirement Benefit Plans [Text Block]	Note 17 : Retirement Benefit Plans Defined Contribution Plans We provide tax-qualified defined contribution plans for the benefit of eligible employees, former employees, and retirees in the US and certain other countries. The plans are designed to provide employees with an accumulation of funds for retirement on a tax-deferred basis. For the benefit of eligible US employees, we also provide an unfunded non-tax-qualified supplemental deferred compensation plan for certain highly compensated employees, which had a balance of $3.3 billion as of December 28, 2024 ($2.9 billion as of December 30, 2023), recorded within other accrued liabilities on the Consolidated Balance Sheets. We expensed $541 million in 2024, $272 million in 2023, and $489 million in 2022 for matching contributions based on the amount of employee contributions under the US qualified defined contribution and non-qualified deferred compensation plans. The matching contribution in the US qualified defined contribution plan was increased from January 1 through December 31, 2024 as compared to 2023 and 2022. The matching contribution in the US qualified defined contribution plan was reduced from March 1 through December 30, 2023 as compared to 2022. US Retiree Medical Plan Upon retirement, we provide certain benefits to eligible US employees who were hired prior to 2014 under the US Retiree Medical Plan. The benefits can be used to pay all or a portion of the cost to purchase eligible coverage in a medical plan. As of December 28, 2024 and December 30, 2023, the projected benefit obligations were $493 million and $490 million, which used the discount rates of 5.7% and 5.3%. The December 28, 2024 and December 30, 2023 corresponding fair values of plan assets were $542 million and $548 million. As of December 28, 2024 and December 30, 2023, the US Retiree Medical Plan was in the net asset position. The investment strategy for US Retiree Medical Plan assets is to invest primarily in liquid assets, due to the level of expected future benefit payments. The assets are invested in tax-aware global equity and fixed-income long credit portfolios. Both portfolios are actively managed by external managers. The tax-aware global equity portfolio is composed of a diversified mix of equities in developed countries. The tax-aware fixed-income long credit portfolio is composed of domestic securities. The allocation to each asset class will fluctuate with market conditions, such as volatility and liquidity concerns, and will typically be rebalanced when outside the target ranges, which are 50% equity and 50% fixed-income investments. As of December 28, 2024 and December 30, 2023, the majority of the US Retiree Medical Plan assets were invested in exchange-traded equity securities and were measured at fair value using Level 1 inputs. The remaining US Retiree Medical Plan assets were invested in fixed-income investments and were measured at fair value using Level 2 inputs. As of December 28, 2024, the estimated benefit payments for this plan over the next 10 years are as follows: (In Millions) 2025 2026 2027 2028 2029 2030-2034 Postretirement medical benefits $ 37 $ 45 $ 45 $ 44 $ 44 $ 209 Pension Benefit Plans We provide defined-benefit pension plans in certain countries, most significantly Ireland, the US, Germany, and Israel. The majority of the plans' benefits have been frozen. Benefit Obligation and Plan Assets for Pension Benefit Plans The vested benefit obligation for a defined-benefit pension plan is the actuarial present value of the vested benefits to which the employee is currently entitled based on the employee's expected date of separation or retirement. Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Changes in projected benefit obligation: Beginning projected benefit obligation $ 2,825 $ 2,705 Service cost 33 36 Interest cost 122 127 Actuarial (gain) loss (40) 57 Currency exchange rate changes (107) 38 Plan settlements (143) (103) Other (44) (35) Ending projected benefit obligation 1 2,646 2,825 Changes in fair value of plan assets: Beginning fair value of plan assets 2,212 2,130 Actual return on plan assets 121 151 Currency exchange rate changes (74) 34 Plan settlements (143) (103) Other 26 — Ending fair value of plan assets 2 2,142 2,212 Net unfunded status $ 504 $ 613 Amounts recognized in the Consolidated Balance Sheets Other long-term assets $ 135 $ 62 Other long-term liabilities $ 639 $ 675 Accumulated other comprehensive loss (income), before tax 3 $ 337 $ 410 Accumulated benefit obligation $ 2,509 $ 2,706 1 The projected benefit obligation was approximately 30% in the US and 70% outside of the US as of December 28, 2024 and December 30, 2023. 2 The fair value of plan assets was approximately 40% in the US and 60% outside of the US as of December 28, 2024 and December 30, 2023. 3 The accumulated other comprehensive loss (income), before tax, was approximately 80% in the US and 20% outside of the US as of December 28, 2024 (approximately 70% in the US and 30% outside of the US as of December 30, 2023). Changes in actuarial gains and losses in the projected benefit obligation are generally driven by discount rate movement. We use the corridor approach to amortize actuarial gains and losses. Under this approach, net actuarial gains or losses in excess of 10% of the larger of the projected benefit obligation or the fair value of plan assets are amortized on a straight-line basis over the average remaining service period of active plan participants. As of December 28, 2024, the accumulated benefit obligations were $763 million and $1.7 billion for the US plan and non-US plans, respectively. As of December 30, 2023, the accumulated benefit obligations were $849 million and $1.9 billion for the US plan and non-US plans, respectively. As of December 28, 2024 and December 30, 2023, only non-US plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets. (In Millions) Dec 28, 2024 Dec 30, 2023 Plans with accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 850 $ 1,857 Plan assets $ 348 $ 1,301 Plans with projected benefit obligation in excess of plan assets Projected benefit obligation $ 987 $ 1,976 Plan assets $ 348 $ 1,301 Assumptions for Pension Benefit Plans Years Ended Dec 28, 2024 Dec 30, 2023 Weighted average actuarial assumptions used to determine benefit obligations Discount rate 4.6 % 4.5 % Rate of compensation increase 3.4 % 3.3 % Years Ended 2024 2023 2022 Weighted average actuarial assumptions used to determine costs Discount rate 4.5 % 4.9 % 2.2 % Expected long-term rate of return on plan assets 5.1 % 5.0 % 3.2 % Rate of compensation increase 3.3 % 3.7 % 3.2 % We establish the discount rate for each pension plan by analyzing current market long-term bond rates and matching the bond maturity with the average duration of the pension liabilities. We establish the expected long-term rate of return on plan assets by developing a forward-looking, long-term return assumption for each pension fund asset class, taking into account factors such as the expected real return for the specific asset class and inflation. A single, long-term rate of return is then calculated as the weighted average of the target asset allocation percentages and the long-term return assumption for each asset class. Funding Our practice is to fund the various pension plans in amounts sufficient to meet the minimum requirements of applicable local laws and regulations. On a worldwide basis, our pension and retiree medical plans were 86% funded as of December 28, 2024. Funded status is not indicative of our ability to pay ongoing pension benefits or of our obligation to fund retirement trusts. Net Periodic Benefit Cost The net periodic benefit cost for pension and US retiree medical benefits was $69 million in 2024 ($107 million in 2023 and $139 million in 2022). Pension Plan Assets December 28, 2024 Fair Value Measured at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Equity securities $ — $ 344 $ — $ 344 Fixed income — 142 24 166 Assets measured by fair value hierarchy $ — $ 486 $ 24 $ 510 Assets measured at net asset value 1,618 Cash and cash equivalents 14 Total pension plan assets at fair value $ 2,142 December 30, 2023 Fair Value Measured at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Equity securities $ — $ 383 $ — $ 383 Fixed income — 139 25 164 Assets measured by fair value hierarchy $ — $ 522 $ 25 $ 547 Assets measured at net asset value 1,648 Cash and cash equivalents 17 Total pension plan assets at fair value $ 2,212 US Plan Assets The investment strategy for US Pension Plan assets is to manage the funded status volatility, taking into consideration the investment horizon and expected volatility to help enable sufficient assets to be available to pay pension benefits as they come due. The allocation to each asset class will fluctuate with market conditions, such as volatility and liquidity concerns, and will typically be rebalanced when outside the target ranges, which are 91% fixed income and 9% equity investments. During 2024 and 2023, the US Pension Plan assets were invested in collective investment trust funds, which are measured at net asset value. Non-US Plan Assets The investments of the non-US plans are managed by insurance companies, pension funds, or third-party trustees, consistent with regulations or market practice of the country where the assets are invested. The investment manager makes investment decisions within the guidelines set by Intel or local regulations. Investments managed by qualified insurance companies or pension funds under standard contracts follow local regulations, and we are not actively involved in their investment strategies. For the assets that we have the discretion to set investment guidelines, the assets are invested in developed country equity investments and fixed-income investments, either through index funds or direct investment. In general, the investment strategy is designed to accumulate a diversified portfolio among markets, asset classes, or individual securities to reduce market risk and to help enable sufficient pension assets to be available to pay benefits as they come due. The equity investments in the non-US plan assets are invested in a diversified mix of equities of developed countries, including the US, and emerging markets throughout the world. We have control over the investment strategy related to the majority of the assets measured at net asset value, which are invested in hedge funds, bond index funds, and equity index funds. The target allocation of the non-US plan assets that we have control over was approximately 50% fixed income, 35% equity, and 15% hedge fund investments in 2024. Estimated Future Benefit Payments for Pension Benefit Plans As of December 28, 2024, estimated benefit payments over the next 10 years are as follows: (In Millions) 2025 2026 2027 2028 2029 2030-2034 Pension benefits $ 145 $ 86 $ 95 $ 97 $ 106 $ 623

Employee Equity Incentive Plans

Employee Equity Incentive Plans	12 Months Ended
	Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]
Employee Equity Incentive Plans [Text Block]	Note 18 : Employee Equity Incentive Plans Our equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests. Our plans include our 2006 Plan and our 2006 ESPP. Under the 2006 Plan, 1.1 billion shares of common stock have been authorized for issuance as equity awards to employees and non-employee directors through June 2026. As of December 28, 2024, 171 million shares of common stock remained available for future grants. Under the 2006 Plan, we may grant RSUs and stock options. We grant RSUs with a service condition as well as RSUs with a market condition, performance condition, and a service condition, which we call PSUs. PSUs are granted to a group of senior officers and employees. For PSUs granted in 2024 and 2023, the number of shares of our common stock to be received at vesting at the end of the three-year performance period will range from 0% to 200% of the target grant amount. The PSU payout will be determined based on our performance (i) relative to annual targets for each year in the performance period with respect to a revenue growth metric, weighted 60%, and a cash flow from operations metric, weighted 40%, which results are then averaged at the end of the three-year performance period; and (ii) as may be adjusted by two equally weighted modifiers: the TSR of our common stock measured against the benchmark TSR of above median of the S&P 500 Index over a three-year period and revenue CAGR for the three-year performance period. TSR is a measure of stock price appreciation plus any dividends paid in this performance period. For 2024 PSUs, overall payout will be capped at the target grant amount if our absolute TSR is negative; additionally, the combined modifiers applied to the payout are capped at +/-25%. As of December 28, 2024, 10 million PSUs were outstanding. PSUs vest three years and one month following the start of the performance period. Other RSU awards and option awards generally vest over four years from the grant date. Share-Based Compensation Share-based compensation recognized in 2024 was $3.4 billion ($3.2 billion in 2023 and $3.1 billion in 2022). During 2024, the actual tax benefit that we realized for the tax deduction from share-based awards totaled $684 million ($571 million in 2023 and $478 million in 2022). We realized a related tax expense of $139 million in 2024 for the share-based awards as a result of the shortfall between the tax deduction being less than the associated deferred tax asset for the awards. We estimate the fair value of RSUs and PSUs with a service condition or performance condition using the value of our common stock on the date of grant, reduced by the present value of dividends expected to be paid on our shares of common stock prior to vesting. We estimate the fair value of PSUs with a market condition using a Monte Carlo simulation model as of the date of grant using historical volatility. Restricted Stock Units and Performance Stock Units Weighted average assumptions used in estimating grant values were as follows: Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Estimated values $ 39.51 $ 28.92 $ 41.12 Risk-free interest rate 4.7 % 4.7 % 2.2 % Dividend yield 1.2 % 1.6 % 3.4 % Volatility 36 % 36 % 40 % Summary of activities: Number of Stock Units Outstanding (In Millions) Weighted Average Grant-Date Fair Value Balance as of December 30, 2023 172.9 $ 37.05 Granted 64.5 39.51 Vested (83.8) 40.33 Forfeited (36.2) 35.54 Balance as of December 28, 2024 117.4 $ 36.52 Expected to vest 104.3 $ 36.70 The aggregate fair value of awards that vested in 2024 was $2.4 billion ($2.2 billion in 2023 and $2.0 billion in 2022), which represents the market value of our common stock on the date that the RSUs vested. The grant-date fair value of awards that vested in 2024 was $3.4 billion ($2.7 billion in 2023 and $2.5 billion in 2022). The number of RSUs vested includes shares of common stock that we withheld on behalf of employees to satisfy the minimum statutory tax withholding requirements. RSUs that are expected to vest are net of estimated future forfeitures. As of December 28, 2024, unrecognized compensation costs related to RSUs granted under our equity incentive plans were $2.7 billion. We expect to recognize those costs over a weighted average period of 1.1 years. Stock Purchase Plan The 2006 ESPP allows eligible employees to purchase shares of our common stock at 85% of the value of our common stock on specific dates. Under the 2006 ESPP, 523 million shares of common stock are authorized for issuance through August 2026. As of December 28, 2024, 118 million shares of common stock remained available for issuance. Employees purchased 39 million shares of common stock in 2024 for $972 million under the 2006 ESPP (43 million shares of common stock for $1.0 billion in 2023 and 27 million shares of common stock for $931 million in 2022). As of December 28, 2024, unrecognized share-based compensation costs related to rights to acquire shares of common stock under the 2006 ESPP totaled $63 million. We expect to recognize those costs over a period of approximately two months.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 19 : Commitments and Contingencies Leases We recognized operating leased assets in other long-term assets of $457 million ($505 million in 2023) and corresponding accrued liabilities of $181 million ($142 million in 2023), and other long-term liabilities of $279 million as of December 28, 2024 ($289 million in 2023). Our operating leases have remaining terms of 1 to 12 years and may include options to extend the leases for up to 37 years. The weighted average remaining lease term was 6.5 years, and the weighted average discount rate was 4.9% as of December 28, 2024 for our operating leases. Operating lease expense was $248 million in 2024 ($407 million in 2023 and $729 million in 2022), including $98 million in variable lease expense in 2024 ($213 million in 2023 and $551 million in 2022). We recognized finance leased assets in property, plant, and equipment of $470 million as of December 28, 2024 ($619 million as of December 30, 2023) of which the majority is related to a prepaid finance lease for supplier capacity. This lease will commence upon start of supplier production and has a term of 6 years. We also incurred non-cash impairment charges of $83 million on certain operating leased assets as a direct result of the 2024 Restructuring Plan (see "Note 7: Restructuring and Other Charges" within Notes to Consolidated Financial Statements). These charges were included within restructuring and other in the third quarter of 2024. Discounted and undiscounted lease payments under non-cancelable leases as of December 28, 2024, were as follows: (In Millions) 2025 2026 2027 2028 2029 Thereafter Total Operating lease payments $ 112 $ 74 $ 59 $ 46 $ 42 $ 119 $ 452 Finance lease payments $ 107 $ 106 $ 16 $ 6 $ — $ — $ 235 Present value of lease payments $ 614 Commitments Commitments for capital expenditures totaled $20.0 billion as of December 28, 2024 ($27.5 billion as of December 30, 2023), a majority of which will be due within the next 12 months. Other purchase obligations and commitments totaled approximately $7.0 billion as of December 28, 2024 (approximately $8.3 billion as of December 30, 2023). Other purchase obligations and commitments include payments due under supply agreements and various types of licenses and agreements to purchase goods or services. Contractual obligations for purchases of goods or services relate to agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Other purchase obligations reflect the non-cancelable portion or the minimum cancellation fee under the agreement. Other purchase commitments also include our unrecognized commitment to fund our respective share of the total construction costs of Arizona SCIP in connection with the definitive agreement entered into with Brookfield during 2022. Our remaining unfunded contribution was $10.5 billion as of December 28, 2024. Legal Proceedings We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. As of December 28, 2024, we have accrued a charge of $1.0 billion related to litigation involving VLSI and a charge of $401 million related to an EC-imposed fine, both as described below. Excluding the VLSI claims described below, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Except as specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. In addition, in the second quarter of 2024, we accrued a charge of $780 million within restructuring and other related to three separate confidential settlement agreements with R2, Third Point, and TRGP (see R2 Semiconductor Patent Litigation below). The remaining unpaid liability was $655 million as of December 28, 2024. European Commission Competition Matter In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged “conditional rebates and payments” that required customers to purchase all or most of their x86 microprocessors from us and by making alleged “payments to prevent sales of specific rival products.” The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009. We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC's 2009 findings against us regarding rebates, as well as the €1.1 billion fine imposed on Intel, which was returned to us in February 2022. The General Court's January 2022 decision did not annul the EC's 2009 finding that we made payments to prevent sales of specific rival products. In April 2022, the EC appealed the General Court's findings regarding rebates to the Court of Justice. In October 2024, the Court of Justice dismissed the EC's appeal, upholding the judgment of the General Court. In September 2023, the EC imposed a €376 million ($401 million) fine against us based on its 2009 finding that we made payments to prevent sales of specific rival products. We have appealed the EC's decision. We have accrued a charge for the fine and are unable to make a reasonable estimate of the potential loss or range of losses in excess of this amount given the procedural posture and the nature of these proceedings. In a related matter, in April 2022, we filed applications with the General Court seeking an order requiring the EC to pay us approximately €593 million ($647 million) in default interest on the original €1.1 billion ($1.2 billion) fine that was held by the EC for 12 years. In November 2024, the EC paid us approximately €516 million ($560 million) in settlement of the applications. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, the first variants of which are now commonly referred to as “Spectre” and “Meltdown,” that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. Consumer class action lawsuits against us were pending in the US and Canada. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with Spectre, Meltdown, and other variants of this class of security vulnerabilities that have been identified since 2018, and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the US, class action suits filed in various jurisdictions between 2018 and 2021 were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs' failure to plead a viable claim. The Ninth Circuit Court of Appeals affirmed the district court's judgment in November 2023, ending the litigation. In November 2023, new plaintiffs filed a consumer class action complaint in the US District Court for the Northern District of California with respect to a further vulnerability variant disclosed in August 2023 and commonly referred to as “Downfall.” In August 2024, the district court dismissed plaintiffs' complaint for failure to plead a viable claim. Plaintiffs filed an amended complaint in September 2024, which we moved to dismiss in October 2024. In Canada, an initial status conference has not yet been scheduled in one case relating to Spectre and Meltdown pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters. Litigation Related to Segment Reporting and Internal Foundry Model A securities class action lawsuit was filed in the US District Court for the Northern District of California in May 2024 against us and certain officers following the modification of our segment reporting in the first quarter of 2024 to align to our new internal foundry operating model. In August 2024 the court ordered the case consolidated with a second, similar lawsuit, and in October 2024 plaintiffs filed an amended consolidated complaint generally alleging that defendants violated the federal securities laws by making false or misleading statements about the growth and prospects of the foundry business and seeking monetary damages on behalf of all persons and entities that purchased or otherwise acquired our common stock or purchased call options or sold put options on our common stock from January 25, 2024 through August 1, 2024. We filed a motion to dismiss the amended consolidated complaint in December 2024. Given the procedural posture and the nature of the case, including that it is in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class being certified or the ultimate size of any class if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter. Several stockholder derivative lawsuits have been filed in the Delaware state and federal courts since the filing of the securities class action lawsuit alleging that our directors and certain officers breached their fiduciary duties and violated the federal securities laws by making or allowing the statements that are challenged in the securities class action lawsuit. A similar derivative lawsuit was filed in the US District Court for the Northern District of California in December 2024, and transferred to the Delaware federal court in January 2025. In each derivative lawsuit, the plaintiff seeks to recover damages from the defendants on behalf of Intel. By stipulation of the parties, the Delaware state and federal courts have ordered the cases before them stayed pending certain developments in the securities class action lawsuit. Litigation Related to Patent and IP Claims We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business. VLSI Technology LLC v. Intel In October 2017, VLSI Technology LLC (VLSI) filed a complaint against us in the US District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents VLSI acquired from NXP Semiconductors, N.V. (NXP). VLSI sought damages, attorneys' fees, costs, and interest. Intel prevailed on all eight patents and the court entered final judgment in April 2024. VLSI appealed the Court's judgment of non-infringement as to one of the eight patents. In April 2019, VLSI filed three infringement suits against us in the US District Court for the Western District of Texas accusing various of our processors of infringement of eight additional patents it had acquired from NXP: ▪ The first Texas case went to trial in February 2021, and the jury awarded VLSI $1.5 billion for literal infringement of one patent and $675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI $2.2 billion in damages and approximately $162 million in pre-judgment and post-judgment interest. We appealed the judgment to the Federal Circuit Court of Appeals, including the court's rejection of Intel's claim to have a license from Fortress Investment Group's acquisition of Finjan. The Federal Circuit Court heard oral argument in October 2023. In December 2023, the Federal Circuit reversed the finding of infringement as to the patent for which VLSI was awarded $675 million. The Federal Circuit affirmed the finding of infringement as to the patent for which VLSI had been awarded $1.5 billion, but vacated the damages award and sent the case back to the trial court for further damages proceedings on that patent. The Federal Circuit also ruled that Intel can advance the defense that it is licensed to VLSI's patents. In December 2021 and January 2022 the Patent Trial and Appeal Board (PTAB) instituted Inter Partes Reviews (IPR) on the claims found to have been infringed in the first Texas case, and in May and June 2023 found all of those claims unpatentable; VLSI has appealed the PTAB's decisions. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents. The motion remains pending. ▪ The second Texas case went to trial in April 2021, and the jury found that we do not infringe the asserted patents. VLSI had sought approximately $3.0 billion for alleged infringement, plus enhanced damages for willful infringement. In September 2024, the court denied VLSI's motion for a new trial. Other post-trial motions remain pending, and the court has not yet entered final judgment. ▪ The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately $949 million in damages, plus interest and a running royalty. The court has not yet entered final judgment. In February 2023, we filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible. In April 2024, Intel moved to add the defense that it is licensed to VLSI's patents, and the court granted Intel's motion that same month. Trial on the license defense has been set for May 2025. In May 2019, VLSI filed a case in Shenzhen Intermediate People's Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserted one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA) which held a hearing in September 2021. The Shenzhen court held trial proceedings in July 2021 and September 2023. VLSI sought an injunction as well as RMB 1.3 million in costs and expenses, but no damages. In September 2023, the CNIPA invalidated every claim of the asserted patent. In November 2023, the trial court dismissed VLSI's case. In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel core processors. The court held a trial hearing in December 2020, where VLSI requested expenses (RMB 300 thousand) and an injunction. In December 2022, we filed a petition to invalidate the patent at issue. In February 2024, the patent was found not invalid, and Intel appealed the decision in May 2024. The appeal remains pending. The court held a second trial hearing in May 2022, and in October 2023, issued a decision finding no infringement and dismissing all claims. In November 2023, VLSI appealed the finding of non-infringement to the Supreme People's Court. The Supreme People's Court held an evidentiary hearing in October 2024, and a trial in November 2024. In July 2024, Intel filed suit against VLSI in US District Court for the District of Delaware requesting the court find Intel is licensed to VLSI's patents. In September 2024, VLSI filed motions requesting that Intel's complaint be dismissed, transferred, or stayed. As of December 28, 2024, we have accrued a charge of approximately $1.0 billion related to the VLSI litigation. While we dispute VLSI's claims and intend to vigorously defend against them, we are unable to make a reasonable estimate of losses in excess of recorded amounts given recent developments and future proceedings. R2 Semiconductor Patent Litigation In November 2022, R2 Semiconductor, Inc. (R2) filed a lawsuit in the High Court of Justice in the UK against Intel Corporation (UK) Limited and Intel Corporation, and a lawsuit in the Dusseldorf Regional Court in Germany against Intel Deutschland GmbH and certain Intel customers. R2 asserts one European patent is infringed by Intel's Ice Lake, Tiger Lake, Alder Lake, and Ice Lake Server (Xeon) processors (the accused products), and customer servers and laptops that contain those processors. In July 2024, the UK High Court of Justice found the UK part of R2's European patent invalid. In February 2024, the Dusseldorf court found Intel's processors infringe and issued an injunction and recall order against Intel and its customers. In March 2024, R2 asserted the same patent against Fujitsu and Amazon Web Services in Dusseldorf Regional Court, accusing Ice Lake and Sapphire Rapids in the AWS suit; and Tiger Lake, Ice Lake, Alder Lake, Raptor Lake, and Sapphire Rapids in the Fujitsu suit. R2 seeks an injunction, recall, and damages. Intel is indemnifying and defending its customers. In March 2024, Intel Corporation Italia S.P.A. filed an action in the Tribunale di Milano seeking an order that Intel processors do not infringe R2's patent. In May 2024, R2 filed suit in Milan against Intel Corporation Italia S.P.A. and Italian affiliates of customers Dell, HP, and HPE, accusing Intel's Ice Lake (server and client), Tiger Lake, Alder Lake, and Raptor Lake processors of infringing its patent, and requesting that its suit be consolidated with Intel Corporation Italia S.P.A.'s suit. R2 is requesting an injunction and damages. In April 2024, R2 filed an action against Intel and its customers Dell, HP, and HPE for patent infringement before the Tribunal Judiciaire of Paris. R2 sought an injunction. Intel and its customers filed a nullity action against the patent in France. In light of the potential disruption to Intel's and its customers' businesses in Europe were the Dusseldorf Regional Court's injunction and recall order to be enforced before a decision by the appeals court was expected, the significant delay expected before a decision by the appeals court, and the additional ongoing and potential litigation across other jurisdictions and with respect to other Intel processors and customers, in August 2024 Intel entered into three separate confidential agreements with R2, Third Point (the controlling shareholder), and TRGP Capital (a third-party organization funding the lawsuits) to resolve the injunction enforcement risk and related pending litigation, and provide for broad-based litigation peace with these entities, which included rights to other technology and services to Intel. Across the three agreements, Intel expects to pay an aggregate amount of $780 million. Business Interruption Insurance Proceeds We received $484 million of insurance proceeds, primarily in the fourth quarter of 2022, to compensate for business interruption and property damage from a temporary electrical breakdown that occurred at one of our facilities in 2020. We recognized these receipts as a reduction of cost of sales

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income	$ (18,756)	$ 1,689	$ 8,014

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 28, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 28, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 28, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	We face significant and persistent cybersecurity risks due to: the breadth of geographies, networks, and systems we must defend against cybersecurity attacks; the complexity, technical sophistication, value, and widespread use of our systems, products and processes; the attractiveness of our systems, products, and processes to threat actors (including state-sponsored organizations) seeking to inflict harm on us or our customers; the substantial level of harm that could occur to us and our customers were we to suffer impacts of a material cybersecurity incident; and our use of third-party products, services, and component s . We are committed to maintaining robust governance and oversight of cybersecurity risks and to implementing mechanisms, controls, technologies, and processes designed to help us assess, identify, and manage these risks. See "Risk Factors" for more information on our cybersecurity risks and product vulnerability risks. While we have not, as of the date of this Form 10-K, experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations, there can be no guarantee that we will not experience such an incident in the future. We have seen an increase in cyberattack volume, frequency, and sophistication. Our cybersecurity program and governance approach are designed to protect our network and information systems, and we have policies, procedures, processes, and controls in place to identify, manage, and respond to risks from cybersecurity threats. We seek to detect and investigate unauthorized attempts and attacks against our network, products, and services, and to prevent their occurrence and recurrence where practicable through changes or updates to our internal processes and tools and changes or updates to our products and services; however, we remain potentially vulnerable to known or unknown threats. In some instances, we, our suppliers, our customers, and the users of our products and services can be unaware of a threat or incident or its magnitude and effects. Further, there is increasing regulation regarding responses to cybersecurity incidents, including reporting to regulators, which could subject us to additional liability and reputational harm. We aim to incorporate industry best practices throughout our cybersecurity program. Our cybersecurity program includes written policies, standards, and procedures for information security, product security, and data privacy; is designed to be aligned with applicable industry standards; and is assessed annually by independent third-party auditors. Our cybersecurity strategy focuses on implementing effective and efficient controls, technologies, and other processes to assess, identify, manage, and address material cybersecurity threats, risks, and incidents. These include, among other things: annual and ongoing security awareness training for employees; mechanisms to detect and monitor unusual network activity; and containment and incident response tools. We actively engage with industry groups for benchmarking and awareness of best practices. We monitor issues that are internally discovered or externally reported and have processes to assess those issues for potential cybersecurity impact or risk. We also have a process in place to manage cybersecurity risks associated with third-party service providers. We impose security requirements upon our suppliers, including: maintaining an effective security management program; abiding by information handling and asset management requirements; and notifying us in the event of any known or suspected cyber incident. Our Board of Directors has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to company priorities, resource allocations, and oversight structures. The Board of Directors is assisted by the Audit & Finance Committee, which regularly reviews our cybersecurity program with management and reports to the Board of Directors. Cybersecurity reviews by the Audit & Finance Committee or the Board of Directors generally occur at least twice annually, or more frequently as determined to be necessary or advisable. A number of Intel directors have experience in assessing and managing cybersecurity risk. Our cybersecurity program is run by our Chief Information Security Officer (CISO), who reports to our Executive Vice President and Chief Technology Officer (CTO). Our CISO is informed about and monitors prevention, detection, mitigation, and remediation efforts through regular communication and reporting from professionals in the information security team—many of whom hold cybersecurity certifications such as a Certified Information Systems Security Professional or Certified Information Security Manager—and through the use of technological tools and software and results from third-party audits. Our CISO and CTO have extensive experience assessing and managing cybersecurity programs and cybersecurity risk. Our CISO has served in that position since 2015 and, before Intel, was the Chief Security Officer at McAfee and the Chief Information Officer and CISO for the US House of Representatives. Our CTO joined Intel in 2021 and was previously Senior Vice President and CTO at VMware, with responsibility for product security. Our CISO and CTO regularly report directly to the Audit & Finance Committee or the Board of Directors on our cybersecurity program and efforts to prevent, detect, mitigate, and remediate issues. In addition, we have an escalation process in place to inform senior management and the Board of Directors of material issues.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our Board of Directors has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to company priorities, resource allocations, and oversight structures.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to company priorities, resource allocations, and oversight structures. The Board of Directors is assisted by the Audit & Finance Committee, which regularly reviews our cybersecurity program with management and reports to the Board of Directors. Cybersecurity reviews by the Audit & Finance Committee or the Board of Directors generally occur at least twice annually, or more frequently as determined to be necessary or advisable. A number of Intel directors have experience in assessing and managing cybersecurity risk. Our cybersecurity program is run by our Chief Information Security Officer (CISO), who reports to our Executive Vice President and Chief Technology Officer (CTO). Our CISO is informed about and monitors prevention, detection, mitigation, and remediation efforts through regular communication and reporting from professionals in the information security team—many of whom hold cybersecurity certifications such as a Certified Information Systems Security Professional or Certified Information Security Manager—and through the use of technological tools and software and results from third-party audits. Our CISO and CTO have extensive experience assessing and managing cybersecurity programs and cybersecurity risk. Our CISO has served in that position since 2015 and, before Intel, was the Chief Security Officer at McAfee and the Chief Information Officer and CISO for the US House of Representatives. Our CTO joined Intel in 2021 and was previously Senior Vice President and CTO at VMware, with responsibility for product security. Our CISO and CTO regularly report directly to the Audit & Finance Committee or the Board of Directors on our cybersecurity program and efforts to prevent, detect, mitigate, and remediate issues. In addition, we have an escalation process in place to inform senior management and the Board of Directors of material issues.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board of Directors is assisted by the Audit & Finance Committee, which regularly reviews our cybersecurity program with management and reports to the Board of Directors.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Cybersecurity reviews by the Audit & Finance Committee or the Board of Directors generally occur at least twice annually, or more frequently as determined to be necessary or advisable. A number of Intel directors have experience in assessing and managing cybersecurity risk.
Cybersecurity Risk Role of Management [Text Block]	Our cybersecurity program is run by our Chief Information Security Officer (CISO), who reports to our Executive Vice President and Chief Technology Officer (CTO). Our CISO is informed about and monitors prevention, detection, mitigation, and remediation efforts through regular communication and reporting from professionals in the information security team—many of whom hold cybersecurity certifications such as a Certified Information Systems Security Professional or Certified Information Security Manager—and through the use of technological tools and software and results from third-party audits. Our CISO and CTO have extensive experience assessing and managing cybersecurity programs and cybersecurity risk. Our CISO has served in that position since 2015 and, before Intel, was the Chief Security Officer at McAfee and the Chief Information Officer and CISO for the US House of Representatives. Our CTO joined Intel in 2021 and was previously Senior Vice President and CTO at VMware, with responsibility for product security. Our CISO and CTO regularly report directly to the Audit & Finance Committee or the Board of Directors on our cybersecurity program and efforts to prevent, detect, mitigate, and remediate issues. In addition, we have an escalation process in place to inform senior management and the Board of Directors of material issues.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our cybersecurity program is run by our Chief Information Security Officer (CISO), who reports to our Executive Vice President and Chief Technology Officer (CTO). Our CISO is informed about and monitors prevention, detection, mitigation, and remediation efforts through regular communication and reporting from professionals in the information security team—many of whom hold cybersecurity certifications such as a Certified Information Systems Security Professional or Certified Information Security Manager—and through the use of technological tools and software and results from third-party audits.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our CISO and CTO have extensive experience assessing and managing cybersecurity programs and cybersecurity risk. Our CISO has served in that position since 2015 and, before Intel, was the Chief Security Officer at McAfee and the Chief Information Officer and CISO for the US House of Representatives. Our CTO joined Intel in 2021 and was previously Senior Vice President and CTO at VMware, with responsibility for product security.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our CISO and CTO regularly report directly to the Audit & Finance Committee or the Board of Directors on our cybersecurity program and efforts to prevent, detect, mitigate, and remediate issues. In addition, we have an escalation process in place to inform senior management and the Board of Directors of material issues.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
Revenue Recognition [Policy Text Block]	Revenue Recognition We recognize net product revenue when we satisfy performance obligations as evidenced by the transfer of control of our products or services to customers. Substantially all of our revenue is derived from product sales. Our products often include a software component, such as firmware, that is highly interdependent and interrelated with the product and is substantially accounted for as a combined performance obligation. In accordance with contract terms, the revenue for combined performance obligations and standalone product sales is recognized at the time of product shipment from our facilities or delivery to the customer location, as determined by the agreed-upon shipping terms. We measure revenue based on the amount of consideration we expect to be entitled to in exchange for products or services. Variable consideration is estimated and reflected as an adjustment to the transaction price. We determine variable consideration, which consists primarily of various sales price concessions, by estimating the most likely amount of consideration we expect to receive from the customer based on historical analysis of customer purchase volumes. Sales rebates earned by customers are offset against their receivable balances. Rebates earned by customers when they do not have outstanding receivable balances are recorded within other accrued liabilities . We make payments to our customers through cooperative advertising programs for marketing activities for some of our products. We generally record the payment as a reduction in revenue in the period that the revenue is earned, unless the payment is for a distinct service, which we record as an expense when the marketing activities occur.
Inventories [Policy Text Block]	Inventories We compute inventory cost on a first-in, first-out basis. Our process and product development life cycle corresponds with substantive engineering milestones. These engineering milestones are regularly and consistently applied in assessing the point at which our activities and associated costs change in nature from R&D to cost of sales, and when cost of sales can be capitalized as inventory. For a product to be manufactured in high volumes and sold to our customers under our standard warranty, it must meet our rigorous technical quality specifications. We have identified the start of manufacturing volume for sale to customers as the point at which the costs incurred to manufacture our products are included in the valuation of inventory. Prior to the start of manufacturing volume for sale to customers, costs that do not meet the criteria for R&D are included in cost of sales in the period incurred. The valuation of inventory includes determining which fixed production overhead costs can be included in inventory based on the normal capacity of our manufacturing and assembly and test facilities. We apply our historical loading compared to our total available capacity to determine our expectations of normal capacity level. If the factory loading is below the established normal capacity level, a portion of our fixed production overhead costs would not be included in the cost of inventory; instead, it would be recognized as cost of sales in that period. We refer to these costs as excess capacity charges. Excess capacity charges were $174 million in 2024, $834 million in 2023, and $423 million in 2022. Inventory is valued at the lower of cost or net realizable value, based upon assumptions about future demand and market conditions. Product-specific facts and circumstances reviewed in the inventory valuation process include a review of our customer base, the stage of the product life cycle, variations in market pricing, and an assessment of selling price in relation to product cost. Lower of cost or net realizable value inventory reserves fluctuate as we ramp new process technologies, with costs generally improving over time due to scale and improved yields. Additionally, inventory valuation is impacted by cyclical changes in market conditions and the associated pricing environment.
Property, Plant and Equipment [Policy Text Block]	Property, Plant, and Equipment We compute depreciation using the straight-line method over the estimated useful life of assets. We also capitalize interest on borrowings related to eligible capital expenditures. Capitalized interest is added to the cost of qualified assets and depreciated over the estimated useful life. At least annually, we evaluate the period over which we expect to recover the economic value of our property, plant, and equipment, considering factors such as the process technology cadence between node transitions, changes in machinery and equipment technology, and re-use of machinery and tools across each generation of process technology. As we make manufacturing process conversions and other factory planning decisions, we use assumptions involving the use of management judgments regarding the remaining useful lives of assets, primarily process-specific semiconductor manufacturing tools and building improvements. When we determine that the useful lives of assets are shorter or longer than we had originally estimated, we adjust the rate of depreciation to reflect the assets' revised useful lives. Effective January 2023, the estimated useful lives of certain machinery and equipment in our wafer fabrication facilities were increased from 5 to 8 years. This change in estimate was applied prospectively beginning in the first quarter of 2023. Assets are categorized and evaluated for impairment at the lowest level of identifiable cash flows. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a business or product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use and fungibility of the assets. If the carrying value of an asset grouping is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.
Identified Intangible Assets [Policy Text Block]	Identified Intangible Assets We amortize acquisition-related intangible assets that are subject to amortization over their estimated useful lives. We perform periodic reviews of significant finite-lived identified intangible assets to determine whether facts and circumstances indicate that the carrying amount may not be recoverable. These reviews can be affected by various factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines. Periodically, we also evaluate the estimated remaining useful lives of purchased intangible assets and whether events or changes in circumstances warrant a revision to the remaining periods of amortization. We may adjust the period over which these assets are amortized to reflect the period over which they are expected to contribute to our cash flows.
Goodwill [Policy Text Block]	Goodwill Our reporting units substantially align with our operating segments. We reevaluate our identified reporting units annually or when triggered, such as upon reorganization of our operating segments. We perform an annual impairment assessment of goodwill at the reporting unit level in the fourth quarter of each year, or more frequently if indicators of potential impairment exist. The reporting unit's carrying value used in an impairment assessment represents the assignment of various assets and liabilities, excluding certain corporate assets and liabilities, such as cash, investments, and debt. The impairment assessment may include both qualitative and quantitative factors to assess the likelihood of an impairment. Qualitative factors used include industry and market considerations, overall financial performance, and other relevant events and factors affecting the reporting unit. We may also perform a quantitative analysis to support the qualitative factors by applying sensitivities to assumptions and inputs used in measuring a reporting unit's fair value. Our quantitative impairment assessment considers both the income approach and the market approach to estimate a reporting unit's fair value. Significant estimates include market segment growth rates, our assumed market segment share, estimated gross margins, operating expenses, and discount rates based on a reporting unit's weighted average cost of capital. We test the reasonableness of the inputs and outcomes of our discounted cash flow analysis against available market data. These estimates change from year to year based on operating results, market conditions, and other factors and could materially affect the determination of the fair value and potential goodwill impairment for each reporting unit. Our quantitative assessment is sensitive to changes in underlying estimates and assumptions, the most sensitive of which is the discount rate.
Government Assistance [Policy Text Block]	Government Incentives Government incentives, including cash grants and refundable tax credits, are recognized when there is reasonable assurance that the incentive will be received and we will comply with the conditions specified in the agreement or statutory requirements. We record capital-related incentives as a reduction to property, plant, and equipment, net within our Consolidated Balance Sheets and recognize a reduction to depreciation expense over the useful life of the corresponding acquired asset. We record operating-related incentives as a reduction to expense in the same line item on the Consolidated Statements of Operations as the expenditure for which the incentive is intended to compensate.
Fair Value [Policy Text Block]	Fair Value When determining fair value, we consider the principal or most advantageous market in which we would transact, as well as assumptions that market participants would use when pricing the asset or liability. Our financial assets are measured and recorded at fair value on a recurring basis, except for equity securities measured using the measurement alternative, equity method investments, certain other receivables, and grants receivable. We assess fair value hierarchy levels for our issued debt and fixed-income investment portfolio based on the underlying instrument type. The three levels of inputs that may be used to measure fair value are: ▪ Level 1 . Quoted prices in active markets for identical assets or liabilities. We evaluate security-specific market data when determining whether a market is active. ▪ Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in less active markets, or model-derived valuations. All significant inputs used in our valuations, such as discounted cash flows, are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. We use yield curves, overnight indexed swap curves, currency spot and forward rates, and credit ratings as significant inputs in our valuations. Level 2 inputs also include non-binding market consensus prices, as well as quoted prices that were adjusted for security-specific restrictions. When we use non-binding market consensus prices, we corroborate them with quoted market prices for similar instruments or compare them to output from internally developed pricing models such as discounted cash flow models. ▪ Level 3. Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. We monitor and review the inputs and results of these valuation models to help confirm that the fair value measurements are reasonable and consistent with market experience in similar asset and liability classes. Level 3 inputs also include non-binding market consensus prices, non-binding broker quotes, and probability-weighted outcomes that we are unable to corroborate with observable market data.
Cash Equivalents [Policy Text Block]	Debt investments include investments in corporate debt, government debt, and financial institution instruments. Unhedged debt investments with original maturities of approximately three months or less from the date of purchase are classified within cash and cash equivalents . Unhedged debt investments with original maturities at the date of purchase greater than approximately three months and all economically hedged debt investments are classified as short-term investments
Debt Investments and Equity Investments [Policy Text Block]	Equity Investments We regularly invest in equity securities of public and private companies to promote business and strategic objectives. Equity investments are measured and recorded as follows: ▪ Marketable equity investments are equity securities with RDFV that are measured and recorded at fair value on a recurring basis with changes in fair value, whether realized or unrealized, recorded through the income statement. ▪ Non-marketable equity investments are equity securities without RDFV that are measured and recorded using a measurement alternative that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. ▪ Equity method investments are equity securities in investees we do not control but over which we have the ability to exercise significant influence. Equity method investments are measured at cost minus impairment, if any, plus or minus our share of equity method investee income or loss. Realized and unrealized gains and losses resulting from changes in fair value or the sale of our equity investments are recorded in gains (losses) on equity investments, net . The carrying value of our non-marketable equity investments is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities in an orderly transaction by the same issuer. Determining whether an observed transaction is similar to a security within our portfolio requires judgment based on the rights and preferences of the securities. Non-marketable equity investments and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. Our quarterly impairment analysis considers both qualitative and quantitative factors. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments using both the market and income approaches. ▪ Non-marketable equity investments are tested for impairment using a qualitative model similar to the model used for goodwill and property, plant, and equipment. Upon determining that an impairment may exist, the security's fair value is calculated and compared to its carrying value, and an impairment is recognized immediately if the carrying value exceeds the fair value. ▪ Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery. Impairments of non-marketable equity investments are recorded in gains (losses) on equity investments, net . Debt Investments Debt investments include investments in corporate debt, government debt, and financial institution instruments. Unhedged debt investments with original maturities of approximately three months or less from the date of purchase are classified within cash and cash equivalents . Unhedged debt investments with original maturities at the date of purchase greater than approximately three months and all economically hedged debt investments are classified as short-term investments , as they represent the investment of cash available for current operations. For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument, or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value. Gains or losses on these investments arising from changes in fair value due to interest rate and currency market fluctuations and credit market volatility, largely offset by losses or gains on the related derivative instruments and balance sheet remeasurement, are recorded in interest and other, net . Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) . We determine the cost of the investment sold at the individual security level and record the interest income and realized gains or losses on the sale of these investments in interest and other, net . Unhedged debt investments are subject to periodic impairment reviews. For investments in an unrealized loss position, we determine whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. We recognize an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and write down the amortized cost basis of the investment if it is more likely than not we will be required or we intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in interest and other, net , and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss) .
Derivative Financial Instruments [Policy Text Block]	Derivative Financial Instruments Our primary objective for holding derivative financial instruments is to manage currency exchange rate risk and interest rate risk, and, to a lesser extent, equity market risk, commodity price risk, and credit risk. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. We also enter into collateral security arrangements with certain of our counterparties to exchange cash collateral when the net fair value of certain derivative instruments fluctuates from contractually established thresholds. For presentation on our Consolidated Balance Sheets, we do not offset fair value amounts recognized for derivative instruments under master netting arrangements. Our derivative financial instruments, including related collateral amounts, are presented at fair value on a gross basis and are included in other current assets , other long-term assets , other accrued liabilities , or other long-term liabilities . Cash flow hedges use foreign currency contracts, such as currency forwards and currency swaps, to hedge exposures for variability in the US-dollar equivalent of non-US-dollar-denominated cash flows associated with our forecasted operating and capital purchases spending. The after-tax gains or losses from the effective portion of a cash flow hedge are reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings in the same period or periods in which the hedged transaction affects earnings, and in the same line item on the Consolidated Statements of Operations as the impact of the hedge transaction. For foreign currency contracts hedging our capital purchases, forward points are excluded from the hedge effectiveness assessment, and are recognized in earnings in the same income statement line item used to present the earnings effect of the hedged item. If the cash flow hedge transactions become improbable, the corresponding amounts deferred in accumulated other comprehensive income (loss) would be immediately reclassified to interest and other, net . Cash flows associated with these derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item. Fair value hedges use interest rate contracts, such as interest rate swaps, to hedge against changes in the fair value on certain of our fixed-rate indebtedness attributable to changes in the benchmark interest rate. The gains or losses on these hedges, as well as the offsetting losses or gains related to the changes in the fair value of the underlying hedged item attributable to the hedged risk, are recognized in earnings in the current period, primarily in interest and other, net . Cash flows associated with these derivatives are classified in the Consolidated Statements of Cash Flows in the same section as the underlying item, primarily within net cash provided by (used for) financing activities . Non-designated hedges use foreign currency contracts to economically hedge the functional currency equivalent cash flows of recognized monetary assets and liabilities, and non-US-dollar-denominated debt instruments classified as hedged investments. We also use interest rate contracts to hedge interest rate risk related to our US-dollar-denominated fixed-rate debt investments classified as hedged investments. The change in fair value of non-designated derivatives is recorded through earnings in the line item on the Consolidated Statements of Operations to which the derivatives most closely relate, primarily in interest and other, net
Credit Risk [Policy Text Block]	Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist principally of investments in debt instruments, derivative financial instruments, reverse repurchase agreements, and trade and other receivables. We generally place investments with high-credit-quality counterparties and, by policy, we limit the amount of credit exposure to any one counterparty based on our analysis of that counterparty's relative credit standing. As required per our investment policy, substantially all of our investments in debt instruments are in investment-grade instruments. Credit-rating criteria for derivative instruments are similar to those for other investments. We enter into master netting arrangements to mitigate credit risk in derivative transactions by permitting net settlement of transactions with the same counterparty. Due to master netting arrangements, the amounts subject to credit risk related to derivative instruments are generally limited to the amounts, if any, by which the counterparty's obligations exceed our obligations with that counterparty. As of December 28, 2024, our total credit exposure to any single counterparty, excluding money market funds invested in US treasury and US agency securities and reverse repurchase agreements collateralized by treasury and agency securities, did not exceed $1.4 billion. To further reduce credit risk, we enter into collateral security arrangements with certain of our derivative counterparties and obtain and secure collateral from counterparties against obligations, including securities lending transactions when we deem it appropriate. Cash collateral exchanged under our collateral security arrangements is included in other current assets , other long-term assets , other accrued liabilities , or other long-term liabilities . For reverse repurchase agreements collateralized by other securities, we do not record the collateral as an asset or a liability unless the collateral is repledged. A substantial majority of our trade receivables are derived from sales to OEMs and ODMs. We also have accounts receivable derived from sales to industrial and communications equipment manufacturers in the computing and communications industries. We believe the net accounts receivable balances from our three largest customers (47% as of December 28, 2024) do not represent a significant credit risk, based on cash flow forecasts, balance sheet analysis, and past collection experience. We have adopted credit policies and standards intended to accommodate industry growth and inherent risk. We believe credit risks are moderated by the financial stability of our major customers. We assess credit risk through quantitative and qualitative analysis. From this analysis, we establish shipping and credit limits and determine whether we will seek to use one or more credit support protection devices, such as obtaining a parent guarantee, standby letter of credit, or credit insurance.
Variable Interest Entities [Policy Text Block]	Variable Interest Entities We have economic interests in entities that are VIEs. If we conclude we are the primary beneficiary of the VIE, we are required to consolidate the entity in our financial statements. To determine if we are the primary beneficiary, we evaluate whether we have the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Our evaluation includes identification of significant activities and an assessment of our ability to direct those activities based on governance provisions and arrangements to provide services to the VIE. Periodically, we assess whether any changes in our interest or relationship with the entity affect our determination of whether the entity is a VIE and, if so, whether we are the primary beneficiary.
Non-Controlling Interests [Policy Text Block]	Non-Controlling Interests Our Consolidated Financial Statements include the accounts of majority-owned subsidiaries consolidated under the variable interest and voting interest models. Non-controlling interests represent the portion of equity not attributable to Intel and are reported as a separate component of equity, net of tax and transaction costs, on our Consolidated Balance Sheets. Net income (loss) and comprehensive income (loss) for majority-owned subsidiaries are attributed to Intel and to non-controlling interest holders on our Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income (Loss) based on respective ownership percentages. We account for changes in ownership of our majority-owned subsidiaries as equity transactions when we retain a controlling financial interest.
Business Combinations Policy [Policy Text Block]	Business Combinations We allocate the purchase price paid for assets acquired and liabilities assumed in connection with our acquisitions based on their estimated fair values at the time of acquisition. This allocation involves a number of assumptions, estimates, and judgments in determining the fair value of the following: ▪ inventory; property, plant, and equipment; pre-existing liabilities or legal claims; and contingent consideration; each as may be applicable; ▪ intangible assets, including the valuation methodology, estimations of future cash flows, discount rates, market segment growth rates, and our assumed market segment share, as well as the estimated useful life of intangible assets; ▪ deferred tax assets and liabilities, uncertain tax positions, and tax-related valuation allowances, which are initially estimated as of the acquisition date; and ▪ goodwill as measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Our assumptions and estimates are based upon comparable market data and information obtained from our management and the management of the acquired companies. These assumptions and estimates are used to value assets acquired and liabilities assumed, and to allocate goodwill to the reporting units of the business that are expected to benefit from the business combination. During the measurement period, which may be up to one year from the business acquisition date, we may recognize adjustments to the assets acquired, liabilities assumed, and related goodwill.
Employee Equity Incentive Plans [Policy Text Block]	Employee Equity Incentive Plans We use the straight-line amortization method to recognize share-based compensation expense over the service period of the award, net of estimated forfeitures. Upon exercise, cancellation, forfeiture, or expiration of stock options, or upon vesting or forfeiture of RSUs, we eliminate deferred tax assets for options and RSUs with multiple vesting dates for each vesting period on a first-in, first-out basis as if each vesting period were a separate award. For the majority of RSUs granted, the number of shares of common stock issued on the date the RSUs vest is net of the minimum statutory withholding requirements that we pay in cash to the appropriate taxing authorities on behalf of our employees. The obligation to pay the relevant taxing authority is contingent upon continued employment. In addition, the amount of the obligation is unknown, as it is based in part on the market price of our common stock when the awards vest.
Income Taxes [Policy Text Block]	Income Taxes We compute the provision for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. We measure deferred tax assets and liabilities using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. We assess the likelihood that we will be able to recover our deferred tax assets. If recovery is not likely, we must increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. Recovery of a portion of our deferred tax assets is affected by management's plans with respect to holding or disposing of certain investments; therefore, such changes could also affect our future provision for taxes. We recognize tax benefits from uncertain tax positions only if (based on the technical merits of the position) it is more likely than not that the tax positions will be sustained on examination by the tax authority. The tax benefits recognized in the financial statements from such positions are measured based on the largest amount that is more than 50% likely to be realized upon ultimate settlement. We recognize interest and penalties related to unrecognized tax benefits within the provision for (benefit from) taxes on the Consolidated Statements of Operations.
Lessee [Policy Text Block]	Leases Leases consist of real property and machinery and equipment. Our lease terms may include options to extend or terminate when it is reasonably certain that we will exercise such options. For leases for supplier capacity, we account for the lease and non-lease components as a single lease component. For all other leases, we account for the lease and non-lease components separately and do not include the non-lease components in our leased assets and corresponding liabilities. Payments on leases may be fixed or variable, and variable lease payments are based on output of the underlying leased assets.
Loss Contingencies [Policy Text Block]	Loss Contingencies

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Dec. 28, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information by Segment	Net revenue, cost of sales, gross margin, operating expenses, and operating income (loss) for each period were as follows: (In Millions) Dec 28, 2024 Intel Products CCG DCAI NEX Total Intel Products Intel Foundry All Other Corporate Unallocated Intersegment Eliminations Total Consolidated Revenue $ 30,290 $ 12,817 $ 5,842 $ 48,949 $ 17,543 $ 3,824 $ — $ (17,215) $ 53,101 Cost of sales 14,569 6,792 2,457 23,818 25,596 1,831 1,919 (17,408) 35,756 Gross margin (loss) 15,721 6,025 3,385 25,131 (8,053) 1,993 (1,919) 193 17,345 Operating expenses 4,801 4,687 2,454 11,942 5,355 2,077 9,299 350 29,023 Operating income (loss) $ 10,920 $ 1,338 $ 931 $ 13,189 $ (13,408) $ (84) $ (11,218) $ (157) $ (11,678) (In Millions) Dec 30, 2023 Intel Products CCG DCAI NEX Total Intel Products Intel Foundry All Other Corporate Unallocated Intersegment Eliminations Total Consolidated Revenue $ 29,258 $ 12,635 $ 5,774 $ 47,667 $ 18,910 $ 5,608 $ — $ (17,957) $ 54,228 Cost of sales 14,606 6,420 3,095 24,121 21,471 2,475 2,136 (17,686) 32,517 Gross margin (loss) 14,652 6,215 2,679 23,546 (2,561) 3,133 (2,136) (271) 21,711 Operating expenses 5,139 4,595 2,475 12,209 4,394 2,054 3,029 (68) 21,618 Operating income (loss) $ 9,513 $ 1,620 $ 204 $ 11,337 $ (6,955) $ 1,079 $ (5,165) $ (203) $ 93 (In Millions) Dec 31, 2022 Intel Products CCG DCAI NEX Total Intel Products Intel Foundry All Other Corporate Unallocated Intersegment Eliminations Total Consolidated Revenue $ 31,773 $ 16,856 $ 8,409 $ 57,038 $ 27,491 $ 5,530 $ — $ (27,005) $ 63,054 Cost of sales 16,826 7,081 3,856 27,763 28,052 2,425 2,875 (24,927) 36,188 Gross margin (loss) 14,947 9,775 4,553 29,275 (561) 3,105 (2,875) (2,078) 26,866 Operating expenses 6,740 5,577 3,021 15,338 4,608 1,931 2,758 (103) 24,532 Operating income (loss) $ 8,207 $ 4,198 $ 1,532 $ 13,937 $ (5,169) $ 1,174 $ (5,633) $ (1,975) $ 2,334 (In Millions) Dec 28, 2024 Cost of Sales Operating Expenses Total Acquisition-related costs $ 879 $ 165 $ 1,044 Share-based compensation 875 2,535 3,410 Restructuring and other charges 1 — 6,970 6,970 Other 165 (371) (206) Total corporate unallocated expenses $ 1,919 $ 9,299 $ 11,218 (In Millions) Dec 30, 2023 Cost of Sales Operating Expenses Total Acquisition-related costs $ 1,235 $ 172 $ 1,407 Share-based compensation 705 2,524 3,229 Restructuring and other charges 1 — (62) (62) Other 196 395 591 Total corporate unallocated expenses $ 2,136 $ 3,029 $ 5,165 (In Millions) Dec 31, 2022 Cost of Sales Operating Expenses Total Acquisition-related costs $ 1,341 $ 185 $ 1,526 Share-based compensation 663 2,465 3,128 Patent settlement 204 — 204 Optane inventory impairment 723 — 723 Restructuring and other charges 1 — 2 2 Other (56) 106 50 Total corporate unallocated expenses $ 2,875 $ 2,758 $ 5,633 1 See "Note 7: Restructuring and Other Charges" within Notes to Consolidated Financial Statements for further information.
Schedule of Revenue by Major Customers by Reporting Segments	In 2024, substantially all of the revenue from our three largest customers was from the sale of platforms and other components by our Intel Products operating segments. Our three largest customers accounted for the following percentage of our net revenue: Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Customer A 19 % 19 % 19 % Customer B 14 % 11 % 12 % Customer C 12 % 10 % 11 % Total percentage of net revenue 45 % 40 % 42 %
Revenue from External Customers by Geographic Areas	Net revenue by region, based on the billing location of the customer, was as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 China $ 15,532 $ 14,854 $ 17,125 United States 12,994 13,958 16,529 Singapore 10,187 8,602 9,664 Taiwan 7,804 6,867 8,287 Other regions 6,584 9,947 11,449 Total net revenue $ 53,101 $ 54,228 $ 63,054

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	12 Months Ended
	Dec. 28, 2024
Noncontrolling Interest [Abstract]
Schedule of Non-Controlling Interests	Non-Controlling Ownership % Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Ireland SCIP 49 % — % — % Arizona SCIP 49 % 49 % 49 % Mobileye 12 % 12 % 6 % IMS Nanofabrication (IMS Nano) 32 % 32 % — % (In Millions) Ireland SCIP Arizona SCIP Mobileye IMS Nano Total Non-controlling interests as of Dec 30, 2023 $ — $ 2,359 $ 1,838 $ 178 $ 4,375 Partner contributions — 1,702 — — 1,702 Partner distributions (43) — — — (43) Changes in equity of non-controlling interest holders — — 205 — 205 Net income (loss) attributable to non-controlling interests 104 (173) (371) (37) (477) Non-controlling interests as of Dec 28, 2024 $ 61 $ 3,888 $ 1,672 $ 141 $ 5,762 (In Millions) Ireland SCIP Arizona SCIP Mobileye IMS Nano Total Non-controlling interests as of Dec 31, 2022 $ — $ 874 $ 989 $ — $ 1,863 Partner contributions — 1,511 — — 1,511 Changes in equity of non-controlling interest holders — — 848 167 1,015 Net income (loss) attributable to non-controlling interests — (26) 1 11 (14) Non-controlling interests as of Dec 30, 2023 $ — $ 2,359 $ 1,838 $ 178 $ 4,375

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 28, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Years Ended (In Millions, Except Per Share Amounts) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Net income (loss) $ (19,233) $ 1,675 $ 8,017 Less: net income (loss) attributable to non-controlling interests (477) (14) 3 Net income (loss) attributable to Intel $ (18,756) $ 1,689 $ 8,014 Weighted average shares of common stock outstanding—basic 4,280 4,190 4,108 Dilutive effect of employee equity incentive plans — 22 15 Weighted average shares of common stock outstanding—diluted 4,280 4,212 4,123 Earnings (loss) per share attributable to Intel—basic $ (4.38) $ 0.40 $ 1.95 Earnings (loss) per share attributable to Intel—diluted $ (4.38) $ 0.40 $ 1.94

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	12 Months Ended
	Dec. 28, 2024
Other Financial Statement Details [Abstract]
Schedule of Inventories	Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Raw materials $ 1,344 $ 1,166 Work in process 7,432 6,203 Finished goods 3,422 3,758 Total inventories $ 12,198 $ 11,127
Property, Plant and Equipment	Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Land and buildings $ 56,544 $ 51,182 Machinery and equipment 103,150 100,033 Construction in progress 50,418 43,442 Total property, plant, and equipment, gross 210,112 194,657 Less: Accumulated depreciation (102,193) (98,010) Total property, plant, and equipment, net $ 107,919 $ 96,647
Long-lived Assets by Geographic Areas	Property, plant, and equipment, net, by country at the end of each period was as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 United States $ 72,068 $ 63,234 Ireland 18,152 16,746 Israel 10,414 9,290 Other countries 7,285 7,377 Total property, plant, and equipment, net $ 107,919 $ 96,647
Schedule of Amounts Recorded for Government Incentives	T he amounts recorded on the Consolidated Balance Sheets related to grants receivable and capital-related refundable tax credits for each period were as follows: Years Ended (In Millions) Location Dec 28, 2024 Dec 30, 2023 Operating-related grants receivables Other current assets $ 272 $ 17 Other long-term assets $ 186 $ 130 Capital-related grants receivables Other current assets $ 859 $ 64 Other long-term assets $ 374 $ 348 Capital-related refundable tax credits Other current assets $ 2,099 $ — Capital-related refundable tax credits Income taxes payable $ — $ 365
Schedule of Interest and Other, Net	Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Interest income $ 1,245 $ 1,335 $ 589 Interest expense (1,034) (878) (496) Other, net 15 172 1,073 Total interest and other, net $ 226 $ 629 $ 1,166

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	12 Months Ended
	Dec. 28, 2024
Restructuring Costs and Asset Impairment Charges [Abstract]
Restructuring and Related Costs	Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Employee severance and benefit arrangements $ 2,481 $ 222 $ 1,038 Litigation charges and other 858 (329) (1,187) Asset impairment charges 3,631 45 151 Total restructuring and other charges $ 6,970 $ (62) $ 2
Schedule of Restructuring Activity	Restructuring activities related to employee severance and benefit arrangements under the 2024 and 2022 Restructuring Plans were as follows: (In Millions) 2024 Restructuring Plan 2022 Restructuring Program Accrued balance as of December 25, 2021 $ — $ — Accruals and adjustments — 1,038 Cash payments — (165) Accrued balance as of December 31, 2022 — 873 Accruals and adjustments — 222 Cash payments — (1,013) Accrued balance as of December 30, 2023 — 82 Accruals and adjustments 2,306 — Cash payments (2,004) (82) Accrued balance as of December 28, 2024 $ 302 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years Ended ($ In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Income (losses) before taxes: US $ (13,450) $ (4,749) $ (1,161) Non-US 2,241 5,511 8,929 Total income before taxes $ (11,210) $ 762 $ 7,768 Provision for (benefit from) taxes: Current: Federal $ 600 $ 538 $ 4,106 State (8) 23 68 Non-US 1,364 535 735 Total current provision for (benefit from) taxes 1,956 1,096 4,909 Deferred: Federal 6,192 (2,048) (5,806) State 67 (21) (40) Non-US (192) 60 688 Total deferred provision for (benefit from) taxes 6,067 (2,009) (5,158) Total provision for (benefit from) taxes $ 8,023 $ (913) $ (249) Effective tax rate 71.6 % (119.8) % (3.2) %
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended ($ In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Income (losses) before taxes: US $ (13,450) $ (4,749) $ (1,161) Non-US 2,241 5,511 8,929 Total income before taxes $ (11,210) $ 762 $ 7,768 Provision for (benefit from) taxes: Current: Federal $ 600 $ 538 $ 4,106 State (8) 23 68 Non-US 1,364 535 735 Total current provision for (benefit from) taxes 1,956 1,096 4,909 Deferred: Federal 6,192 (2,048) (5,806) State 67 (21) (40) Non-US (192) 60 688 Total deferred provision for (benefit from) taxes 6,067 (2,009) (5,158) Total provision for (benefit from) taxes $ 8,023 $ (913) $ (249) Effective tax rate 71.6 % (119.8) % (3.2) %
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The difference between the tax provision (benefit) at the statutory federal income tax rate and the tax provision as a percentage of income before income taxes (effective tax rate) for each period was as follows: Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Expected provision (benefit) at statutory federal income tax rate (21.0) % 21.0 % 21.0 % Increase (reduction) in rate resulting from: Federal valuation allowance 93.2 — — Goodwill impairment 2.1 — — Share-based compensation 4.2 34.3 3.0 Unrecognized tax benefits and settlements 1.3 16.3 4.5 Non-US income taxed at different rates (5.3) (60.6) (13.4) Research and development tax credits (5.6) (99.0) (11.4) Foreign derived intangible income benefit — (25.1) (9.7) Restructuring of certain non-US subsidiaries — (15.8) (2.2) Non-deductibility of European Commission fine — 11.1 (4.1) Other 2.7 (2.0) 9.1 Effective tax rate 71.6 % (119.8) % (3.2) %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and liabilities at the end of each period were as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Deferred tax assets: R&D expenditures capitalization $ 10,709 $ 7,726 State credits and net operating losses 2,830 2,624 Inventory 1,054 1,430 Accrued compensation and other benefits 970 931 Share-based compensation 444 586 Litigation charge 447 308 Other, net 1,510 926 Gross deferred tax assets 17,964 14,531 Valuation allowance (13,974) (3,047) Total deferred tax assets 3,990 11,484 Deferred tax liabilities: Property, plant, and equipment (4,063) (5,156) Licenses and intangibles (159) (494) Unrealized gains on investments and derivatives (224) (358) Other, net (403) (203) Total deferred tax liabilities (4,849) (6,211) Net deferred tax assets (liabilities) $ (859) $ 5,273 Reported as: Deferred tax assets 603 5,459 Deferred tax liabilities (1,462) (186) Net deferred tax assets (liabilities) $ (859) $ 5,273
Summary of Valuation Allowance [Table Text Block]	Changes in the valuation allowance for deferred tax assets were as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Valuation allowance for deferred tax assets: Balance at Beginning of Year $ 3,047 $ 2,586 Additions Charged to Expenses/Other Accounts 10,927 461 (Deductions) Recoveries, Net — — Balance at End of Year $ 13,974 $ 3,047
Schedule of Unrecognized Tax Benefits Roll Forward	Uncertain Tax Positions Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Beginning gross unrecognized tax benefits $ 1,124 $ 1,229 $ 1,020 Settlements and effective settlements with tax authorities (59) (288) (18) Changes in balances related to tax position taken during prior periods (8) — (120) Changes in balances related to tax position taken during current period 73 183 347 Ending gross unrecognized tax benefits $ 1,130 $ 1,124 $ 1,229

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 28, 2024
Investments [Abstract]
Schedule of Investments Classified by Contractual Maturity Date	The fair value of marketable debt investments, by contractual maturity, as of December 28, 2024, was as follows: (In Millions) Fair Value Due in 1 year or less $ 5,690 Due in 1–2 years 2,321 Due in 2–5 years 6,182 Due after 5 years 168 Instruments not due at a single maturity date 1 4,316 Total $ 18,677 1 Instruments not due at a single maturity date is composed of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents.
Schedule of Equity Investments	Equity Investments Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Marketable equity investments 1 $ 848 $ 1,194 Non-marketable equity investments 4,535 4,635 Total $ 5,383 $ 5,829 1 Most of our marketable equity investments are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading-volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
Schedule of Gain (Loss) on Equity Investments	The components of gains (losses) on equity investments, net for each period were as follows: Years Ended (in Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Unrealized gains (losses) on marketable equity investments $ (218) $ (99) $ (829) Unrealized gains (losses) on non-marketable equity investments 1 92 17 299 Impairment charges (347) (214) (190) Unrealized gains (losses) on equity investments, net (473) (296) (720) Realized gains (losses) on sales of equity investments, net $ 715 $ 336 $ 4,988 Gains (losses) on equity investments, net $ 242 $ 40 $ 4,268 1 Unrealized gains (losses) on non-marketable investments includes observable price adjustments and our share of equity method investee gains (losses) and certain distributions.

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 28, 2024
Business Combination, Goodwill [Abstract]
Schedule of Goodwill [Table Text Block]	(In Millions) Dec 30, 2023 Acquisitions Transfers Impairments Dec 28, 2024 Client Computing $ 4,749 $ — $ (130) $ — $ 4,619 Data Center and AI 8,721 — (777) — 7,944 Network and Edge 2,809 — (29) — 2,780 Intel Foundry — — 222 (222) — Mobileye 10,919 — — (2,613) 8,306 Altera — — 781 — 781 All Other 393 86 (67) (149) 263 Total $ 27,591 $ 86 $ — $ (2,984) $ 24,693 (In Millions) Dec 31, 2022 Acquisitions Transfers Other Dec 30, 2023 Client Computing $ 4,254 $ — $ 495 $ — $ 4,749 Data Center and AI 9,013 — (292) — 8,721 Network and Edge 2,809 — — — 2,809 Mobileye 10,919 — — — 10,919 Accelerated Computing Systems and Graphics 596 — (596) — — All other — — 393 — 393 Total $ 27,591 $ — $ — $ — $ 27,591

Identified Intangible Assets (T

Identified Intangible Assets (Tables)	12 Months Ended
	Dec. 28, 2024
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 28, 2024 December 30, 2023 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 8,007 $ (6,445) $ 1,562 $ 10,520 $ (7,996) $ 2,524 Customer relationships and brands 1,907 (1,372) 535 1,986 (1,286) 700 Licensed technology and patents 3,387 (1,852) 1,535 3,088 (1,728) 1,360 Internal-use software 128 (73) 55 — — — Other non-amortizing intangibles 4 — 4 5 — 5 Total identified intangible assets $ 13,433 $ (9,742) $ 3,691 $ 15,599 $ (11,010) $ 4,589
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	December 28, 2024 December 30, 2023 (In Millions) Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Developed technology $ 8,007 $ (6,445) $ 1,562 $ 10,520 $ (7,996) $ 2,524 Customer relationships and brands 1,907 (1,372) 535 1,986 (1,286) 700 Licensed technology and patents 3,387 (1,852) 1,535 3,088 (1,728) 1,360 Internal-use software 128 (73) 55 — — — Other non-amortizing intangibles 4 — 4 5 — 5 Total identified intangible assets $ 13,433 $ (9,742) $ 3,691 $ 15,599 $ (11,010) $ 4,589
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expenses recorded for and the weighted average useful life assigned to identified intangible assets in the Consolidated Statements of Operations for each period were as follows: Years Ended (In Millions) Location Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Weighted Average Useful Life 1 Developed technology Cost of sales $ 879 $ 1,235 $ 1,341 9 years Customer relationships and brands Marketing, general, and administrative 165 172 185 12 years Licensed technology and patents Cost of sales 360 348 381 12 years Internal-use software Marketing, general, and administrative 24 — — 5 years Total amortization expenses $ 1,428 $ 1,755 $ 1,907 1
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	We expect future amortization expense for the next five years and thereafter to be as follows: (In Millions) 2025 2026 2027 2028 2029 Thereafter Total Future amortization expenses $ 998 $ 858 $ 655 $ 431 $ 252 $ 493 $ 3,687

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 28, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-Term Debt Dec 28, 2024 Dec 30, 2023 ($ In Millions) Effective Interest Rate Amount Amount Fixed-rate senior notes: 2.88%, due May 2024 —% $ — $ 1,250 2.70%, due June 2024 —% — 600 3.40%, due March 2025 3.44% 1,500 1,500 3.70%, due July 2025 7.49% 2,250 2,250 4.88%, due February 2026 4.93% 1,500 1,500 2.60%, due May 2026 5.97% 1,000 1,000 3.75%, due March 2027 3.78% 1,000 1,000 3.15%, due May 2027 6.54% 1,000 1,000 3.75%, due August 2027 3.81% 1,250 1,250 4.88%, due February 2028 4.92% 1,750 1,750 1.60%, due August 2028 1.67% 1,000 1,000 4.00%, due August 2029 4.05% 850 850 2.45%, due November 2029 2.38% 2,000 2,000 5.13%, due February 2030 5.14% 1,250 1,250 3.90%, due March 2030 3.91% 1,500 1,500 5.00%, due February 2031 4.99% 500 — 2.00%, due August 2031 2.02% 1,250 1,250 4.15%, due August 2032 4.17% 1,250 1,250 4.00%, due December 2032 6.59% 750 750 5.20%, due February 2033 5.23% 2,250 2,250 5.15%, due February 2034 5.20% 900 — 4.60%, due March 2040 4.59% 750 750 2.80%, due August 2041 2.81% 750 750 4.80%, due October 2041 7.33% 802 802 4.25%, due December 2042 6.70% 567 567 5.63%, due February 2043 5.61% 1,000 1,000 4.90%, due July 2045 7.46% 772 772 4.10%, due May 2046 6.74% 1,250 1,250 4.10%, due May 2047 6.70% 1,000 1,000 4.10%, due August 2047 6.27% 640 640 3.73%, due December 2047 7.11% 1,967 1,967 3.25%, due November 2049 3.19% 2,000 2,000 4.75%, due March 2050 4.73% 2,250 2,250 3.05%, due August 2051 3.05% 1,250 1,250 4.90%, due August 2052 4.89% 1,750 1,750 5.70%, due February 2053 5.68% 2,000 2,000 5.60%, due February 2054 5.61% 1,150 — 3.10%, due February 2060 3.10% 1,000 1,000 4.95%, due March 2060 4.98% 1,000 1,000 3.20%, due August 2061 3.20% 750 750 5.05%, due August 2062 5.03% 900 900 5.90%, due February 2063 5.88% 1,250 1,250 Dec 28, 2024 Dec 30, 2023 ($ In Millions) Effective Interest Rate Amount Amount Oregon and Arizona bonds 1 : 3.80% - 4.10%, due December 2035 - 2040 3.87% 423 423 5.00%, due September 2042 3.63% 131 131 5.00%, due June 2049 —% — 438 4.00%, due June 2049 3.99% 438 — 5.00%, due September 2052 4.24% 445 445 Total senior notes and other borrowings 50,985 50,285 Unamortized premium/discount, issuance costs and other (392) (445) Hedge accounting fair value adjustments (582) (574) Long-term debt 50,011 49,266 Current portion of long-term debt 2 (3,729) (2,288) Total long-term debt $ 46,282 $ 46,978 1 These bonds may be remarketed or tendered on a periodic basis and will be classified within the current portion of long-term debt in the 12 months before remarketing or tendering. 2 As of December 28, 2024, current portion of long-term debt includes $36M of hedge accounting fair value adjustments ($0 as of December 30, 2023)
Schedule of Maturities of Long-term Debt	Our aggregate debt maturities, based on outstanding principal as of December 28, 2024, by year payable, are as follows: (In Millions) 2025 2026 2027 2028 2029 2030 and thereafter Total $ 3,750 $ 2,500 $ 3,826 $ 3,173 $ 3,288 $ 34,448 $ 50,985

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 28, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis December 28, 2024 December 30, 2023 Fair Value Measurements Total Fair Value Measurements Total (In Millions) Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Assets Cash equivalents: Corporate debt $ — $ — $ — $ — $ — $ 769 $ — $ 769 Financial institution instruments 1 4,121 743 — 4,864 2,241 835 — 3,076 Reverse repurchase agreements — 2,654 — 2,654 — 2,554 — 2,554 Short-term investments: Corporate debt — 5,365 — 5,365 — 6,951 — 6,951 Financial institution instruments 1 195 3,356 — 3,551 33 4,215 — 4,248 Government debt 2 33 4,864 — 4,897 — 6,756 — 6,756 Other current assets: Derivative assets 348 733 — 1,081 366 809 — 1,175 Marketable equity securities 848 — — 848 1,194 — — 1,194 Other long-term assets: Derivative assets — 1 — 1 — 21 — 21 Total assets measured and recorded at fair value $ 5,545 $ 17,716 $ — $ 23,261 $ 3,834 $ 22,910 $ — $ 26,744 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 562 $ 134 $ 696 $ — $ 541 $ 99 $ 640 Other long-term liabilities: Derivative liabilities 3 — 416 755 1,171 — 479 — 479 Total liabilities measured and recorded at fair value $ — $ 978 $ 889 $ 1,867 $ — $ 1,020 $ 99 $ 1,119 1. Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, commercial paper, time deposits, notes, and bonds issued by financial institutions 2. Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt 3. Level 3 derivative liabilities include liquidated damage provisions related to our Ireland SCIP arrangement

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 28, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The changes in accumulated other comprehensive income (loss) by component and related tax effects for each period were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 25, 2021 $ 211 $ (1,114) $ 23 $ (880) Other comprehensive income (loss) before reclassifications (910) 923 (28) (15) Amounts reclassified out of accumulated other comprehensive (income) loss 410 82 (6) 486 Tax effects (10) (150) 7 (153) Other comprehensive income (loss) (510) 855 (27) 318 Balance as of December 31, 2022 (299) (259) (4) (562) Other comprehensive income (loss) before reclassifications 3 57 11 71 Amounts reclassified out of accumulated other comprehensive (income) loss 328 33 — 361 Tax effects (59) (24) (2) (85) Other comprehensive income (loss) 272 66 9 347 Balance as of December 30, 2023 (27) (193) 5 (215) Other comprehensive income (loss) before reclassifications (652) 54 (4) (602) Amounts reclassified out of accumulated other comprehensive (income) loss 96 11 2 109 Tax effects 1 (5) 1 (3) Other comprehensive income (loss) (555) 60 (1) (496) Balance as of December 28, 2024 $ (582) $ (133) $ 4 $ (711)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Foreign currency contracts $ 25,472 $ 30,064 $ 31,603 Interest rate contracts 17,899 18,363 16,011 Other 2,593 2,103 2,094 Total $ 45,964 $ 50,530 $ 49,708
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments in the Consolidated Balance Sheets December 28, 2024 December 30, 2023 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 40 $ 405 $ 255 $ 142 Interest rate contracts — 582 — 578 Total derivatives designated as hedging instruments 40 987 255 720 Derivatives not designated as hedging instruments: Foreign currency contracts 3 510 100 314 363 Interest rate contracts 184 25 261 36 Equity contracts 348 — 366 — Other 4 — 755 — — Total derivatives not designated as hedging instruments 1,042 880 941 399 Total derivatives $ 1,082 $ 1,867 $ 1,196 $ 1,119 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. 4 Embedded derivative related to our Ireland SCIP arrangement. The amounts recorded on the Consolidated Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Items in the Consolidated Balance Sheets in Which the Hedged Item Is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 28, 2024 Dec 30, 2023 Long-term debt $ (9,201) $ (11,419) $ 546 $ 578 Short-term debt (2,214) — 36 — Total $ (11,415) $ (11,419) $ 582 $ 578
Offsetting Assets [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: December 28, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 948 $ — $ 948 $ (269) $ (679) $ — Reverse repurchase agreements 2,654 — 2,654 — (2,654) — Total assets $ 3,602 $ — $ 3,602 $ (269) $ (3,333) $ — Liabilities: Derivative liabilities subject to master netting arrangements 1,084 — 1,084 (269) (745) 70 Total liabilities $ 1,084 $ — $ 1,084 $ (269) $ (745) $ 70 December 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements 1,111 — 1,111 (617) (399) 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95
Offsetting Liabilities [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: December 28, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 948 $ — $ 948 $ (269) $ (679) $ — Reverse repurchase agreements 2,654 — 2,654 — (2,654) — Total assets $ 3,602 $ — $ 3,602 $ (269) $ (3,333) $ — Liabilities: Derivative liabilities subject to master netting arrangements 1,084 — 1,084 (269) (745) 70 Total liabilities $ 1,084 $ — $ 1,084 $ (269) $ (745) $ 70 December 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements 1,111 — 1,111 (617) (399) 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95
Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Statements of Operations Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Interest rate contracts $ (4) $ 198 $ (1,551) Hedged items 4 (198) 1,551 Total $ — $ — $ —
Derivatives Not Designated as Hedging Instruments [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Statements of Operations for each period were as follows: Years Ended (In Millions) Location of Gains (Losses) Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Foreign currency contracts Interest and other, net $ 651 $ 106 $ 1,492 Interest rate contracts Interest and other, net 182 50 309 Other Various (411) 325 (502) Total $ 422 $ 481 $ 1,299 Our Ireland SCIP agreement with Apollo contains construction-related liquidated damage provisions that meet the definition of an embedded derivative that is not clearly and closely related to the relevant host contract, thus requiring bifurcation and separate accounting as a derivative liability. As of December 28, 2024, we assessed the probability of paying damages to Apollo and recognized a loss of $755 million in 2024 within Interest and other, net , and a derivative liability within Other long-term liabilities . We will periodically reassess the probability of paying such liquidated damages and recognize changes in the fair value of the underlying liability through Interest and other, net .

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 28, 2024
Defined Benefit Plan Disclosure [Line Items]
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	The vested benefit obligation for a defined-benefit pension plan is the actuarial present value of the vested benefits to which the employee is currently entitled based on the employee's expected date of separation or retirement. Years Ended (In Millions) Dec 28, 2024 Dec 30, 2023 Changes in projected benefit obligation: Beginning projected benefit obligation $ 2,825 $ 2,705 Service cost 33 36 Interest cost 122 127 Actuarial (gain) loss (40) 57 Currency exchange rate changes (107) 38 Plan settlements (143) (103) Other (44) (35) Ending projected benefit obligation 1 2,646 2,825 Changes in fair value of plan assets: Beginning fair value of plan assets 2,212 2,130 Actual return on plan assets 121 151 Currency exchange rate changes (74) 34 Plan settlements (143) (103) Other 26 — Ending fair value of plan assets 2 2,142 2,212 Net unfunded status $ 504 $ 613 Amounts recognized in the Consolidated Balance Sheets Other long-term assets $ 135 $ 62 Other long-term liabilities $ 639 $ 675 Accumulated other comprehensive loss (income), before tax 3 $ 337 $ 410 Accumulated benefit obligation $ 2,509 $ 2,706 1 The projected benefit obligation was approximately 30% in the US and 70% outside of the US as of December 28, 2024 and December 30, 2023. 2 The fair value of plan assets was approximately 40% in the US and 60% outside of the US as of December 28, 2024 and December 30, 2023. 3
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]	(In Millions) Dec 28, 2024 Dec 30, 2023 Plans with accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 850 $ 1,857 Plan assets $ 348 $ 1,301 Plans with projected benefit obligation in excess of plan assets Projected benefit obligation $ 987 $ 1,976 Plan assets $ 348 $ 1,301
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]	(In Millions) Dec 28, 2024 Dec 30, 2023 Plans with accumulated benefit obligation in excess of plan assets Accumulated benefit obligation $ 850 $ 1,857 Plan assets $ 348 $ 1,301 Plans with projected benefit obligation in excess of plan assets Projected benefit obligation $ 987 $ 1,976 Plan assets $ 348 $ 1,301
Defined Benefit Plan, Assumptions [Table Text Block]	Assumptions for Pension Benefit Plans Years Ended Dec 28, 2024 Dec 30, 2023 Weighted average actuarial assumptions used to determine benefit obligations Discount rate 4.6 % 4.5 % Rate of compensation increase 3.4 % 3.3 % Years Ended 2024 2023 2022 Weighted average actuarial assumptions used to determine costs Discount rate 4.5 % 4.9 % 2.2 % Expected long-term rate of return on plan assets 5.1 % 5.0 % 3.2 % Rate of compensation increase 3.3 % 3.7 % 3.2 %
Schedule of Allocation of Plan Assets [Table Text Block]	Pension Plan Assets December 28, 2024 Fair Value Measured at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Equity securities $ — $ 344 $ — $ 344 Fixed income — 142 24 166 Assets measured by fair value hierarchy $ — $ 486 $ 24 $ 510 Assets measured at net asset value 1,618 Cash and cash equivalents 14 Total pension plan assets at fair value $ 2,142 December 30, 2023 Fair Value Measured at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Equity securities $ — $ 383 $ — $ 383 Fixed income — 139 25 164 Assets measured by fair value hierarchy $ — $ 522 $ 25 $ 547 Assets measured at net asset value 1,648 Cash and cash equivalents 17 Total pension plan assets at fair value $ 2,212
Postretirement Health Coverage
Defined Benefit Plan Disclosure [Line Items]
Schedule of Expected Benefit Payments [Table Text Block]	As of December 28, 2024, the estimated benefit payments for this plan over the next 10 years are as follows: (In Millions) 2025 2026 2027 2028 2029 2030-2034 Postretirement medical benefits $ 37 $ 45 $ 45 $ 44 $ 44 $ 209
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Schedule of Expected Benefit Payments [Table Text Block]	As of December 28, 2024, estimated benefit payments over the next 10 years are as follows: (In Millions) 2025 2026 2027 2028 2029 2030-2034 Pension benefits $ 145 $ 86 $ 95 $ 97 $ 106 $ 623

Employee Equity Incentive Pla_2

Employee Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]
Restricted Stock Units Estimated Values And Weighted Average Assumptions [Table Text Block]	Restricted Stock Units and Performance Stock Units Weighted average assumptions used in estimating grant values were as follows: Years Ended Dec 28, 2024 Dec 30, 2023 Dec 31, 2022 Estimated values $ 39.51 $ 28.92 $ 41.12 Risk-free interest rate 4.7 % 4.7 % 2.2 % Dividend yield 1.2 % 1.6 % 3.4 % Volatility 36 % 36 % 40 %
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Summary of activities: Number of Stock Units Outstanding (In Millions) Weighted Average Grant-Date Fair Value Balance as of December 30, 2023 172.9 $ 37.05 Granted 64.5 39.51 Vested (83.8) 40.33 Forfeited (36.2) 35.54 Balance as of December 28, 2024 117.4 $ 36.52 Expected to vest 104.3 $ 36.70

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, Maturity	Discounted and undiscounted lease payments under non-cancelable leases as of December 28, 2024, were as follows: (In Millions) 2025 2026 2027 2028 2029 Thereafter Total Operating lease payments $ 112 $ 74 $ 59 $ 46 $ 42 $ 119 $ 452 Finance lease payments $ 107 $ 106 $ 16 $ 6 $ — $ — $ 235 Present value of lease payments $ 614

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Change in Accounting Estimate [Line Items]
Gross margin	$ 17,345	$ 21,711	$ 26,866
Decrease in R&D expenses	(16,546)	(16,046)	$ (17,528)
Inventories	$ 12,198	11,127
Service Life
Change in Accounting Estimate [Line Items]
Gross margin		2,500
Decrease in R&D expenses		400
Inventories		$ 1,300

Accounting Policies (Details)

Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Jan. 01, 2023
Revenue, Major Customer [Line Items]
Cost of sales	$ 35,756	$ 32,517	$ 36,188
Capacity
Revenue, Major Customer [Line Items]
Cost of sales	174	$ 834	$ 423
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure	$ 1,400
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest Customers
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	47%
Maximum | Machinery and equipment
Revenue, Major Customer [Line Items]
Property, plant and equipment, useful life	8 years			8 years
Minimum | Machinery and equipment
Revenue, Major Customer [Line Items]
Property, plant and equipment, useful life	3 years		5 years

Operating Segments, Narrative (

Operating Segments, Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenue from external customers	$ 53,101	$ 54,228	$ 63,054
Operating Segments | Intel Foundry
Segment Reporting Information [Line Items]
Revenue from external customers	17,543	18,910	27,491
Operating Segments | Assembly And Test | Intel Foundry
Segment Reporting Information [Line Items]
Revenue from external customers	$ 385	$ 953	$ 474

Operating Segments, Financial I

Operating Segments, Financial Information by Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 53,101	$ 54,228	$ 63,054
Cost of sales	35,756	32,517	36,188
Gross margin	17,345	21,711	26,866
Operating expenses	29,023	21,618	24,532
Operating income (loss)	(11,678)	93	2,334
CCG
Segment Reporting Information [Line Items]
Operating income (loss)	10,920	9,513	8,207
DCAI
Segment Reporting Information [Line Items]
Operating income (loss)	1,338	1,620	4,198
NEX
Segment Reporting Information [Line Items]
Operating income (loss)	931	204	1,532
Operating Segments | Total Intel Products
Segment Reporting Information [Line Items]
Revenue	48,949	47,667	57,038
Cost of sales	23,818	24,121	27,763
Gross margin	25,131	23,546	29,275
Operating expenses	11,942	12,209	15,338
Operating income (loss)	13,189	11,337	13,937
Operating Segments | CCG
Segment Reporting Information [Line Items]
Revenue	30,290	29,258	31,773
Cost of sales	14,569	14,606	16,826
Gross margin	15,721	14,652	14,947
Operating expenses	4,801	5,139	6,740
Operating Segments | DCAI
Segment Reporting Information [Line Items]
Revenue	12,817	12,635	16,856
Cost of sales	6,792	6,420	7,081
Gross margin	6,025	6,215	9,775
Operating expenses	4,687	4,595	5,577
Operating Segments | NEX
Segment Reporting Information [Line Items]
Revenue	5,842	5,774	8,409
Cost of sales	2,457	3,095	3,856
Gross margin	3,385	2,679	4,553
Operating expenses	2,454	2,475	3,021
Operating Segments | Intel Foundry
Segment Reporting Information [Line Items]
Revenue	17,543	18,910	27,491
Cost of sales	25,596	21,471	28,052
Gross margin	(8,053)	(2,561)	(561)
Operating expenses	5,355	4,394	4,608
Operating income (loss)	(13,408)	(6,955)	(5,169)
Operating Segments | All Other
Segment Reporting Information [Line Items]
Revenue	3,824	5,608	5,530
Cost of sales	1,831	2,475	2,425
Gross margin	1,993	3,133	3,105
Operating expenses	2,077	2,054	1,931
Operating income (loss)	(84)	1,079	1,174
Corporate Unallocated
Segment Reporting Information [Line Items]
Cost of sales	1,919	2,136	2,875
Gross margin	(1,919)	(2,136)	(2,875)
Operating expenses	9,299	3,029	2,758
Operating income (loss)	(11,218)	(5,165)	(5,633)
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenue	(17,215)	(17,957)	(27,005)
Cost of sales	(17,408)	(17,686)	(24,927)
Gross margin	193	(271)	(2,078)
Operating expenses	350	(68)	(103)
Operating income (loss)	$ (157)	$ (203)	$ (1,975)

Operating Segments, Corporate U

Operating Segments, Corporate Unallocated Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Restructuring and other charges	$ 6,970	$ (62)	$ 2
Cost of Sales	35,756	32,517	36,188
Operating expenses	29,023	21,618	24,532
Operating Income (Loss)	11,678	(93)	(2,334)
Corporate Unallocated
Segment Reporting Information [Line Items]
Acquisition-related costs	1,044	1,407	1,526
Share-based compensation	3,410	3,229	3,128
Patent settlement			204
Optane inventory impairment			723
Restructuring and other charges	6,970	(62)	2
Other	(206)	591	50
Cost of Sales	1,919	2,136	2,875
Operating expenses	9,299	3,029	2,758
Operating Income (Loss)	11,218	5,165	5,633
Corporate Unallocated | Cost of Sales
Segment Reporting Information [Line Items]
Acquisition-related costs	879	1,235	1,341
Share-based compensation	875	705	663
Patent settlement			204
Optane inventory impairment			723
Restructuring and other charges	0	0	0
Other	165	196	(56)
Corporate Unallocated | Operating Expenses
Segment Reporting Information [Line Items]
Acquisition-related costs	165	172	185
Share-based compensation	2,535	2,524	2,465
Patent settlement			0
Optane inventory impairment			0
Restructuring and other charges	6,970	(62)	2
Other	$ (371)	$ 395	$ 106

Operating Segments, Revenue by

Operating Segments, Revenue by Major Customers (Details)	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Largest Customers
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	45%	40%	42%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Dell Inc. [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	19%	19%	19%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Lenovo Group Limited [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	14%	11%	12%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | HP Inc. [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	12%	10%	11%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest Customers
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	47%

Operating Segments, Revenues fr

Operating Segments, Revenues from External Customers by Country (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 53,101	$ 54,228	$ 63,054
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	15,532	14,854	17,125
Singapore
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	10,187	8,602	9,664
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	12,994	13,958	16,529
Taiwan
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	7,804	6,867	8,287
Other regions
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 6,584	$ 9,947	$ 11,449

Non-Controlling Interests, Owne

Non-Controlling Interests, Ownership (Details)	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Ireland SCIP
Noncontrolling Interest [Line Items]
Non-Controlling Ownership %	49%	0%	0%
Arizona SCIP
Noncontrolling Interest [Line Items]
Non-Controlling Ownership %	49%	49%	49%
Mobileye
Noncontrolling Interest [Line Items]
Non-Controlling Ownership %	12%	12%	6%
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Non-Controlling Ownership %	32%	32%	0%

Non-Controlling Interests, Roll

Non-Controlling Interests, Rollforward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Equity, Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests, beginning balance	$ 4,375	$ 1,863
Partner contributions	1,702	1,511
Partner distributions	(43)
Changes in equity of non-controlling interest holders	205	1,015
Net income (loss) attributable to non-controlling interests	(477)	(14)	$ 3
Non-controlling interests, ending balance	5,762	4,375	1,863
Ireland SCIP
Equity, Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests, beginning balance	0	0
Partner contributions	0	0
Partner distributions	(43)
Changes in equity of non-controlling interest holders	0	0
Net income (loss) attributable to non-controlling interests	104	0
Non-controlling interests, ending balance	61	0	0
Arizona SCIP
Equity, Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests, beginning balance	2,359	874
Partner contributions	1,702	1,511
Partner distributions	0
Changes in equity of non-controlling interest holders	0	0
Net income (loss) attributable to non-controlling interests	(173)	(26)
Non-controlling interests, ending balance	3,888	2,359	874
Mobileye
Equity, Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests, beginning balance	1,838	989
Partner contributions	0	0
Partner distributions	0
Changes in equity of non-controlling interest holders	205	848
Net income (loss) attributable to non-controlling interests	(371)	1
Non-controlling interests, ending balance	1,672	1,838	989
IMS Nano
Equity, Attributable to Noncontrolling Interest [Roll Forward]
Non-controlling interests, beginning balance	178	0
Partner contributions	0	0
Partner distributions	0
Changes in equity of non-controlling interest holders	0	167
Net income (loss) attributable to non-controlling interests	(37)	11
Non-controlling interests, ending balance	$ 141	$ 178	$ 0

Non-Controlling Interests, Narr

Non-Controlling Interests, Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Jun. 29, 2024	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares		$ 12,714	$ 1,511	$ 874
Assets		196,485	191,572
Increase from sale of subsidiary equity interest		205	1,015
Not Designated as Hedging Instrument
Noncontrolling Interest [Line Items]
Derivative gain (loss)		422	481	$ 1,299
Fab 34 | Not Designated as Hedging Instrument
Noncontrolling Interest [Line Items]
Derivative gain (loss)		(755)
Semiconductor Co-Investment Program, Construction Costs
Noncontrolling Interest [Line Items]
Unrecognized commitment		10,500
Semiconductor Co-Investment Program, Construction Costs | Intel and Brookfield
Noncontrolling Interest [Line Items]
Unrecognized commitment		$ 29,000
Ireland SCIP
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares	$ 11,000
Percentage of factory output with the right to purchase		100%
Increase from sale of subsidiary equity interest		$ 0	0
Arizona SCIP
Noncontrolling Interest [Line Items]
Percentage of factory output with the right to purchase		100%
Increase from sale of subsidiary equity interest		$ 0	0
Variable Interest Entity, Primary Beneficiary
Noncontrolling Interest [Line Items]
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount		1,100
Variable Interest Entity, Primary Beneficiary | Asset Pledged as Collateral
Noncontrolling Interest [Line Items]
Assets		11,500	$ 4,800
Mobileye
Noncontrolling Interest [Line Items]
Conversion of stock, shares converted (in shares)			38,500,000
Conversion of stock, shares converted, percentage of outstanding shares			0.05
Shares issued per share (in dollars per share)			$ 42
Net proceeds			$ 1,600
Increase from sale of subsidiary equity interest		205	848
Mobileye | Capital in excess of par value
Noncontrolling Interest [Line Items]
Increase from sale of subsidiary equity interest			663
IMS Nano
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares			1,400
Increase from sale of subsidiary equity interest		$ 0	167
IMS Nano | Capital in excess of par value
Noncontrolling Interest [Line Items]
Increase from sale of subsidiary equity interest			$ 958
Ireland SCIP
Noncontrolling Interest [Line Items]
Ownership percentage sold	49%
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Ownership percentage sold			32%
IMS Nanofabrication | Bain Capital
Noncontrolling Interest [Line Items]
Ownership percentage sold			20%
IMS Nanofabrication | TSMC
Noncontrolling Interest [Line Items]
Ownership percentage sold			10%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss)	$ (19,233)	$ 1,675	$ 8,017
Less: net income (loss) attributable to non-controlling interests	(477)	(14)	3
Net income (loss) attributable to Intel	$ (18,756)	$ 1,689	$ 8,014
Weighted average shares of common stock outstanding-basic	4,280	4,190	4,108
Dilutive effect of employee equity incentive plans (shares)	0	22	15
Weighted average shares of common stock outstanding-diluted	4,280	4,212	4,123
Earnings (loss) per share attributable to Intel—basic	$ (4.38)	$ 0.40	$ 1.95
Earnings (loss) per share attributable to Intel—diluted	$ (4.38)	$ 0.40	$ 1.94
Securities excluded from the computation of diluted earnings per share (shares)	114		70

Other Financial Statement Det_3

Other Financial Statement Details, Accounts Receivable (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Other Income and Expenses [Abstract]
Accounts Receivable, Sale	$ 2,300	$ 2,000	$ 665

Other Financial Statement Det_4

Other Financial Statement Details, Inventories (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Inventory, Net [Abstract]
Raw materials	$ 1,344	$ 1,166
Work in process	7,432	6,203
Finished goods	3,422	3,758
Total inventories	$ 12,198	$ 11,127

Other Financial Statement Det_5

Other Financial Statement Details, Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Jan. 01, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 210,112	$ 194,657
Less: Accumulated depreciation	(102,193)	(98,010)
Total property, plant, and equipment, net	107,919	96,647
Impairment of property, plant and equipment	2,300
Depreciation	$ 9,951	7,847	$ 11,128
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Sales
Unpaid amounts related to the acquisition of property, plant, and equipment	$ 3,200
United States
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment, net	72,068	63,234
Ireland
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment, net	18,152	16,746
Israel
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment, net	10,414	9,290
Other countries
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment, net	7,285	7,377
2024 Restructuring Program
Property, Plant and Equipment [Line Items]
Impairment of assets to be disposed of	442
Value of Manufacturing Asset Portfolio
Property, Plant and Equipment [Line Items]
Depreciation	$ 992
Minimum
Property, Plant and Equipment [Line Items]
Capital vendor extended payment period	90 days
Land and buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 56,544	51,182
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 103,150	100,033
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years		5 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	8 years			8 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 50,418	$ 43,442
Buildings | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Buildings | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	25 years

Other Financial Statement Det_6

Other Financial Statement Details, Government Incentives (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Nov. 30, 2024	Sep. 30, 2024
Government Assistance [Line Items]
Government Assistance, Asset, Decrease, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Property, plant, and equipment, net	Property, plant, and equipment, net
Government Assistance, Operating Expense, Decrease (Increase), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Sales	Cost of Sales	Cost of Sales
Government incentives recognized as non-cash investing activities	$ 3,300	$ 1,100	$ 128
Government incentives amount awarded				$ 7,900
Government Assistance, Operating Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Sales	Cost of Sales	Cost of Sales
Government Assistance, Effect on Statement of Financial Position
Grant related liabilities, current	$ 0	$ 365
Government Assistance, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Income taxes payable	Income taxes payable
Government Assistance, Asset, Current, Statement of Financial Position [Extensible Enumeration]	Receivable recorded in other current assets	Receivable recorded in other current assets
Government Assistance, Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Maximum
Government Assistance [Line Items]
Government incentives duration	15 years
Government incentives amount awarded					$ 3,000
Capital-Related Grants
Government Assistance [Line Items]
Government incentives reduction to property, plant and equipment	$ 9,500	$ 5,500
Government incentives reduction to property, plant and equipment during the period	4,100	2,200
Government incentives reduction to depreciation	594	226	$ 230
Government Assistance, Effect on Statement of Financial Position
Grants related assets, current	859	64
Grant related assets, noncurrent	374	348
Federal Capital-Related Grants and Operating-Related Grants
Government Assistance [Line Items]
Government assistance recognized	1,300
Federal Operating-Related Grants
Government Assistance [Line Items]
Government incentives benefit to operating income	253
Federal Non-cash Refundable Advanced Manufacturing Investment Tax Credit
Government Assistance [Line Items]
Government incentives reduction to property, plant and equipment during the period	2,600	845
State Capital-Related Grants
Government Assistance [Line Items]
Government incentives reduction to property, plant and equipment during the period	115	723
Foreign Capital-Related Grants
Government Assistance [Line Items]
Government incentives reduction to property, plant and equipment during the period	384	645
Operating-Related Grants
Government Assistance [Line Items]
Government incentives benefit to operating income	442	202	$ 104
Government Assistance, Effect on Statement of Financial Position
Grants related assets, current	272	17
Grant related assets, noncurrent	186	130
Capital-Related Refundable Tax Credits
Government Assistance, Effect on Statement of Financial Position
Grants related assets, current	$ 2,099	$ 0

Other Financial Statement Det_7

Other Financial Statement Details, Advertising (Details) - USD ($)	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Statement [Abstract]
Advertising Expense	$ 856,000,000	$ 950,000,000	$ 1,200,000,000

Other Financial Statement Det_8

Other Financial Statement Details, Interest and Other, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Other Nonoperating Income (Expense) [Abstract]
Interest income	$ 1,245	$ 1,335	$ 589
Interest expense	(1,034)	(878)	(496)
Other, net	15	172	1,073
Total Interest and other, net	226	629	1,166
Interest capitalized	1,500	1,500	785
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest received on litigation related matter	560
Gains on divestitures	0	0	1,059
Not Designated as Hedging Instrument
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Derivative gain (loss)	422	481	$ 1,299
Not Designated as Hedging Instrument | Fab 34
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Derivative gain (loss)	$ (755)
NAND Memory Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gains on divestitures		$ 1,000

Restructuring and Other Charg_3

Restructuring and Other Charges, Components (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Restructuring Costs and Asset Impairment Charges [Abstract]
Employee severance and benefit arrangements	$ 2,481	$ 222	$ 1,038
Litigation charges and other	858	(329)	(1,187)
Asset impairment charges	3,631	45	151
Total restructuring and other charges	$ 6,970	$ (62)	$ 2

Restructuring and Other Charg_4

Restructuring and Other Charges, Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 30, 2024	Sep. 28, 2024	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Employee severance and benefit arrangements			$ 2,481	$ 222	$ 1,038
Charge (benefit) included in litigation charges and other			858	(329)	(1,187)
Goodwill impairment charge	$ 222	$ 2,800	$ 2,984
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]			Restructuring and other charges
Impairment of acquired intangible assets			$ 108
Tower Semiconductor, Ltd.
Restructuring Cost and Reserve [Line Items]
Charge (benefit) included in litigation charges and other				353
R2 Semiconductor Patent Litigation
Restructuring Cost and Reserve [Line Items]
Charge (benefit) included in litigation charges and other			780
VSLI Litigation
Restructuring Cost and Reserve [Line Items]
Charge (benefit) included in litigation charges and other				(1,200)
EC Fine
Restructuring Cost and Reserve [Line Items]
Charge (benefit) included in litigation charges and other			401	$ 401	$ (1,200)
2024 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges			3,000
Cumulative restructuring cost			2,800
Employee severance and benefit arrangements			2,200
Impairment of assets to be disposed of			442
Impairment of operating leased assets			103
2024 Restructuring Program | Other long-term assets
Restructuring Cost and Reserve [Line Items]
Impairment of operating leased assets			83
Streamline Operations
Restructuring Cost and Reserve [Line Items]
Employee severance and benefit arrangements			294
2022 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Cumulative restructuring cost			$ 1,300

Restructuring and Other Charg_5

Restructuring and Other Charges, Restructuring Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Restructuring Reserve [Roll Forward]
Accruals and adjustments	$ 3,491	$ (424)	$ 1,074
2024 Restructuring Program
Restructuring Reserve [Roll Forward]
Accrued restructuring beginning balance	0	0	0
Accruals and adjustments	2,306	0	0
Cash payments	(2,004)	0	0
Accrued restructuring ending balance	302	0	0
2022 Restructuring Program
Restructuring Reserve [Roll Forward]
Accrued restructuring beginning balance	82	873	0
Accruals and adjustments	0	222	1,038
Cash payments	(82)	(1,013)	(165)
Accrued restructuring ending balance	$ 0	$ 82	$ 873

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income before taxes: U.S.	$ (13,450)	$ (4,749)	$ (1,161)
Income before taxes: Non-U.S.	2,241	5,511	8,929
Income (loss) before taxes	(11,210)	762	7,768
Provision for taxes, Current: Federal	600	538	4,106
Provision for taxes, Current: State	(8)	23	68
Provision for taxes, Current: Non-U.S.	1,364	535	735
Total current provision for taxes	1,956	1,096	4,909
Provision for taxes, Deferred: Federal	6,192	(2,048)	(5,806)
Deferred State and Local Income Tax Expense (Benefit)	67	(21)	(40)
Deferred Other Tax Expense (Benefit)	(192)	60	688
Total deferred provision for taxes	6,067	(2,009)	(5,158)
Total Provision for taxes	$ 8,023	$ (913)	$ (249)
Effective tax rate	(71.60%)	(119.80%)	(3.20%)
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate	21%	21%	21%
Increase (reduction) in rate resulting from:
Federal valuation allowance	(93.20%)	0%	0%
Goodwill impairment	(2.10%)	0%	0%
Share-based compensation	(4.20%)	34.30%	3%
Unrecognized tax benefits and settlements	(1.30%)	16.30%	4.50%
Non-US income taxed at different rates	5.30%	(60.60%)	(13.40%)
Research and development tax credits	5.60%	(99.00%)	(11.40%)
Foreign derived intangible income benefit	0%	(25.10%)	(9.70%)
Restructuring of certain non-US subsidiaries	0%	(15.80%)	(2.20%)
Non-deductibility of European Commission fine	0%	11.10%	(4.10%)
Other	(2.70%)	(2.00%)	9.10%
Effective tax rate	(71.60%)	(119.80%)	(3.20%)
Income Tax Disclosure [Line Items]
Income tax holiday benefit	$ 67	$ 129	$ 220
Income tax holiday, impact on diluted earnings per share (in dollars per share)	$ 0.02	$ 0.03	$ 0.05
Statutory federal income tax rate	21%	21%	21%
Income Tax Holiday, Termination Date	2056
Income Tax Expense (Benefit)	$ 8,023	$ (913)	$ (249)
Valuation Allowance	13,974	3,047
Change in valuation allowance	10,900
Undistributed earnings on certain foreign subsidiaries	21,000
Income Taxes Receivable, Current	2,600	59
Long-term income taxes payable	1,600	2,600
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred Tax Assets, Research and Development Capitalized	10,709	7,726
Deferred tax assets, State credits and net operating losses	2,830	2,624
Deferred tax assets, Inventory	1,054	1,430
Deferred tax assets, Accrued compensation and other benefits	970	931
Deferred tax assets, Share-based compensation	444	586
Deferred Tax Assets, Tax Deferred Expense, Litigation Expense	447	308
Deferred tax assets, Other, net	1,510	926
Gross deferred tax assets	17,964	14,531
Deferred tax assets, Valuation allowance	(13,974)	(3,047)
Total deferred tax assets	3,990	11,484
Deferred tax liabilities, Property, plant and equipment	(4,063)	(5,156)
Deferred tax liabilities, Licenses and intangibles	(159)	(494)
Deferred Tax Liabilities, Unrealized Gains On Investments And Derivatives	(224)	(358)
Deferred tax liabilities, Other, net	(403)	(203)
Total deferred tax liabilities	(4,849)	(6,211)
Deferred Tax Liabilities, Net	(859)
Net deferred tax assets		5,273
Deferred tax assets	603	5,459
Deferred tax liabilities	(1,462)	(186)
Unrecognized Tax Benefits [Roll Forward]
Beginning gross unrecognized tax benefits	1,124	1,229	1,020
Settlements and effective settlements with tax authorities	(59)	(288)	(18)
Changes in balances related to tax position taken during prior periods	(8)	0	(120)
Changes in balances related to tax position taken during current period	73	183	347
Ending gross unrecognized tax benefits	1,130	1,124	$ 1,229
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	946	$ 962
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 314
Minimum
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent	12.50%
Maximum
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent	24%
US
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	$ 279
Non-U.S.
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	$ 2,700

Income Taxes, Valuation Allowan

Income Taxes, Valuation Allowance (Details) - Valuation Allowance, Deferred Tax Asset - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 3,047	$ 2,586
Additions Charged to Expenses/Other Accounts	10,927	461
(Deductions) Recoveries, Net	0	0
Balance at End of Year	$ 13,974	$ 3,047

Investments, Short-term Investm

Investments, Short-term Investments Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Gains (losses) on hedged investments	$ 464	$ 534	$ 748
Adjusted cost for unhedged investments	5,200	4,700
Available-for-sale Securities
Debt Securities, Available-for-sale [Line Items]
Value of hedged investments	$ 13,500	$ 17,100

Investments, Marketable Debt In

Investments, Marketable Debt Investments Contractual Maturity (Details) $ in Millions	Dec. 28, 2024 USD ($)
Investments [Abstract]
Due in 1 year or less	$ 5,690
Due in 1–2 years	2,321
Due in 2–5 years	6,182
Due after 5 years	168
Instruments not due at a single maturity date	4,316
Debt Securities, Available-for-Sale, Total	$ 18,677

Investments, Components of Equi

Investments, Components of Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Investments [Abstract]
Marketable equity securities	$ 848	$ 1,194
Non-marketable equity securities	4,535	4,635
Equity Investments	$ 5,383	$ 5,829
Marketable equity securities threshold percentage of shares owned resulting in trading volume restrictions	1%

Investments, Gains (Losses) on

Investments, Gains (Losses) on Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Unrealized gains (losses) on marketable equity investments	$ (218)	$ (99)	$ (829)
Unrealized gains (losses) on non-marketable equity investments	92	17	299
Impairment charges	(347)	(214)	(190)
Unrealized gains (losses) on equity investments, net	(473)	(296)	(720)
Realized gains (losses) on sales of equity investments, net	715	336	4,988
Gains (losses) on equity investments, net	$ 242	$ 40	$ 4,268

Investments, Equity Investments

Investments, Equity Investments Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Gain (Loss) on Securities [Line Items]
Cumulative impairment for equity securities without readily determinable fair value	$ 1,400	$ 1,100
Upward observable price adjustments for equity securities without readily determinable fair value	1,400	1,400
Proceeds from sales of equity investments	$ 1,047	$ 472	$ 4,961
McAfee
Gain (Loss) on Securities [Line Items]
Proceeds from sales of equity investments			4,600
Gain on sale of equity method investment			$ 4,600

Divestitures (Details)

Divestitures (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Receivable recorded in other current assets	$ 9,586	$ 3,706
NAND Memory Business Divestiture | Affiliated Entity
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Receivable recorded in other current assets	98	$ 145
NAND Memory Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds receivable	2,000
Maximum exposure annually	500
Maximum exposure	$ 1,500

Goodwill, Rollforward (Details)

Goodwill, Rollforward (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 30, 2024	Sep. 28, 2024	Dec. 28, 2024	Dec. 30, 2023
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 27,591	$ 27,591	$ 27,591	$ 27,591
Acquisitions			86	0
Transfers			0	0
Impairments	(222)	(2,800)	(2,984)
Other				0
Goodwill, Ending Balance			24,693	27,591
CCG
Goodwill [Roll Forward]
Goodwill, Beginning Balance	4,749	4,749	4,749	4,254
Acquisitions			0	0
Transfers			(130)	495
Impairments			0
Other				0
Goodwill, Ending Balance			4,619	4,749
DCAI
Goodwill [Roll Forward]
Goodwill, Beginning Balance	8,721	8,721	8,721	9,013
Acquisitions			0	0
Transfers			(777)	(292)
Impairments			0
Other				0
Goodwill, Ending Balance			7,944	8,721
NEX
Goodwill [Roll Forward]
Goodwill, Beginning Balance	2,809	2,809	2,809	2,809
Acquisitions			0	0
Transfers			(29)	0
Impairments			0
Other				0
Goodwill, Ending Balance			2,780	2,809
Intel Foundry
Goodwill [Roll Forward]
Goodwill, Beginning Balance	0	0	0
Acquisitions			0
Transfers			222
Impairments			(222)
Goodwill, Ending Balance			0	0
Mobileye
Goodwill [Roll Forward]
Goodwill, Beginning Balance	10,919	10,919	10,919	10,919
Acquisitions			0	0
Transfers			0	0
Impairments			(2,613)
Other				0
Goodwill, Ending Balance			8,306	10,919
Altera
Goodwill [Roll Forward]
Goodwill, Beginning Balance	0	0	0
Acquisitions			0
Transfers			781
Impairments			0
Goodwill, Ending Balance			781	0
Accelerated Computing Systems and Graphics
Goodwill [Roll Forward]
Goodwill, Beginning Balance	0	0	0	596
Acquisitions				0
Transfers				(596)
Other				0
Goodwill, Ending Balance				0
All Other
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 393	$ 393	393	0
Acquisitions			86	0
Transfers			(67)	393
Impairments			(149)
Other				0
Goodwill, Ending Balance			$ 263	$ 393

Goodwill, Narrative (Details)

Goodwill, Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 30, 2024 USD ($)	Sep. 28, 2024 USD ($)	Dec. 28, 2024 USD ($)	Dec. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Goodwill [Line Items]
Goodwill impairment loss	$ 222	$ 2,800	$ 2,984
Accumulated impairment loss			3,900
Goodwill			24,693	$ 27,591	$ 27,591
Measurement Input, Discount Rate
Goodwill [Line Items]
Goodwill measurement input increase (decrease)		0.01
Intel Foundry
Goodwill [Line Items]
Goodwill			0
Mobileye
Goodwill [Line Items]
Accumulated impairment loss			2,600
CCG
Goodwill [Line Items]
Accumulated impairment loss			364
DCAI
Goodwill [Line Items]
Accumulated impairment loss			275
NEX
Goodwill [Line Items]
Accumulated impairment loss			$ 79

Identified Intangible Assets, C

Identified Intangible Assets, Components (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Finite Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (9,742)	$ (11,010)
Total	3,687
Indefinite-lived Intangible Assets [Line Items]
Total identified intangible assets, Gross	13,433	15,599
Total identified intangible assets, Net	3,691	4,589
Other non-amortizing intangibles
Indefinite-lived Intangible Assets [Line Items]
Gross and Net Assets	4	5
Developed technology
Finite Lived Intangible Assets [Line Items]
Gross Assets	8,007	10,520
Accumulated Amortization	(6,445)	(7,996)
Total	1,562	2,524
Customer relationships and brands
Finite Lived Intangible Assets [Line Items]
Gross Assets	1,907	1,986
Accumulated Amortization	(1,372)	(1,286)
Total	535	700
Licensed technology and patents
Finite Lived Intangible Assets [Line Items]
Gross Assets	3,387	3,088
Accumulated Amortization	(1,852)	(1,728)
Total	1,535	1,360
Internal-use software
Finite Lived Intangible Assets [Line Items]
Gross Assets	128	0
Accumulated Amortization	(73)	0
Total	$ 55	$ 0

Identified Intangible Assets, N

Identified Intangible Assets, Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Licensed Technology
Finite Lived Intangible Assets [Line Items]
Intangible assets acquired	$ 562	$ 309

Identified Intangible Assets, A

Identified Intangible Assets, Amortization Expense and Weighted Average Useful Lives (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 1,428	$ 1,755	$ 1,907
Developed technology
Finite Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 879	1,235	1,341
Weighted Average Useful Life (in years)	9 years
Customer relationships and brands
Finite Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 165	172	185
Weighted Average Useful Life (in years)	12 years
Licensed technology and patents
Finite Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 360	348	381
Weighted Average Useful Life (in years)	12 years
Internal-use software
Finite Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 24	$ 0	$ 0
Weighted Average Useful Life (in years)	5 years

Identified Intangible Assets, E

Identified Intangible Assets, Expected Future Amortization Expense (Details) $ in Millions	Dec. 28, 2024 USD ($)
Intangible Assets, Net (Excluding Goodwill) [Abstract]
2025	$ 998
2026	858
2027	655
2028	431
2029	252
Thereafter	493
Total	$ 3,687

Borrowings, Short-term Debt (De

Borrowings, Short-term Debt (Details) - USD ($)	Dec. 28, 2024	Dec. 30, 2023
Short-term Debt [Line Items]
Short-term debt	$ 3,729,000,000	$ 2,288,000,000
Commercial Paper	0	$ 0
Commercial Paper
Short-term Debt [Line Items]
Maximum borrowing capacity	$ 10,000,000,000

Borrowings, Long-term Debt (Det

Borrowings, Long-term Debt (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Total	$ 50,985	$ 50,285
Unamortized premium/discount, issuance costs and other	(392)	(445)
Hedge accounting fair value adjustments	(582)	(574)
Long-term debt	50,011	49,266
Current portion of long-term debt2	(3,729)	(2,288)
Total long-term debt	$ 46,282	46,978
2017 Senior notes due May 2024 at 2.88%
Debt Instrument [Line Items]
Stated interest rate	2.88%
Effective Interest Rate	0%
Total	$ 0	1,250
2017 Senior notes due June 2024 at 2.70%
Debt Instrument [Line Items]
Stated interest rate	2.70%
Effective Interest Rate	0%
Total	$ 0	600
Fixed-rate Senior Notes, 3.40% due March 2025
Debt Instrument [Line Items]
Stated interest rate	3.40%
Effective Interest Rate	3.44%
Total	$ 1,500	1,500
2015 Senior notes due July 2025 at 3.70%
Debt Instrument [Line Items]
Stated interest rate	3.70%
Effective Interest Rate	7.49%
Total	$ 2,250	2,250
Fixed-Rate Senior Notes, 4.88% Due February 2026
Debt Instrument [Line Items]
Stated interest rate	4.88%
Effective Interest Rate	4.93%
Total	$ 1,500	1,500
2016 Senior notes due May 2026 at 2.60%
Debt Instrument [Line Items]
Stated interest rate	2.60%
Effective Interest Rate	5.97%
Total	$ 1,000	1,000
Fixed-rate Senior Notes, 3.75% due March 2027
Debt Instrument [Line Items]
Stated interest rate	3.75%
Effective Interest Rate	3.78%
Total	$ 1,000	1,000
2017 Senior notes due May 2027 at 3.15%
Debt Instrument [Line Items]
Stated interest rate	3.15%
Effective Interest Rate	6.54%
Total	$ 1,000	1,000
Fixed-rate Senior Notes, 3.75% due August 2027
Debt Instrument [Line Items]
Stated interest rate	3.75%
Effective Interest Rate	3.81%
Total	$ 1,250	1,250
Fixed-Rate Senior Notes, 4.88% Due February 2028
Debt Instrument [Line Items]
Stated interest rate	4.88%
Effective Interest Rate	4.92%
Total	$ 1,750	1,750
Fixed-rate Senior Notes, 1.60% due August 2028
Debt Instrument [Line Items]
Stated interest rate	1.60%
Effective Interest Rate	1.67%
Total	$ 1,000	1,000
Fixed-Rate Senior Notes, 4.00 Percent due August 2029
Debt Instrument [Line Items]
Stated interest rate	4%
Effective Interest Rate	4.05%
Total	$ 850	850
2019 Senior Notes due December 2029 at 2.45%
Debt Instrument [Line Items]
Stated interest rate	2.45%
Effective Interest Rate	2.38%
Total	$ 2,000	2,000
Fixed-Rate Senior Notes, 5.13% Due February 2030
Debt Instrument [Line Items]
Stated interest rate	5.13%
Effective Interest Rate	5.14%
Total	$ 1,250	1,250
Fixed-rate Senior Notes, 3.90%, due March 2030
Debt Instrument [Line Items]
Stated interest rate	3.90%
Effective Interest Rate	3.91%
Total	$ 1,500	1,500
Fixed-Rate Senior Notes, 5.00%, Due February 2031
Debt Instrument [Line Items]
Stated interest rate	5%
Effective Interest Rate	4.99%
Total	$ 500	0
Fixed-rate Senior Notes, 2.00% due August 2031
Debt Instrument [Line Items]
Stated interest rate	2%
Effective Interest Rate	2.02%
Total	$ 1,250	1,250
Fixed-rate Senior Notes, 4.15% due August 2032
Debt Instrument [Line Items]
Stated interest rate	4.15%
Effective Interest Rate	4.17%
Total	$ 1,250	1,250
2012 Senior notes due December 2032 at 4.00%
Debt Instrument [Line Items]
Stated interest rate	4%
Effective Interest Rate	6.59%
Total	$ 750	750
Fixed-Rate Senior Notes, 5.20% Due February 2033
Debt Instrument [Line Items]
Stated interest rate	5.20%
Effective Interest Rate	5.23%
Total	$ 2,250	2,250
Fixed-Rate Senior Notes, 5.15% Due February 2034
Debt Instrument [Line Items]
Stated interest rate	5.15%
Effective Interest Rate	5.20%
Total	$ 900	0
Fixed-rate Senior Notes, 4.60%, due March 2040
Debt Instrument [Line Items]
Stated interest rate	4.60%
Effective Interest Rate	4.59%
Total	$ 750	750
Fixed-rate Senior Notes, 2.80%, due August 2041
Debt Instrument [Line Items]
Stated interest rate	2.80%
Effective Interest Rate	2.81%
Total	$ 750	750
2011 Senior notes due October 2041 at 4.80%
Debt Instrument [Line Items]
Stated interest rate	4.80%
Effective Interest Rate	7.33%
Total	$ 802	802
2012 Senior notes due December 2042 at 4.25%
Debt Instrument [Line Items]
Stated interest rate	4.25%
Effective Interest Rate	6.70%
Total	$ 567	567
Fixed-Rate Senior Notes, 5.63% Due February 2043
Debt Instrument [Line Items]
Stated interest rate	5.63%
Effective Interest Rate	5.61%
Total	$ 1,000	1,000
2015 Senior notes due July 2045 at 4.90%
Debt Instrument [Line Items]
Stated interest rate	4.90%
Effective Interest Rate	7.46%
Total	$ 772	772
2016 Senior notes due May 2046 at 4.10%
Debt Instrument [Line Items]
Stated interest rate	4.10%
Effective Interest Rate	6.74%
Total	$ 1,250	1,250
2017 Senior notes due May 2047 at 4.10%
Debt Instrument [Line Items]
Stated interest rate	4.10%
Effective Interest Rate	6.70%
Total	$ 1,000	1,000
$640, 4.10%, Senior Notes due August 2047
Debt Instrument [Line Items]
Stated interest rate	4.10%
Effective Interest Rate	6.27%
Total	$ 640	640
2017 Senior notes due December 2047 at 3.73%
Debt Instrument [Line Items]
Stated interest rate	3.73%
Effective Interest Rate	7.11%
Total	$ 1,967	1,967
2019 Senior Notes due December 2049 at 3.25%
Debt Instrument [Line Items]
Stated interest rate	3.25%
Effective Interest Rate	3.19%
Total	$ 2,000	2,000
Fixed-rate Senior Notes, 4.75%, due March 2050
Debt Instrument [Line Items]
Stated interest rate	4.75%
Effective Interest Rate	4.73%
Total	$ 2,250	2,250
Fixed-rate Senior Notes, 3.05% due August 2051
Debt Instrument [Line Items]
Stated interest rate	3.05%
Effective Interest Rate	3.05%
Total	$ 1,250	1,250
Fixed-rate Senior Notes, 4.90% due August 2052
Debt Instrument [Line Items]
Stated interest rate	4.90%
Effective Interest Rate	4.89%
Total	$ 1,750	1,750
Fixed-Rate Senior Notes, 5.70% Due February 2053
Debt Instrument [Line Items]
Stated interest rate	5.70%
Effective Interest Rate	5.68%
Total	$ 2,000	2,000
Fixed-Rate Senior Notes, 5.60% Due February 2054
Debt Instrument [Line Items]
Stated interest rate	5.60%
Effective Interest Rate	5.61%
Total	$ 1,150	0
Fixed-rate Senior Notes, 3.10%, due February 2060
Debt Instrument [Line Items]
Stated interest rate	3.10%
Effective Interest Rate	3.10%
Total	$ 1,000	1,000
Fixed-rate Senior Notes, 4.95%, due March 2060
Debt Instrument [Line Items]
Stated interest rate	4.95%
Effective Interest Rate	4.98%
Total	$ 1,000	1,000
Fixed-rate Senior Notes, 3.20% due August 2061
Debt Instrument [Line Items]
Stated interest rate	3.20%
Effective Interest Rate	3.20%
Total	$ 750	750
Fixed-rate Senior Notes, 5.05% due August 2062
Debt Instrument [Line Items]
Stated interest rate	5.05%
Effective Interest Rate	5.03%
Total	$ 900	900
Fixed-Rate Senior Notes, 5.90% Due February 2063
Debt Instrument [Line Items]
Stated interest rate	5.90%
Effective Interest Rate	5.88%
Total	$ 1,250	1,250
Oregon and Arizona Bonds Due 2035 - 2040
Debt Instrument [Line Items]
Effective Interest Rate	3.87%
Total	$ 423	423
5.00% Oregon and Arizona Bonds due September 2042
Debt Instrument [Line Items]
Stated interest rate	5%
Effective Interest Rate	3.63%
Total	$ 131	131
Industrial Authority of the City of Chandler, Arizona
Debt Instrument [Line Items]
Stated interest rate	5%
Effective Interest Rate	0%
Total	$ 0	438
4.00% Oregon and Arizona Bonds Due June 2049
Debt Instrument [Line Items]
Stated interest rate	4%
Effective Interest Rate	3.99%
Total	$ 438	0
5.00% Oregon and Arizona Bonds due September 2052
Debt Instrument [Line Items]
Stated interest rate	5%
Effective Interest Rate	4.24%
Total	$ 445	$ 445
Minimum | Oregon and Arizona Bonds Due 2035 - 2040
Debt Instrument [Line Items]
Stated interest rate	0%
Maximum | Oregon and Arizona Bonds Due 2035 - 2040
Debt Instrument [Line Items]
Stated interest rate	4.10%

Borrowings, Narrative (Details)

Borrowings, Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2025	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Dec. 27, 2024
Debt Instrument [Line Items]
Debt settled		$ 2,288,000,000	$ 423,000,000	$ 4,984,000,000
Oregon and Arizona Bonds Due 2035 - 2040
Debt Instrument [Line Items]
Debt issued			$ 423,000,000
Oregon and Arizona Bonds Due 2035
Debt Instrument [Line Items]
Stated interest rate			3.80%
Oregon and Arizona Bonds Due 2040
Debt Instrument [Line Items]
Stated interest rate			4.10%
4.00% Oregon and Arizona Bonds Due June 2049
Debt Instrument [Line Items]
Debt issued		$ 438,000,000
Stated interest rate		4%
Senior Notes
Debt Instrument [Line Items]
Debt issued		$ 2,600,000,000	$ 11,000,000,000
Debt settled		1,900,000,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowings outstanding		$ 0	$ 0
Line of Credit | 5 Year Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument term		5 years
Maximum borrowing capacity		$ 7,000,000,000			$ 5,000,000,000
Debt instrument extension term		1 year
Line of Credit | 364 Day Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument term		364 days
Maximum borrowing capacity		$ 8,000,000,000			$ 5,000,000,000
Debt instrument extension term		1 year
Line of Credit | 364 Day Credit Facility | Revolving Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Debt instrument term	364 days
Maximum borrowing capacity	$ 5,000,000,000
Debt instrument extension term	1 year

Borrowings, Debt Maturities (De

Borrowings, Debt Maturities (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Debt Disclosure [Abstract]
2025	$ 3,750
2026	2,500
2027	3,826
2028	3,173
2029	3,288
2030 and thereafter	34,448
Total	$ 50,985	$ 50,285

Fair Value (Details)

Fair Value (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]	Receivable recorded in other current assets	Receivable recorded in other current assets
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Long-term Debt, Fair Value	$ 43,500	$ 47,600
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Current	1,081	1,175
Derivative Assets, Fair Value Disclosure	1	21
Assets, Fair Value Disclosure	23,261	26,744
Derivative Liability, Current	696	640
Derivative Liability, Noncurrent	1,171	479
Liabilities, Fair Value Disclosure	1,867	1,119
Fair Value, Nonrecurring | Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants receivable	1,700	559
Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	848	1,194
Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	769
Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,864	3,076
Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,654	2,554
Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	5,365	6,951
Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,551	4,248
Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,897	6,756
Level 1 | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Current	348	366
Derivative Assets, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	5,545	3,834
Derivative Liability, Current	0	0
Derivative Liability, Noncurrent	0	0
Liabilities, Fair Value Disclosure	0	0
Level 1 | Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	848	1,194
Level 1 | Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 | Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,121	2,241
Level 1 | Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 | Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 | Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	195	33
Level 1 | Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	33	0
Level 2 | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Current	733	809
Derivative Assets, Fair Value Disclosure	1	21
Assets, Fair Value Disclosure	17,716	22,910
Derivative Liability, Current	562	541
Derivative Liability, Noncurrent	416	479
Liabilities, Fair Value Disclosure	978	1,020
Level 2 | Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 2 | Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	769
Level 2 | Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	743	835
Level 2 | Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,654	2,554
Level 2 | Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	5,365	6,951
Level 2 | Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,356	4,215
Level 2 | Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,864	6,756
Level 3 | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Current	0	0
Derivative Assets, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	0	0
Derivative Liability, Current	134	99
Derivative Liability, Noncurrent	755	0
Liabilities, Fair Value Disclosure	889	99
Level 3 | Equity securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 | Cash Equivalents [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 | Cash Equivalents [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 | Cash Equivalents [Member] | Repurchase Agreements [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 | Short-Term Investments [Member] | Corporate debt | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 | Short-Term Investments [Member] | Financial institution instruments | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 | Short-Term Investments [Member] | Government Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	$ 0	$ 0

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss), Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022	Dec. 25, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 105,032	$ 109,965	$ 103,286	$ 95,391
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(602)	71	(15)
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	109	361	486
Tax effects	(3)	(85)	(153)
Other comprehensive income (loss)	(496)	347	318
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(711)	(215)	(562)	(880)
Unrealized holding gains (losses) on derivatives [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(582)	(27)	(299)	211
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(652)	3	(910)
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	96	328	410
Tax effects	1	(59)	(10)
Other comprehensive income (loss)	(555)	272	(510)
Actuarial gains (losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	(133)	(193)	(259)	(1,114)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	54	57	923
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	11	33	82
Tax effects	(5)	(24)	(150)
Other comprehensive income (loss)	60	66	855
Foreign Currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4	5	(4)	$ 23
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(4)	11	(28)
Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Loss), before Tax	2	0	(6)
Tax effects	1	(2)	7
Other comprehensive income (loss)	$ (1)	$ 9	$ (27)

Derivative Financial Instrume_3

Derivative Financial Instruments (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 28, 2024	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Gross Notional Amounts [Abstract]
Derivative, notional amount	$ 45,964	$ 45,964	$ 50,530	$ 49,708
Fair value of derivative assets	948	948	1,047
Fair value of derivative liabilities	1,084	1,084	1,111
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	948	948	1,047
Derivative Assets Subject To Master Netting Arrangements, Gross Amounts Offset In The Balance Sheet	0	0	0
Derivative Asset, Subject to Master Netting Arrangement, after Offset	948	948	1,047
Derivative Asset, Not Offset, Policy Election Deduction	(269)	(269)	(617)
Derivative, Collateral, Obligation to Return Cash	(679)	(679)	(430)
Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	0	0	0
Reverse Repurchase Agreements, Gross Amounts Recognized	2,654	2,654	2,554
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0	0	0
Securities Purchased under Agreements to Resell	2,654	2,654	2,554
Securities Purchased under Agreements to Resell, Not Offset, Policy Election Deduction	0	0	0
Reverse Repurchase Agreements, Gross Amounts Not Offset In The Balance Sheet - Financial Instruments	(2,654)	(2,654)	(2,554)
Securities Purchased under Agreements to Resell, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	0	0	0
Total Assets, Gross Amounts Recognized	3,602	3,602	3,601
Total Assets, Gross Amounts Offset In The Balance Sheet	0	0	0
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed	3,602	3,602	3,601
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Not Offset, Policy Election Deduction	(269)	(269)	(617)
Total Assets, Gross Amounts Not Offset In The Balance Sheet - Cash and Non-Cash Collateral Received Or Pledged	(3,333)	(3,333)	(2,984)
Derivative Asset, Securities Purchased under Agreements to Resell, Securities Borrowed, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	0	0	0
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	1,084	1,084	1,111
Derivative Liabilities Subject To Master Netting Arrangements, Gross Amounts Offset In The Balance Sheet	0	0	0
Derivative Liability, Subject to Master Netting Arrangement, after Offset	1,084	1,084	1,111
Derivative Liability, Not Offset, Policy Election Deduction	(269)	(269)	(617)
Derivative, Collateral, Right to Reclaim Cash	(745)	(745)	(399)
Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election	70	70	95
Effect of Cash Flow Hedges on Results of Operations [Abstract]
Gail (loss) excluded from effectiveness testing		(205)	(221)	(117)
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge		4	(198)	1,551
Designated as Hedging Instrument
Effect of Fair Value Hedges on Results of Operations [Abstract]
Derivative gain (loss)		0	0	0
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Derivative gain (loss)		0	0	0
Not Designated as Hedging Instrument
Effect of Fair Value Hedges on Results of Operations [Abstract]
Derivative gain (loss)		422	481	1,299
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Derivative gain (loss)		422	481	1,299
Not Designated as Hedging Instrument | Fab 34
Effect of Fair Value Hedges on Results of Operations [Abstract]
Derivative gain (loss)		(755)
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Derivative gain (loss)		(755)
Assets
Gross Notional Amounts [Abstract]
Fair value of derivative assets	1,082	1,082	1,196
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	1,082	1,082	1,196
Assets | Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	40	40	255
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	40	40	255
Assets | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	1,042	1,042	941
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	1,042	1,042	941
Liabilities
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	1,867	1,867	1,119
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	1,867	1,867	1,119
Liabilities | Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	987	987	720
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	987	987	720
Liabilities | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	880	880	399
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	880	880	399
Foreign currency contracts
Gross Notional Amounts [Abstract]
Derivative, notional amount	$ 25,472	25,472	30,064	31,603
Effect of Cash Flow Hedges on Results of Operations [Abstract]
Before-tax net gains (losses) attributed to the effective portion of cash flow hedges recognized in other comprehensive income (loss)		(652)	3	(910)
Foreign currency contracts | Not Designated as Hedging Instrument
Effect of Fair Value Hedges on Results of Operations [Abstract]
Derivative gain (loss)		$ 651	$ 106	$ 1,492
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest and other, net	Interest and other, net	Interest and other, net	Interest and other, net
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Derivative gain (loss)		$ 651	$ 106	$ 1,492
Foreign currency contracts | Assets | Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	$ 40	40	255
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	40	40	255
Foreign currency contracts | Assets | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	510	510	314
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	510	510	314
Foreign currency contracts | Liabilities | Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	405	405	142
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	405	405	142
Foreign currency contracts | Liabilities | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	100	100	363
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	100	100	363
Interest Rate Contracts
Gross Notional Amounts [Abstract]
Derivative, notional amount	17,899	17,899	18,363	16,011
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments		(4)	198	(1,551)
Interest Rate Contracts | Not Designated as Hedging Instrument
Effect of Fair Value Hedges on Results of Operations [Abstract]
Derivative gain (loss)		$ 182	$ 50	$ 309
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Interest and other, net	Interest and other, net	Interest and other, net
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Derivative gain (loss)		$ 182	$ 50	$ 309
Interest Rate Contracts | Assets | Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	0	0	0
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	0	0	0
Interest Rate Contracts | Assets | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	184	184	261
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	184	184	261
Interest Rate Contracts | Liabilities | Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	582	582	578
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	582	582	578
Interest Rate Contracts | Liabilities | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	25	25	36
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	25	25	36
Equity Contract | Assets | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	348	348	366
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	348	348	366
Equity Contract | Liabilities | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	0	0	0
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	0	0	0
Other
Gross Notional Amounts [Abstract]
Derivative, notional amount	2,593	2,593	2,103	2,094
Other | Not Designated as Hedging Instrument
Effect of Fair Value Hedges on Results of Operations [Abstract]
Derivative gain (loss)		(411)	325	(502)
Derivative Instruments Not Designation as Hedging Instruments [Abstract]
Derivative gain (loss)		$ (411)	$ 325	$ (502)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income, Not Disclosed Flag		Other	Other	Other
Other | Assets | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative assets	0	$ 0	$ 0
Offsetting Derivative Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	0	0	0
Other | Liabilities | Not Designated as Hedging Instrument
Gross Notional Amounts [Abstract]
Fair value of derivative liabilities	755	755	0
Offsetting Derivative Liabilities [Abstract]
Total Liabilities, Gross Amounts Recognized	755	755	0
Interest Rate Swaps
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Carrying Amount of the Hedged Item Assets/(Liabilities)	(11,415)	(11,415)	(11,419)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities)	582	582	578
Interest Rate Swaps | Long-term Debt
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Carrying Amount of the Hedged Item Assets/(Liabilities)	(9,201)	(9,201)	(11,419)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities)	546	546	578
Interest Rate Swaps | Short-Term Debt
Derivative Assets (Liabilities), at Fair Value, Net, by Balance Sheet Classification [Abstract]
Carrying Amount of the Hedged Item Assets/(Liabilities)	(2,214)	(2,214)	0
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities)	36	36	$ 0
Interest Rate Swaps | Long-term Debt | Fair Value Hedging
Gross Notional Amounts [Abstract]
Derivative, Amount of Hedged Item	$ 12,000	$ 12,000

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation liabilities	$ 3,300	$ 2,900
Beginning projected benefit obligation	2,646	2,825	$ 2,705
Service cost	33	36
Interest cost	$ 122	$ 127
Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible ListNotDisclosedFlag	Interest cost	Interest cost
Actuarial (gain) loss	$ (40)	$ 57
Currency exchange rate changes	(107)	38
Plan settlements	(143)	(103)
Other changes in projected benefit obligation	(44)	(35)
Fair value of plan assets	2,142	2,212	$ 2,130
Actual return on plan assets	121	151
Currency exchange rate changes	(74)	34
Defined Benefit Plan, Plan Assets, Payment for Settlement	(143)	(103)
Other	26	0
Net unfunded status	504	613
Accumulated other comprehensive loss (income), before tax3	$ 337	410
Defined Benefit Plan, Additional Information [Abstract]
Net Actuarial (Gain) Loss Amortization Percent	10%
Accumulated benefit obligations	$ 2,509	2,706
Defined Benefit Plan, Funded Status Percentage [Abstract]
Defined Benefit Plan, Funded Percentage	86%
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]
Accumulated benefit obligation	$ 850	1,857
Plan assets	348	1,301
Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]
Projected benefit obligation	987	1,976
Plan assets	$ 348	$ 1,301
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	4.60%	4.50%
Rate of compensation increase	3.40%	3.30%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	4.50%	4.90%	2.20%
Expected long-term rate of return on plan assets	5.10%	5%	3.20%
Rate of compensation increase	3.30%	3.70%	3.20%
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2025	$ 145
2026	86
2027	95
2028	97
2029	106
2030-2034	623
Other long-term assets
Defined Benefit Plan Disclosure [Line Items]
Net unfunded status	(135)	$ (62)
Other long-term liabilities
Defined Benefit Plan Disclosure [Line Items]
Net unfunded status	639	675
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 510	$ 547
United States
Defined Benefit Plan Disclosure [Line Items]
Projected Benefit Obligations Percentage Split	30%
Fair Value of Plan Assets Percentage Split	40%
AOCI Percentage Split	80%	70%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 541	$ 272	$ 489
Defined Benefit Plan, Additional Information [Abstract]
Accumulated benefit obligations	763	849
United States | Pension Plan
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	69	107	$ 139
United States | Postretirement Health Coverage
Defined Benefit Plan Disclosure [Line Items]
Beginning projected benefit obligation	493	490
Fair value of plan assets	$ 542	$ 548
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	5.70%	5.30%
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2025	$ 37
2026	45
2027	45
2028	44
2029	44
2030-2034	$ 209
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Projected Benefit Obligations Percentage Split	70%
Fair Value of Plan Assets Percentage Split	60%
AOCI Percentage Split	20%	30%
Defined Benefit Plan, Additional Information [Abstract]
Accumulated benefit obligations	$ 1,700	$ 1,900
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	35%
Fair value of plan assets	$ 344	383
Equity securities | United States
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	9%
Equity securities | United States | Postretirement Health Coverage
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	50%
Fixed income
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	50%
Fair value of plan assets	$ 166	164
Fixed income | United States
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	91%
Fixed income | United States | Postretirement Health Coverage
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	50%
Assets measured at net asset value
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,618	1,648
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 14	17
Hedge Funds | Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Plan Asset Allocations (percent)	15%
Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	0
Level 1 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	486	522
Level 2 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	344	383
Level 2 | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	142	139
Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24	25
Level 3 | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 24	$ 25

Employee Equity Incentive Pla_3

Employee Equity Incentive Plans (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Market-Based Restricted Stock Units Performance Period (In Years)	3 years
Share-based Payment Arrangement, Noncash Expense	$ 3,410	$ 3,229	$ 3,128
Tax Benefit from Compensation Expense	684	571	478
Tax expense for share-based awards resulting from shortfall of tax deduction	$ 139
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Award Requisite Service Period	4 years
RSUs Vested in Period, Total Fair Value	$ 2,400	2,200	2,000
RSUs Aggregate Intrinsic Value, Vested	3,400	$ 2,700	$ 2,500
Compensation Cost Not yet Recognized	$ 2,700
Compensation Cost Not yet Recognized, Period for Recognition	1 year 1 month 6 days
Estimated Values And Weighted Average Assumptions [Abstract]
Estimated values (in dollars per share)	$ 39.51	$ 28.92	$ 41.12
Risk-free interest rate	4.70%	4.70%	2.20%
Dividend yield	1.20%	1.60%	3.40%
Restricted Stock Units Activity [Roll Forward]
Number of RSUs outstanding, beginning balance	172.9
Number of RSUs granted	64.5
Number of RSUs vested	(83.8)
Number of RSUs forfeited	(36.2)
Number of RSUs outstanding, ending balance	117.4	172.9
Number of RSUs expected to vest	104.3
Weighted average grant date fair value, RSUs outstanding	$ 36.52	$ 37.05
Weighted average grant date fair value, RSUs granted	39.51
Weighted average grant date fair value, RSUs vested	40.33
Weighted average grant date fair value, RSUs forfeited	35.54
Weighted average grant date fair value, RSUs expected to vest	$ 36.70
Market-Based Restricted Stock Units (OSUs) [Member]
Estimated Values And Weighted Average Assumptions [Abstract]
Volatility (percent)	36%	36%	40%
Restricted Stock Units Activity [Roll Forward]
Number of RSUs outstanding, ending balance	10
Market-Based Restricted Stock Units (OSUs) [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Vesting range (percent)	0%
Market-Based Restricted Stock Units (OSUs) [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Vesting range (percent)	200%
Stock Purchase Plan RIghts [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Compensation Cost Not yet Recognized	$ 63
Compensation Cost Not yet Recognized, Period for Recognition	2 months
Stock Purchase Plan Shares Issued in Period	39	43	27
Employee Purchases, Amount	$ 972	$ 1,000	$ 931
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Number of Shares Authorized	1,100
Number of Shares Available for Grant	171
2006 Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Number of Shares Authorized	523
Number of Shares Available for Grant	118
Stock Purchase Plan, Purchase Price of Common Stock, Percent	85%

Commitments and Contingencies,

Commitments and Contingencies, Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Operating Lease, Right-of-Use Asset	$ 457	$ 505
Lessor, Operating Lease, Renewal Term	37 years
Operating Lease, Weighted Average Remaining Lease Term	6 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent	4.90%
Lease, Cost	$ 248	407	$ 729
Variable Lease, Cost	$ 98	213	$ 551
Term of finance lease contract	6 years
Finance leased assets	$ 470	619
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	12 years
Accrued Liabilities
Lessee, Lease, Description [Line Items]
Operating Lease, Liability	$ 181	142
Other Long-Term Liabilities
Lessee, Lease, Description [Line Items]
Operating Lease, Liability	$ 279	$ 289

Commitments and Contingencies_2

Commitments and Contingencies, Commitments (Details) - USD ($) $ in Millions	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation	$ 7,000	$ 8,300
Goodwill	24,693	27,591	$ 27,591
Semiconductor Co-Investment Program, Construction Costs
Unrecorded Unconditional Purchase Obligation [Line Items]
Unfunded commitment	10,500
Semiconductor Co-Investment Program, Construction Costs | Intel and Brookfield
Unrecorded Unconditional Purchase Obligation [Line Items]
Unfunded commitment	29,000
Capital Addition Purchase Commitments [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation	$ 20,000	$ 27,500

Commitments and Contingencies_3

Commitments and Contingencies, Contingencies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Litigation charges and other	$ 858	$ (329)	$ (1,187)
Gain on Business Interruption Insurance Recovery	$ 484
Gain on Business Interruption Insurance Recovery, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Sales
EC Fine
Loss Contingencies [Line Items]
Litigation charges and other	$ 401	$ 401	$ (1,200)
R2 Semiconductor Patent Litigation
Loss Contingencies [Line Items]
Accrued litigation liability	655
Litigation charges and other	780
VLSI Technology LLC v. Intel
Loss Contingencies [Line Items]
Accrued litigation liability	$ 1,000

Commitments and Contingencies_4

Commitments and Contingencies, Schedule of Payments on Operating Lease Liabilities (Details) $ in Millions	Dec. 28, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 112
Lessee, Operating Lease, Liability, to be Paid, Year Two	74
Lessee, Operating Lease, Liability, to be Paid, Year Three	59
Lessee, Operating Lease, Liability, to be Paid, Year Four	46
Lessee, Operating Lease, Liability, to be Paid, Year Five	42
Lessee, Operating Lease, Liability, to be Paid, Thereafter	119
Lessee, Operating Lease, Liability, to be Paid	452
Finance Lease, Liability, to be Paid, Year One	107
Finance Lease, Liability, to be Paid, Year Two	106
Finance Lease, Liability, to be Paid, Year Three	16
Finance Lease, Liability, to be Paid, Year Four	6
Finance Lease, Liability, to be Paid, Year Five	0
Finance Lease, Liability, to be Paid, after Year Five	0
Finance Lease, Liability, Payment, Due	235
Present value of lease payments	$ 614